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INTRODUCTION :
The chemistry of 1,4-dihydropyridine began with compounds having
carboxylic alkyl ester groups at 3 and 5 position, when first 1, 4-dihydro
pyridine was introduced by Hantzsch et al1 in 1882. Later on, Arthur
Phillips2 of Welcome Research Laboratories, in his well-recognized work,
used Hantzsch synthesis to get symmetrical compounds for the curare
like activity who for the first time reported pharmacological activity of
these compounds.  Such compounds are devoid of undesirable side
effects during clinical trials.
The discovery in the 1930’s that a dihydropyridine  was a “hydrogen-
transfering coenzyme” and consequently of utmost importance in
biological systems3,4 has generated numerous studies of the biochemical
properties of dihydropyridines. However, there have been relatively few
studies of the pharmacological activites of such compounds. At the time
this work was initiated, the only such reports described weak analgesic
and curare-like properties5. Consequently, work had been explored to
evaluate some of these compounds, in particular the “Hantzsch-type”
dihydropyridines6,7  in a number of standard test systems,. Subsequent
to this work, antitumor8and coronary dilating activities have been reported9
for certain dihydropyridines.
1. Hantzsch A., Ann. 215, 1 (1882).
2. Phillips A. P., J. Am. Chem. Soc., 73, 2248 (1951).
3. T. C. Bruice and S. J. Benkovic, “Bioorganic Mechanisms,”Vol. 2, W. A.
Benjamin,New York,  p 301 (1966).
4. M. Florlkin and E. H . Stotz Ed., ‘Comprehensive Biochemistry,” Vol. 14, Elsevier,
Amsterdam, (1966).
5. A. P. Phillips, J. Amer.Chem. Soc., 71, 4003 (1949); A. P. Phillips and L. O.
Randall, U. S. Patent 2,359,329 (1944).
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1,4-dihydropyridine activators, since it does not shift phytohormone
abscisic acid has prominent calcium channel activating properties in plant
cells and this may extent to mammalian systems. In recent years, 1, 4-
dihydropyridines, which are showing predominant pharmacological ef-
fects of these studies, appeared to correlate with physiological activities
determined by in vivo studies10. Calcium Channel (Antagonists) or -block-
ing agents have made their way into clinical medicine for treatment of
umpteen number of disorders.  They are most commonly used for pa-
tients with cardiovascular diseases11.  The predominant pharmacological
effects of calcium channel antagonists are coronary, peripheral and ce-
rebral vasodilation12, negative ionotropic effect13-15, and also as postitive
ionotropic agents.
6. R. A. Barbes, F. Bridt, and P.R. Ryby, Pyridine Its Deriv., 1960-1964, Part I,
80,500 (1960).
7. Eusner U. and Kuthan J., Chem, Rev., 72, 1 (1982).
8. Zidermane A.,Duburs G.,Zilbere A.,Veree A.,Uldrikis K., and Kumsars K.,
Latu.PSR Zinat. Akad. Vestis, 4, 77 ((1971); Chem. Abstr.,75, 47266e (1971).
9. Belgium Patent 689 , 377 (1967).
10. Rojstaczer N. and Triggle, D.J. Biochem. Pharmacol., 51, 141–150 (1996).
11. Cozzi, P., Carganico, G., Fusar, D., Grossoni, M., Mewichinchero, Pinciroli, V., Tanani,
12. Takenaka, T., Usuda, S., Nomura, T., Maino, H., Sado, T., Arzneim-Forsch. / Drug. Res.,
26, 2172 (1976).
13. Hoff, R., Scholtysik, G., Loutzenhiser, R., Vuorela, H. and Neumann, P., J. Card. Pharm.,
6,399 - 406 (1996).
14. Jamis, R., Silver, P. and Triggle, D.; Adv. Drug. Res., 16, 309 (1987).
15. Janero, D. R., Burghardt, B.; Biochem. Pharm., 38, 4344-4348 (1989).
16. Epstein, M. S. Editor : Calcium Antagonists in Clinical Medicine,2ndEdition,
Hanley and Belfus , Philadelphia, PA, (1998).
17. Peterson, B.Z., Tanada, T.M., Catterall, W.A. J. Biol. Chern. ,271, 5293- 5296
(1996).
18. Hockerman, G.H., Petrson, B.Z., Sharp, E., Tanada, T.N., Scheuer,  T.,
Catterall,W.A. Pi-oc. Nat. Acad. Sci. USA , 94, 14906-14911 (1997).
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Nifedipine (2,6-dimethyl-3,5-dicarbomethoxy-4-(2-nitro)phenyl-1,4-
dihydropyridine is a first generation calcium channel blocker that interacts
at a specific class of voltage-gated calcium channel-the-L-type channel
to produce its cardiovascular effects, including the relief of hypertension
and angina16.  First introduced in 1975 nifedipine interacts at a discrete
receptor si te on the channel that is l inked in complex al losteric
relationships to other, and structurally quite distinct, calcium channel
blocker binding sites (receptors) for the phenylalkylamine verapamil and
the benzothiazepinone diltiazem   The receptor for 1,4-dihydropyridines
has been localized to segments IIIS5, IIIS6 and IVS6 of the major a1
submit of the channel and some nine critical amino acid residues have
been identified as constituting the binding domain17-18.
The receptor site for nifedipine on the L-type class of calcium
channel is shared not only by the 1,4-dihydropyridine antagonists of Figure
1, but also by potent and structurally related 1,4-dihydropyridine
activators, including Bay K 8644 that serve as vasoconstrictors, positive
inotropic agents and secretagogues. The availability of extremely potent
and structurally specific antagonist and activator ligands for this channel
has raised the issue for the whether there exist endogenous regulatory
species  “endogenous ligands”  for which the 1,4-dihydropyridines are
merely surrogate species.  However, such species have not, despite much
efforts, been unambiguously indentified19 .
19. Wappl, E., Mitterdirfer, J., Glossmann, H., Striessnig, J. J. Biol. Chem., 276,
12730-12735 (2001).
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20.  D Scherling, J . labelled compd. radiopharm.  27(5), 599-603 (1989);
 Chem. Abstr., 111,23252p (1989).
21. Cupka Pavol; Rybar Marian; Cupka Pavol; Ryabar Alfonz; Svobodova,
Xenia; Kosalko Rudolf; and martvon Augstin; Chem. Abstr., 110,8051c(1989)
22. Cooper, Kelvin and fray, Mray, Richardson Kenneth ; Eur. Pat.applied Ep
294, 074,23144a(1989).
23. Johnson, Carl R., Hann Kenneth V, and Cheng Soan;U.s.pat. 4,758,669,
Chem. Abstr., 109,149366a (1988).
24 Frigerio Marco, zaliani Andrea, Gandolfi CarmeloA, Germini, Mauro,
Tofanetti,and Tangnella Sergio, Fur. pat.272 ,693.Abstr., 109,190259f (1988).
1,4-dihydropyridines, whether symmetrical or unsymmetrical are
expected for their cardiovascular and other pharmacological property.
Sufficient literature is available regarding structure-activity studies20-24.
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1,4-dihydropyridines may have tremendous applications with
different modification in its structure. a number of good reviews on the
structure, synthesis, stereochemistry and hydrogen transfer mechanism
of the pyridine nucleoside are well reported in literature 25-30.
These compounds have been synthesized and developed as
calcium antagonists which inhibit smooth and cardiac muscle contractions
by blocking the influx of Ca+2 through calcium channels  31-39.
25. Love, B., Good, M. M., Snader, K. M., Tedeschi, R. and Macko, E. J. Med.
Chem. Abstr., 17, 956 (1974).
26. Bossert, V. F., Hortsmann, H., Meyer, H. and Vater, W.; Arzneim.- Forsch./
DrugRes., 29(I) 226 (1979).
27. Iwanami, M., Shibanuma, T., Fujimato, M., Kawai, R., Tamazawa, K., Takenaka,
T.,Takahashi, K., and Murakami, M., Chem. Pharm. Bull. 27,1426 (1979).
28. Imai, H., Matsui, K., Ochi, S., Nakazawa, M., Nakagawa, Y., and Imai, S ; Arzneim-
Forsch / Drug Res. 37(II),12(1978).
29. Derk, K., Stopel, K., Leibowits, D., Taylor, R., and Vanov, S.; In Nitredipine, E.
Scriabine, S. Vanov, K. Derk, (eds.), Urban & Schwarzenbrg, Balti more-Munich,
397 (1984).
30. Triggle, D, J.; In Handbook of Experimental Pharmacology ; Calcium in Drug
Actions– The Chemistry of Calcium Channel Agonists and Antagoists, G.V.R.Born
(ed.),Springer-Verlag, Heidelberg, 115 (1986).
31. Wehinger, E. and Gross, R.; Ann. Rep. Med. Chem.  21, 85 (1986).
32. Janis, R. A. and Triggle, D. J.; J. Med Chem., 26, 775 (1983).
33. Alker, D., Arrowsmith, J. E., Campbell, S. F. and cross, P. E.; J. Med. Chem.
26(9),907-13 (1991).
34. Singer, T. P. and Kearney, E. B. Advan. Enzymol., 15, 79 (1964).
35. Kaplan. N. O.; Rec. Chem. Prorgr., 16, 177 (1955).
36. Hirayama, N . &Shimizu, E. ; Acta crystallography C 47, 458 (1991).
37. Sund, H., Diekmann, K. and Wallenfels, K.; Advan. Enzymol. 26, 115 (1964).
38. Colowick, S. P., Vand Eys, J. and Park, J. H.; Compr. Biochem,  14, 1 (1966).
39. Berson,J. A. & Brown, E.;J. Am. Chem. Soc. 77, 444 (1955).
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The design of tissue selective1,4-dihydropyridine(1,4-DHP) cal-
cium channel agonists to treat congestive heart failure necessitates re-
moval of their contraindicated smooth muscle vasoconstrictor effect while
the target cardiac positive inotropic action is maintained. in this regard,
racemic methyl 1,4-DHP (Bay K8644) produced a Ca+2 channel agonist
effect on both smooth and cardic muscle since the agonist (-)-(S)-enan-
tiomer (1) is about  10-fold more potent relative to the antagonist(+)-(R)-
enantiomer .
2, R=CH2CH2ONO2 4, R=CH2CH2ONO2
3 ,R= Me1, R=Me 5 ,PN202-791
Figure structures for the (-)-(S)-1 and (+)-(R)-3 enantiomers of Bay K8644, the (-)-(S)
-2 and (+) -(R)-4 enantiomers of 2-nitroxyethyl 1,4-dihydro-2,6dimethyl-3-nitro-4-(2-
trifluoromethylphenyl)pyridine-5-carboxylate, and PN 202-791 (5).
N
H
CH3CH3
CO2RO2N
CH3
H
N
H
CH3 CH3
CO2RO2N
CH3
H
N
H
CH3 CH3
CO2Pr-iO2N
N
O
N
H
Major investigation  done by Tsuruo et.al.41 on Ca2+ channel
blockers (Verapamil and some 1, 4-dihydropyridines) activity suggested
that 1, 4-DHP’s possesses multidrug resistance (MDR) reversal activity40.
This investigation further confirmed by Hollt V. and co-workers42 in 1992.
The development of multidrug resistance (MDR) of tumor cells is a major
problem in malignant tumor chemotherapy, as tumor cells, by increasing
drug efflux, acquire cross-resistance to many structurally and functionally
unrelated anticancer agents, which therefore never achieve effective
intracellular concentrations43.
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Multidrug resistance (MDR) of cancer cells has often been
correlated with the over expression of P-glycoprotein (P-gp).  An ABC
transporter ATP binding cassette act as a cellular pump membrane
transporter by extruding the anticancer agents and preventing their
Antitumor effect.
The nitric oxide releasing action of the 1,4-dihydropyridines appear
to be a class action, to be exerted at therapeutic concentrations and to
involve the stimulation of calcium influx into endothelial cells though a
anion-L-type process43-a,b,c .
1,4-dihydropyridines may have at least two other effect on the nitric
oxide mediated vasorelaxant system. Pranidipuine (0PC-13340, methyl-
3-pheny 2(E)-propenyl-1,4-dihydro-2,6-dimethyl-4(3-nitrophenyl)-3,5-
pyridine dicarboxylate) enhances nitric oxide-mediated vasorelaxation by
a mechanism apparently distinct from NO release43-d additionally, a series
of 1,4-dihydropyridines exist with “dual” pharmacological properties –
blockade of L-type calcium channels and direct release of nitr ic
oxide43-e,f,g.
40. Shah A., Gaveriya H., Motohashi N. and Kawase M., Anticancer Res., 20, 373
(2000).
41. Tsuruo T., Prog. Clin. Biol. Res., 223, 203-216 (1986).
42. Hollt V., Kouba M., Dietel M., Biochem. Pharmacol. 43, 2601-2608 (1992).
43. Krishna R. and Mayer L. D., Eur. J. Pharm. Sci., 11, 265-283 (2000).
43(a) Dhein S.,Zhao Y.,Simsek S. and Klaus W., Actions of dihydropyridiens in
isolated mesentric vascular beds, J.Cardiovas. Pharmacol., 26, 784-791,
(1995).
43(b) Zhang X.and Hinke T.H., Amlodipine releases nitric oxide from canine
coronary microvessel: and unexpected mechanism of a calcium channel-
blocking agent, Circulation., 97, 576-580, (1998).
43(c) Crespi F., Vecchiato E., Lazzarini C, Andreoli M. and Gaviraghi G.,
J.Cardiovas., Pharmacol ., 39,471-477 (2002).
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Many researchers have synthesized 1,4-DHPs having aliphatic
ester group44, aromatic ester group45 and heterocyclic ester46 group at 3
and 5 position.  After almost 80 years, later structure and hypotensive
activity of Hantzsch type symmetrical 3,5-disubstituted 1,4-DHPs
thoroughly investigated by Love and co-workers 47.  As a result, Nifedipine
36
came out as a promising compound which exerted its cardiovascular
effects through a direct action on vascular smooth muscles.  Several
other drugs discovered and used such as Niludipine, Darodipine,
Riodipine, Lacidipine, Flordipine in last two decades.
43(d) Mori T.,TakaseK., Toide K., Nakayama N. and Schwartz A., Cardiovas., Drug
Revs.,19,1-8, (2001).
43(e) Cena S., Visentin A., Fruttero R. and Gasio A., Pharm. Res.,18,157-165
(2002).
43(f) Ogawa T., Nakazatu A., Tschchida and Hatayama K., Chem. Bull.
Pharm.,41,1049-1054 (1993).
43(g) Vo D., Nguyen T., Shan R. and Knaus K.K., Drug Dev. Res., 9,123-180
(1989)
44. a)Brignell P. J., Bullock E., Eisner U., Gergorg B.. Johnson A W., Williams H.,
J.Chem. Soc., 4819 (1963) b) Kamal A. and Qureshi A. A. Pakistan, J.Sc.
Ees. 15,35 (1963);  C. A., 60, 1689 (1964).
45. a)Phillips A. P., J. Am. Chem. Soc., 73, 2248 (1951).  b)  Furdik M. and
Gvozdjakova A ., Acta. Fac. Rerum, Natur. Uni. Comeniance Chem., 8, 581
(1964).
46. a)Homer R. F ., J. Chem. Soc., 1574 (1958)    b) Wileg R. H. and Ridgeway J.
J. Org. Chem.  26, 595 (1961).
47. Love, Goodman, Snader Tedeshi and Marko, J. Med. Chem., 17, 956
(1974).
48. a) Stefan M. and Josef K; Collect; Czech. Chem. Commun. 48(11), 3112-22
(1983); C.A., 100, 85559v (1984)
49. James W.T., U.S.Patent 3,973,025; C.A. 85, 177262t (1976)
50.  Roman B., Marian M., Pol. 86, 477 (1977); C.A., 87, 135104d (1977)
51. Josef K., Anotonin K., Zdenek P., Jaroslav P., Collect. Czech. Chem.
Commun.,43(4), 1068-79 (1978); C.A., 89, 10891u (1978).
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Similarly symmetrical & unsymmetrical  1,4-dihyropyridines48 having
cyano group at 3 and 5 position and para biphenyl group at 2 and 6
pos i t ion  a re  repor ted .  When ace tophenone reac ted  w i th  3 -
aminocrotonitrile gave sym. 3, 5-dicyano-2, 4, 6-trimethyl-4-phenyl-1, 4-
dihydropyridine49 (VI) and aldehyde condensation with 3-aminocrotonitrile
in suitable acidic medium like acetic acid or hydrochloric acid gave sym.
3, 5-dicyano-2, 6-dimethyl-4-substituted phenyl-1, 4-dihydropyridine50,51.
COCH3
+
CH3
CNNH2
N
H
CH3CH3
CNNC
CH3
Reaction of Aryl Grignard reagents with pyridine-3,4-dicarboxylic
ester gave the 4-aryl-2,6-disubstituted dihydropyridines(XXI). Methyl
Grignard is reported to give mixtures of 2- and 4-substituted products52.
N
COOC2H5H5C2OOC
ArMgX
N
H
Ar
COOC2H5H5C2OOC
52.  Brignell P. G. , Eisner U., and Farrell P. G. , J. Chem. Soc. B ,1083 (1966);
Palecek J. ,Ptackova L. , and Kuthan J., Collect. Czech. Chem. Commun ., 34.27
(1969).
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Shah and Nal iapara53 have synthesized few ser ies of  3,5-
disubstitute carbamoyl derivatives and studied 2D QSAR of 4-substituted
phenyl 2,6-dimethyl-3,5-bis[(N-substituted phenyl)carbomoyl]-1,4-
dihydropyridine as potent antituberculer agents. These compounds show
>90% inhibition comparable to rifampicin and MIC value<12.5mg.
R = -OC6H5,Cl,NO2,Br.... R1 = -NO2,OCH3,Cl...
N
H
NH
OO
NH
CH3CH3
R
R1R1
53. Naliapara Y. T. ,Desai B. ,Sureja D. ,Shah A. ,Saxena  A. K. ,Bio. Org. &
Med.Chem.,9 ,1993-98 (2001).
53(a) Ruediagerwolf Ulrich., Bernhard Kohl., Flockerzi Dieter., WO 8809,331 (1988).
Ulrich et.al53a. has obtained 3, 5-dicarboxylic acid substituted 1, 4-
DHP’s.
N
R
CH3CH3
CH3
OO
CH3
O
CH3
R=alkyl, phenyl
The 1,4-dihydropyridine having acetyl or benzoyl groups on 3 and
5 position are still subject of intensive study due to recent development
on MDR reversal activity in tumor cells which has a new dimension of
application. This recent findings were contribution of this laboratory. Detail
of its chemistry, pharmacological activity is given in synthetic aspects.
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The interest is growing towards pharmacological activities that are
not connected with their calcium channel antagonist properties, like neu-
rotropic (antiamnestic, anticonvulsant, neuroregulatory), antidiabetic, and
membrane protectging as well as anticancer, antibacterial, and antiviral
activities54-57.
54. Misane, I.; Klusa, V.; Dambrova, M.; Germane, S.; Duburs, G.;Bisenieks, E.; Rimondini,
R.; Ogren, S. O. Eur. Neuropsychopharmacol., 8, 329-347, (1998).
55. Krauze, A.; Germane, S.; Eberlins, O.; Sturms, I.; Klusa, V.; Duburs, G. Eur. J. Med.
Chem.  34, 301-310,(1994).
56. Klusa, V. Drugs Future  20, 135-138, (1995).
57. Briede, J.; Daija, D.; Stivrina, M.; Duburs, G. Cell. Biochem. Func.  17,89-96,(1999).
58. Liou SF, Wu JR, Lai WT, Sheu SH, Chen IJ, and Yeh JL.,J Cardiovasc
Pharmacol.; 45(3):232-240, (2005).
N
H
CH3 CH3
O
O
CH3
O
O
CH3
O
CH3
OH
NH
O
O
CH3
Labedipinedi lol-A(X), a novel dihydropyridine-type calcium
antagonist, has been shown to induce hypotension and vasorelaxation.
Yeh JL et al.58, investigated the effect of labedipinedilol-A on vascular
function of rat aortic rings and cultured human umbilical vein endothelial
cells (HUVECs).
12
Chapter-1
Synthesis of 1,4-DHP-3,5-dicarboxmide......
The pharmacology and clinical applications of these agents have
been reviewed on numerous occasions. Nifedipine has now been joined
in the clinical market place by several second and third-generation 1,4-
dihydropyr id ines including – amlodipine,  fe lodip ine,  isradipine,
nicardipine, nimodipine, nitrendipine, lacidipine and lercanidipine.  These
agents differ in detail in their overall pharmacological and pharmacokinetic
characteristics, although they do share a fundamental similarity of action.
Calcium channel blockers (CCBs) of the 1,4-dihydropyridine de-
rivatives (DHPs), exemplified by nifedipine (Adalat) and nilvadipine
(Nivadil), are well-know as clinically important drugs since they first ap-
peared in the market in 1975. Till date, these compounds have become
almost indispensable for the clinical treatment of cardiovascular diseases
such as angina pectoris, hypertension, and cardiac arrhythmias59,60 and
anticancer61.
59. Triggle, D.J. In, The Calcium Channel: Structure, Function and complications,
Eds.M. Morad, W. Nayler, S. Kazda and M. Schramm. Springer-Verlag, Berlin
and Heidelberg, (1988) .
60. For reviews, see: (a) Bissert, F.; Vater, W. Med. Res. Rev. , 9, 291 (1989) .
(b) Goldmann, S.; Stoleefuss, J. Angew. Chem., Int. Ed. Engl.,30,1559(1991)
and references therein.
(c) Marchalin, S.; Chudik, M.: Mastihuba, V.; Decroix, B.Heterocycles 48,1998
and references therein.
61. Chudik, M.; Marchalin, S,; Daich, A,; Decroix, B. Res Adv. Synth. Org. Chem.
1, 1,2000.
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62. Sibikev, A.; Franssen, M. C. R.; Vigante, B.; Cekvaicus, B.; Makarova, N.;
Daburs G.; De Groot, A. Tetrahedron: Asymmetry , 12, 3251 (2001).
63. Rudong Shah, Carlos Velazquez, and Edward E. Knaus, J .Med . chem ,47,
254-261 (2004).
64. Albert Gasco, Sonja Visertin, Barbara Ronaldo,et. al., J,. Med. Chem.,47, 2688-
2693 (2004).
65.       Desai, B., Sureja, D., Naliapara,Y., Shah, A. And saxena, A. K. ;  Bioorg. Med.
chem., 9 ,1993-1998 (2001).
66. Swamy, S. K. Reddy, T. M., Reddy , V. M.; Indian J. Pharm. Sci., 60(2) , 102-
06(1998).
Interestingly, it has been now recognized that the absolute
configuration at the C4 position of the 1,4-DHP nucleus is indispensable
for activity modulation. Indeed, enantiomers of an unsymmetrial, 1,4-
DHPs usually differ in the their biological properties, and sometimes they
could have exactly the opposite action profile (calcium antagonist vs
calcium agonist for example)62.   Consequently, the synthesis of
enantiometrically pure 4-aryl 1,4-DHPs, and their biological evaluation
continue to present significant challenge for the scientific community.
Rudong Shah & Edward E. Knaus63 studied synthesis, calcium
channel agonist-antagonist modulation activities and nitric oxide release
of nitrooxyalkyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-
4-yl)pyridine-5-carboxylate racemates,enantiomers and diastereomers.
New 1,4-dihydropyridines endowed with NO-Donor and calcium
channel agonist properties reported by Sonja Visentin et. al 64.
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R1=NO2, OCH3, Cl.....
Later on Shah et al65 synthesized some new series of 4-substi-
tuted phenyl-2,6-dimethyl-3,5-bis-(N-substitutedphenyl)-carbomyl-1,4-
dihydropyridine and studied their 3D-QSAR  as well as antituberculer
activity aganist M.tuberculosis H37 Rv. Among them, some derivatives
showed >90% inhibition comparable to Rifampicin.
N
H
CH3CH3
NH
OO
NH
R1
R1
R
R =Cl, F, NO2, H
Almost parallel to Shah & co-workers, Reddy and coworkers 66 syn-
thesized 4-aryl / heteroaryl,2,6 -dimethyl-3,5-bis-N-(2-methyl phenyl )car-
bamoyl-1,4-dihydropyridines and reported pharmacological screening of
the new 1,4-dihyropyridines such as CNS depressant (anticonvulsant and
analgesic) and cardiovascular activities by standard methods.
R=OH, NO2, di-OCH3, N(CH3)2, etc...
N
H
CH3 CH3
NH
OO
NH
CH3 CH3
R
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New Generation of 1,4-dihydropyridine Introduced:
Generic Name : Benidipine hydrochloride67
Highest Phase : Launched-1991
Therapeutic Group : Treatment of Hypertension
Chemical Structure :
N
H
O
OO
O
CH3
CH3 CH3
NO2
N
Generic Name : Nicardipine hydrochloride68
Highest Phase : Launched-1981
Therapeutic Group : Treatment of Hypertension
Chemical Structure :
HCl
N
H
O
O
O
CH3 CH3
NCH3
O
NO 2
CH3 CH3
CH3
Generic Name : Amlodipine69
Highest Phase : Launched-1990
Therapeutic Group :    Treatment of Hypertension and Angina Pectoris
Chemical Structure :
N
H
O
O
O
CH3
CH3
O
CH3
O
NH2
Cl
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Generic Name : Aranidipine70
Highest Phase : Launched-1996
Therapeutic Group : Treatment of Hypertension
Chemical Structure :
N
H
O
O
O
CH3 CH3
CH3
O
CH3
NO2
O
Generic Name : Lercanidipine hydrochloride71
Highest Phase : Launched-1997
Therapeutic Group : Treatment of Hypertension and Stroke
Chemical Structure :
N
H
O
O
O
CH3 CH3
NCH3
O
NO2
CH3 CH3
CH3
HCl
Generic Name : Isradipine72
Highest Phase : Launched-1989
Therapeutic Group : Treatment of Hypertension
Chemical Structure :
N
H
O
O
O
CH3 CH3
CH3
CH3
OCH3 N
O
N
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Generic Name : Nilvadipine73
Highest Phase : Launched-1989
Therapeutic Group : Treatment of Hypertension
Chemical Structure :
N
H
O
O
O
CH3 CN
CH3
CH3
O
CH3
NO2
Generic Name : Lacidipine74
Highest Phase : Launched-1991
Therapeutic Group : Treatment of Hypertension
Chemical Structure :
N
H
O
O
O
CH3 CH3
CH3
CH3
O
O
O
CH3
CH3
CH3
Generic Name : Nisoldipine75
Highest Phase : Launched-1990
Therapeutic Group : Treatment of Hypertension
Chemical Structure
N
H
O
O
CH3
CH3
O
O
CH3
CH3 CH3
NO2
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67. Mehler P.S., Coll J.R., Estacio R., Esler A., Schrier R.W., and Hiatt R.,
Circulation, 107(5): 753(2003).
68. Nomura M., Nakaya Y., and Uemora E. et al.,Arzneim-Forsch Drug Res , 53(5):
314(2003).
69. Martell N., Am J Hypertens , 16 (5, Part 2) Abst P-235(2003).
70. Fernandes C.M., Veiga, F.J.B., BMC - Biomed Chromatogr, 17(1): 33(2003)
71. Belal F., J Pharm Biomed Anal , 31(5): 989(2003).
72. Drug Data Rep , 14(4): 316(1992).
73. Pepine C.J., Cooper-DeHoff R.M.,and  Weiss R.J. et al., Am J Cardiol , 91(3):
274(2003).
74. Drug News Perspect , 9(5): 288 (1996).
75. Drug Data Rep , 13(11): 952 (1991).
Looking to the synthetic work done so far in literature and in
continution of our earlier work, few 1,4-dihydropyridines were synthe-
s ized  us ing  mod i f ied  Hantzsch  syn thes is .  Thus ,  the  s ta r t ing
acetoacetanilide derivative was prepared &activated in appropriate sol-
vent & furthur treated with appropriate aldehyde and ammonia at reflux
temperature for several hour to obtain the desired compounds in this
chapter. (Reaction Scheme 1)
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REACTION SCHEME : 1
NH2
+
CH3
O
O
O
CH3
Toluene
NH
O
O CH3
R
R
110 0C
Step - 1
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Where R = Different substitute
REACTION SCHEME : 1
NH
O
CH3
O
F
Cl
NH O
CH3
O
F
Cl
CHO
R
+
N
H
CH3 CH3
NH
OO
NH
F F
ClCl
R
N
HH
H
Methanol Hantzsch synthesis
Step - 2
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Experimental :
Experimental protocols :
Except substituted acetoacetanil ide, all the chemicals were
obtained from industrial sources. The TLC was carried out on silica Gel-
G as stationary phase purchased from Merck India Ltd. Ethyl acetate:
Hexane (4:6) was used as a mobile phase. The other solvent system like
acetone: benzene, methanol: chloroform was also employed but the best
results were obtained in mixture of ethyl acetate and hexane(4:6) .
Preparation of Acetoacetanilide :
3-Chloro-4-Fluoroaniliine (0.1), ethylacetoacetate (0.1 mole) and
caustic lye (0.2gm NaOH+0.5ml water) were heated at 110 oC in 50 ml
toluene as solvent for 10-12 hrs. After completion of reaction, most of
toluene was disti l led out. The reaction mass was cooled at room
temperature and then taken in an ice bath which formed light yellow
crystals of crude acetoacetanilide. It was then extracted with diethyl ether/
petroleum ether and filtered. The ethereal solution was evaporated &
afforded to ger pure acetoaceanilide. Yield 55-65 %.
 TLC System = (Ethyl acetate: Hexane : 4: 6)
 Yield =  55-65%
Elemental Analysis
Calculated        =  C (52.30%) H(3.95%)  N(6.10%)
Experimental               =   C (52.74%) H(3.51%) N(6.39%)
Molecular formula      =  C10 H9ClFNO2
         Formula Weight         =  229.63
M.P.                             =  73-76oC.
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Preparat ion of  4- (3-bromophenyl) -N3,N5-bis(3-Cl ,4-
f luorophenyl) -2 ,6-dimethyl -1 ,4-dihydropyridine-3,5-
dicarboxamide:
        Acetoacetanilide(0.02mol) and 3-chlorobenzaldehyde(0.01mol)
were dissolved in 25ml methanol and heated on water bath till the solid
disappeared in the reaction mass. Concentrated ammonia(3ml) was
added to the reaction and it was further refluxed on a water bath for a
period of 10-12hrs. The completion was monitored by TLC(Merck 60 F 254).
After completion of reaction it was allowed to cool to room temperature
and solid mass appeared in the flask. The product was filtered and
washed with ether. It was recrystallized from ethanol+acetone.
Elemental Analysis
Calculated = C (57.62%) H(3.58%)  N(7.47%)
Experimental =   C (57.74%) H(3.51%) N(7.39%)
Molecular formula =  C27H20Cl3F2N3O2
         Formula Weight =  562.82
M.P. =  220-24oC.
TLC System = (Ethyl acetate: Hexane : 5: 5)
Yield =  45%
Similarly other compounds were prepared by taking different sub-
stituted aromatic aldehydes & acetoacetanilide.
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SPECTRAL STUDY :
The constitutions of newly synthesized compounds were supported
by IR, 1H NMR, Mass and 13C NMR spectral study. The details are as
under.
IR Spectral Study :
Instrument  : SHIMADZU FT IR-8400 Spectrophotometer
Sample technique  :  KBr pellet
Frequency  range  : 400-4000 cm-1
In dihydropyridines, theoretically carbamoyl carbonyl group is
present at C3 and C5  observed  between frequency 1900-1700 cm
-1, while
amide linkage is confirmed due to -NH streching appeared at 3400-
3200cm -1 and -CONH stretching appeared between 3400-3200 cm-1.
Aromatic skeleton frequencies are observed in the range 1600-1400
cm -1. The halogen linkage(C-Cl &C-F) is observed at 800-700 &1200-
1100 cm -1.
In case of   4-(2-Chlorophenyl)-N3,N5-bis(3-Cloro ,4-Fluorophenyl)-
2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxamide (AM-13), a sharp
band of -NH was observed at 3224 cm -1.  The sharp carbonyl band (>C=O)
was seen at 1676cm -1 which is slightly lower due to presence of -NH link-
age compare to 1700 cm -1. The  amide stretching was observed at 3292
cm -1.The aromatic moiety and ring skeleton (like C-C double bond stretch-
ing) were observed at 1600.8, 1494.7, and 1442 cm -1. The halogen(C-
Cl&C-F) group was confirmed due to band observed at frequency 752 &
1122.5 cm -1.
Similarly other compounds were characterized. The tabular form
of IR frequency is given on page 34 & 35.
27
Chapter-1
Synthesis of 1,4-DHP-3,5-dicarboxmide......
1H NMR Spectral Study :-
Instrument :BRUKER AC 300 MHz FT-NMR
Internal reference :TMS
Solven :CDCl3  or DMSO d6
During 1H NMR study of 1,4-DHP’s synthesized in this chapter, a
singlet of methyl proton(-CH3) is observed in the range 2-3 dppm. The
most important identity of 1,4-DHP is achiral proton at C4 position, is
observed as singlet in the region 5-6 dppm. In the aromatic region, two
doublet of 4-Fluoro phenyl ring with J value  6-9Hz. should be observed
but due to presence of fluorine at C23 and C31 position it is observed as
triplet and quartet in the aromatic region. The aromatic protons of the
phenyl ring joined at C4  position shows the signal in the region of 7-9
dppm. Due to presence of methyl protons (-CH3), the -NH of pyridine ring
is very much in downfield  and is observed in the region 1-10 dppm. Due
to presence of carbonyl group (-CO), the -CONH protons are in the
downfield and singal of this proton is observed around 9 dppm.
In 1H NMR spectra of 4-(3-methoxyphenyl)-N3,N5-bis(3-chloro-4-
fluorophenyl )-2,6-Dimethyl -1,4-dihydropyridine-3,5-dicarboxamide
(AM-34), singlet at 2.09 dppm, confirms the presence of two identical
protons of methyl -CH3(C18,C7) group. Achiral proton(C4) is in downfield
due to presence of electron withdrawing group(-OCH3) at C4 phenyl ring
which is confirmed by presence of singlet at 5.07 d ppm. ton is showing
singlet in downfield at 9.22 dppm.
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In the aromatic region, a triplet at 6.92 dppm(J= 8.6 Hz)  and mul-
t ip le t  a t  7 .50 d ppm(J=3.79Hz)  conf i rms amide l inkage o f  -CH
(C22,C24,C31,C33) and -CH(C21,C25,C34,C30) of the phenyl ring with moiety.
Meta coupling of Nitrophenyl at C4 (-CH13) is obtained at 7.67 dppm(J =
7.5 Hz) as doublet of doublet (d,d) due to coupling with -CH(C13) and
-CH(C14), while one triplet of -CH(-C14)is seen at 7.39 dppm and singlet
of -CH(-C11)at  8.79 dppm. The -NH (N19,N28)proton is showing singlet in
downfield at  9.22 dppm .
Similarly other derivatives of the series are confirmed. The NMR
data mentioned on page 36-39.
Mass Spectral Study :-
Instrument : VG 70-S (70eV) Spectrograph for El
Instrument : JEOL SX 102/DA-6000 Spectrograph for FAB
The molecular ion peak is in concormitant with the molecular weight.
The newly synthesized compounds were subjected to FAB Mass study.
The Fast bombardment study revealed the Molecular ion peak, base
peaks and other relevant fragmentation pattern to confirm the structure
of the molecules.
In  the Fab Mass o f  4- (3-Phenoxyphenyl )-b i s (3-Ch loro-4-
Fluorophenyl )-2,6-dimethyl-1,4-D ihydropyridine-3,5 dicaboxamide
(AM-25), base peak is observed at 620.0 m/z, while molecular ion peak
is also at 620.00 m/z.
In  the  Fab Mass o f  4- (2-ch loropheny l ) -b i s (3-Ch loro-4-
Fluorophenyl )-2,6-dimethyl-1,4-dihydropyridine-3,5 dicaboxamide
(AM-13), base peak is observed at 417.0 m/z, while molecular ion peak
is  at 563.00 m/z as (M+1) peak.
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In the FAB Mass of 4-(3-bromophenyl )-bis(3-chloro-4-fluorophenyl)-
2,6-dimethyl-1,4-dihydropyridine-3,5-dicaboxamide (AM-15) base peak
is at m/z 154.00 and the molecular ion peak is observed at m/z 608.00
(M+1) peak..
In  the  Fab Mass o f  4- (4-methoxypheny l ) -b i s (3-ch lo ro -4-
fluorophenyl)-2,6-dimethyl -1,4-dihydropyridine-3,5-dicaboxamide (AM-26)
base peak is at m/z 449.0, while the molecular ion peak is observed at
m/z  558.0 (M+).
The mass fragmentation pattern of newly synthesized molecules
are in total agreement with the suggested structures.
13C NMR :
The compounds AM-13, AM-15, AM-25 and AM-26 were subjected
for 13C NMR spctroscopy and the results of these data shows the pre-
dicted sturctures is in agreement with the carbon skeletons of respective
compounds.
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NH
OO
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FCl
A M-13
IR Spectrum of 4-(2-chlorophenyl) -N 3,N 5-bis  (3-Chloro-4-
fluorphenyl)-2, 6-dimethyl -1, 4-dihydro-3, 5-pyridinedicarboxamide
(AM-13)
Type Vibration mode Frequency cm-1
Amine -NH str. 3224.8
Amide
>C=O str. 1676.0
>C-N str. 1600.8
Methyl
-CH str. (Asym.) 2927.7
-CH str. (sym.) 3066.8
Aromatic
>C=C< ring str.
vibn.
1494.7
1652.8
o.o.p.bending vib.
(1,3,4-tri sub.)
752.2
810.0
Halogen C-Cl & C-F str. 688 &1122.5
Instrument                                     : SHIMADZU FT IR-8400
Sample technique                         : KBr Pellet
Frequency range                           : 4000-400 cm-1
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AM-15
Type Vibration mode Frequency cm-1
Amine -NH str. 3280.7
Amide
>C=O str. 1660.6
>C-N str. 1598.9
Methyl
-CH str. (Asym.) ~2900.0
-CH str. (sym.) 3062.7
Aromatic
>C=C< ring str.
vibn.
1461.1
1469.7
o.o.p.bending vib.
(1,3,4-tri sub.)
781.1
817.5
Halogen C-Cl & C-F str. ~711 & 1118.6
 IR Spectrum  of  4-(3-bromophenyl)-N
3,N 5-bis  (3-Chloro-4-
fluorphenyl)-2, 6-dimethyl -1, 4-dihydro-3, 5-pyridinedicarboxamide
(AM-15)
Instrument                                     : SHIMADZU FT IR-8400
Sample technique                         : KBr Pellet
Frequency range                           : 4000-400 cm-1
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IR Spectrum  of  4-(3-phenoxyphenyl)-N 3,N 5-bis (3-Chloro-4-
fluorphenyl)-2, 6-dimethyl -1, 4-dihydro-3, 5-pyridinedicarboxamide
(AM-25)
Type Vibration mode Frequency cm-1
Amine -NH str. 3309.6
Amide
>C=O str. 1685.7
>C-N str. 1604.7
Methyl
-CH str. (Asym.) 2923.3
-CH str. (sym.) 3055.0
Aromatic
>C=C< ring str.
vibn.
1452.3
1660
o.o.p.bending vib.
(1,3,4-tri sub.)
771.5
875.6
Halogen C-Cl & C-F str. 694 & 1120.6
Instrument                                    : SHIMADZU FT IR-8400
Sample technique                         : KBr Pellet
Frequency range                           : 4000-400 cm-1
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IR Spectrum of 4-(2,5dimethoxyphenyl)-N3,N 5-bis (3-Chloro-4-
fluorphenyl)-2, 6-dimethyl -1, 4-dihydro-3,5-pyridinedicarboxamide
(AM-49)
Type Vibration mode Frequency cm-1
Amine -NH str. 3288.4
Amide
>C=O str. 1668.7
>C-N str. 1604.7
Methyl
-CH str. (Asym.) 2939.3
-CH str. (sym.) 3078.2
Aromatic
>C=C< ring str.
vibn.
1429.2
o.o.p.bending vibn.
(1,3,4-tri sub.)
756.0
812.0
Halogen C-Cl & C-F str. ~686.0 &1128.3
Instrument                                    : SHIMADZU FT IR-8400
Sample technique                         : KBr Pellet
Frequency range                           : 4000-400 cm-1
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N
H
NH
OO
NH
CH3 CH3
Cl Cl
FF
Cl
AM-13
1H NMR Spectrum of 4-(2-chlorophenyl)-N,N-bis (3-chloro-4-fluoro
phenyl)-2, 6-dimethyl -1, 4-dihydropyridine-3, 5-dicarboxamide
(AM-13).
Instrument  : BRUKER AC 300 MHz  FT-NMR
Standard                  : TMS
Solvent                     :  DMSO d6
C h e m i c a l
S h i f t
d  p p m
N o .  o f
P r o t o n
M u l i p l i c i t y I n t e r e n c e J .  V a l u e
2 . 0 7 6 H s - C H 3 -
5 . 4 0 1 H s H 1 -
7 . 0 8 - 7 . 1 3 2 1 H m H 2 7 -
7 . 1 9 - 7 . 2 1 1 H d H 1 3 J 1 3 , 1 4 = H 2
7 . 2 5 - 7 . 3 4 3 H q C 2 1 , 2 1 , 1 9 -
7 . 4 2 - 7 . 4 7 3 H m C 2 2  C 3 1  C 1 7 -
7 . 8 7 - 7 . 9 0 2 H d ( d ) C 1 4 C 2 8 J 1 4 , 1 3 = 9 H
8 . 2 8 1 H s N H -
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1H NMR Spectra of 4-(3-bromophenyl)-N3,N5-bis (3-chloro-4-fluoro
phenyl)-2, 6-dimethyl -1, 4-dihydropyridine-3,5-dicarboxamide
(AM-15)
N
H
NH
OO
NH
CH3 CH3
Cl Cl
FF
Br
AM-15
C h e m i c a l
Shi f t
d  p p m
N o .  o f
P r o t o n
Mulipl ici ty I n t e r e n c e J .  Va lue
2 . 0 9 9 3 H X 2 s C - C H 3 ---
5 . 0 9 3 1 H s Ar-H 1 ---
7 .19 2H d  ( b ) Ar-H 8,9 ---
7 .27 -7 .36 5H m
Ar-H 7,11,9
Ar-H 2 3 , 1 6
J , 2 3 , 2 4 = 9 H2
J , 1 6 , 1 7 = 9 H2
7 .46-7 .51 2H m Ar-H 2 7 , 2 0 ---
7 .87 2H d  ( b )
Ar-H 2 4
A-rH 1 7
J ,24 ,23=H 2
J , 1 7 , 1 6 = 9 H2
8 .27 - N H s  ( b ) -NH --
Instrument :BRUKER AC 300 MHz  FT-NMR
Standard                  : TMS
Solvent                    :  DMSO d6
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1H NMR Spectra of 4-(4-chlorophenyl)-N3,N5-bis (3-chloro-4-fluoro
phenyl)-2, 6-dimethyl -1, 4-dihydropyridine-3, 5-dicarboxamide
(AM-27)
N
H
NH
OO
NH
CH3 CH3
Cl Cl
FF
Cl
AM-27
C h e m i c a l
S h i f t
d  p p m
N o . o f
P r o t o n
M u l i p l i c i t y I n t e r e n c e J .  V a l u e
2 . 0 8 3 H X  2 S i n g l e t - C - C H 3 -
5 . 0 8 1 H S i n g l e t A r  H 1 -
7 . 2 0 - 7 . 3 3 6 H p e n t l e t
A r  H 7 ,  8  1 0
A r  H
1 6 ,  2 3
J 1 0 , 1 1 = J 1 1 -
, 1 0 =  9 H z
7 . 4 6 - 7 . 5 1 2 H m u l t i p l a t e
A r  H 2 7
A r  H  2 0
-
7 . 8 6 - 7 . 8 9 2 H
d o u b l e
d o u b l e t
A r  H 2 4
A r  H 1 7
A r  H  2 4 , 2 3 =
8 H z
A r  h  1 7 , 6 =
8 . 7  H Z
8 . 2 4 - N H S i n g l e t - N H -
Instrument  : BRUKER AC 300 MHz  FT-NMR
Standard                  : TMS
Solvent                     : DMSO d6
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N
H
NH
OO
NH
CH3 CH3
Cl Cl
FF
OCH3
AM-34
C h e m i c a l
S h i f t
d  p p m
N o .  o f
P r o t o n
M u l i p l i c i t y I n t e r e n c e J .  V a l u e
2 . 0 9 6 H S i n g l e t - C - C H 3 -
3 . 6 2 3 H S i n g l e t - O C H 3 -
5 . 0 7 1 H S i n g l e t - A r  H 1 -
6 . 6 6 - 6 . 6 9 1 H D o u b l e
D o u b l e t
A r  H 1 0 J 1 0 , 9 = 9 H z
J 1 0 , 8 = 2 - 4 H z
6 . 7 5 1 H S i n g l e t A r  H 2 -
6 . 8 0 1 H  D o u b l e t A r  H 8 J 8 , 9 = 7 - 8 H z
7 . 1 3 8 1 H T r i p l e t A r  H 9
J 9 , 1 0 = 9 H z
J 9 , 8 = 7 - 8 H z
7 . 3 0 2 H T r i p l e t
A r  H 1 6
A r  H 2 7
J 1 6 , 1 7 = 9 H z
J 2 7 , 2 6 = 9 H z
7 . 4 9 2 H Mul t ip la te
A r  H 2 0
A r  H 2 3 -
7 . 9 0 5 2 H
D o u b l e
D o u b l e t
A r  H 1 7
A r  H 2 6
J 1 7 , 1 6 - 9 H z
J 2 6 , 2 7 = 9 H z
8 . 1 8 - S i n g l e t - N H - -
Instrument : BRUKER AC 300 MHz  FT-NMR
Standard                  : TMS
Solvent                    :  DMSO d6
1H NMR Spectra of 4-(3-methoxyphenyl)-N3,N5-bis (3-chloro-4-fluoro
phenyl)-2, 6-dimethyl -1, 4-dihydropyridine-3, 5-dicarboxamide
(AM-34)
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AM-13
Instrument  :  BRUKER AC 300 MHz  FT-NMR
Solvent      :  DMSO d6
13C Spectra of 4-(2-chlorophenyl)-N3,N5-bis(3-chloro-4-fluoro
phenyl)-2,6 dimethyl -1,4-dihydropyridine-3,5-dicarboxamide
(AM-13)
C h e m i c a l
S h i f t
d  p p m
N o .o f  c a r b o n s I n t e r f e r e n c e
3 9 . 8
1 0 5 . 6
1 1 9 . 6
1 1 8 . 4
1 3 6 . 8
1 3 8 . 5
1 4 4 . 8
1 3 0 . 1
1 3 0 . 9
1 2 8 . 8
1 2 7 . 7
1 1 9 . 4
1 5 1 . 2
1 5 4 . 4
2 C
1 C
1 C
4 C
2 C
2 C
1 C
2 C
2 C
2 C
2 C
2 C
1 C
1 C
- C H
3
( 1 2 , 1 3 )
- C H ( 1 )
- C H ( 6 )
-C H ( 7 , 8 , 9 , 1 0 )
- C H ( 1 8 , 2 5 )
- C H ( 1 9 , 2 6 )
- C H ( 1 1 )
- C H ( 3 , 4 )
- C H ( 2 , 5 )
- C H ( 1 5 , 2 2 )
- C H ( 2 0 , 2 7 )
- C H ( 1 6 , 2 3 )
- C H ( 1 4 )
- C H ( 2 1 )
N
H
CH3 CH3
NH
O
NH
Cl
F
Cl
F
O
Cl
1
2
34
5
6
7
8
9
10
11
12 13
14 15
16
17
18
19
20
2122
23
24
25
26
27
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AM-15
13 C Spectra of 4-(3-bromophenyl)-N3,N5-bis(3-chloro-4-fluoro
phenyl)-2,6-dimethyl -1,4-dihydropyridine-3,5-dicarboxamide
(AM-15)
    C h e m ic a l
S h i f t
d  p p m
N o .o f  c a r b o n s In t e r f e r e n c e
3 8 .8
1 0 5 . 3
1 1 6 . 6
1 3 6 . 8
1 3 8 . 9
1 2 9 . 2
1 3 0 . 2
1 2 1 .1
1 2 1 . 9
1 2 1 . 2
1 4 9 . 8
1 5 1 . 6
1 5 4 . 8
1 6 7 . 7
2 C
1 C
1 C
2 C
2 C
2 C
2 C
2 C
2 C
4 C
2 C
2 C
1 C
2 C
- C H
3
( 1 2 , 1 3 )
- C H ( 1 )
- C H ( 1 )
- C H ( 3 , 4 )
- C H ( 2 ,5 )
- C H ( 2 2 ,1 5 )
- C H ( 1 6 ,2 3 )
- C H ( 2 0 ,2 7 )
- C H ( 1 9 ,1 6 )
- C H ( 7 , 8 , 9 , 1 1 )
- C H ( 1 8 ,2 5 )
- C H ( 1 7 ,2 4 )
- C H ( 1 0 )
- C H ( 1 4 ,2 1 )
N
H
CH3 CH3
NH
OO
NH
Cl
F
Cl
F
Br
1
2
34
5
6
7
8
9
10
11
12 13
14 15
16
17
18
19
20
2122
23
24
25
26
27
Instrument  :  BRUKER AC 300 MHz  FT-NMR
Solvent      :  DMSO d6
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AM-25
13 C Spectra of 4-(3-phenoxyphenyl)-N3, N5-bis(3-chloro-4-fluoro
phenyl)-2,6-dimethyl -1,4-dihydropyridine-3,5-dicarboxamide
(AM-25)
N
H
CH3 CH3
NH
OO
NH
Cl
F
Cl
F
O
1
2
34
5
67
8
9
10
11
1213
14
15
16
17
18 19
2021
22
23
24
25
26
27 28
29
30
31
32
33
    C h e m i c a l
S h i f t
d  p p m
N o . o f  c a r b o n s In t e r f e r e n c e
3 9 . 2
1 0 5 . 5
1 1 9 . 2
1 1 6 . 6
1 1 7 . 8
1 1 8 . 4
1 1 9 . 8
1 2 1 . 0
1 2 2 . 8
1 2 6 . 9
1 2 9 . 9
1 3 0 . 0
1 3 6 . 8
1 3 8 . 5
1 5 6 . 3
1 5 6 . 8
1 5 6 . 9
1 6 7 . 8
2 C
1 C
1 C
2 C
2 C
2 C
4 C
2 C
2 C
1 C
1 C
1 C
1 C
1 C
1 C
1 C
1 C
1 C
- C H 3 ( 1 8 , 1 9 )
- C H ( 6 )
- C H ( 1 )
- C H ( 2 2 , 2 9 )
- C H ( 2 6 , 2 3 )
- C H ( 2 5 , 3 2 )
- C H ( 7 , 8 , 9 , 1 1 )
- C H ( 1 3 , 1 7 )
- C H ( 1 4 , 1 6 )
- C H ( 1 5 )
- C H ( 2 1 )
- C H ( 2 8 )
- C H ( 2 3 , 3 0 )
- C H ( 2 4 , 3 1 )
- C H ( 1 0 )
- C H ( 2 0 )
- C H ( 2 7 )
- C H ( 1 2 )
Instrument  :  BRUKER AC 300 MHz  FT-NMR
Solvent      :  DMSO d6
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AM-26
13C Spectra of 4-(4-methoxyphenyl)-N3,N5-bis(3-chloro-4-fluoro
phenyl)-2,6-dimethyl -1,4-dihydropyridine-3,5-dicarboxamide
(AM-26)
     C h e m i c a l
S h i f t
d  p p m
N o . o f  c a r b o n s I n t e r f e r e n c e
3 9 . 5
5 5 . 5
1 0 6 . 2
1 1 6 . 6
1 1 8 . 8
1 1 9 . 2
1 1 9 . 6
1 2 0 . 8
1 1 9 . 8
1 3 8 . 3
1 3 6 . 9
1 5 1 . 4
1 5 4 . 6
1 5 7 . 8
1 6 7 . 8
2 C
1 C
1 C
1 C
1 C
2 C
2 C
2 C
1 C
2 C
2 C
2 C
2 C
2 C
2 C
- C H 3 ( 1 2 , 1 3 )
- C H ( 2 8 )
- C H ( 6 )
- C H ( 1 )
- C H ( 2 6 , 1 9 )
- C H ( 2 0 , 2 7 )
- C H ( 1 6 , 2 3 )
- C H ( 7 , 1 1 )
- C H ( 8 , 1 0 )
- C H ( 3 , 4 )
- C H ( 2 , 5 )
- C H ( 2 2 , 1 5 )
- C H ( 1 8 , 2 5 )
- C H ( 1 7 , 2 4 )
- C H ( 1 4 , 2 1 )
N
H
CH3 CH3
NH
OO
NH
Cl
F
Cl
F
OCH3
1
2
34
5
6
7
8
9
10
11
12 13
14 15
16
17
18
1920
2122
23
24
25
26
27
Instrument  :  BRUKER AC 300 MHz  FT-NMR
Solvent      :  DMSO d6
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INTRODUCTION  :
Pyrano fused heterocycles are commercially important as antibac-
terials1-4, antihistamines5, antimicrobials6, enzyme substrates7 and alka-
loids8. Several patents describe the synthesis and technical importance of
pyrano fused derivatives in high technology applications such as liquid crys-
tal display devices9, ink-jets10, photochromic materials11, electroluminescent
materials12, and fluorescent whitening agents13.
Yoshiuki Kawase et al14, has studied some benzofuro[2,3-b]quinolines
and benzofuro[3,2-c]quinolines activities as mutagens, carcinogens and
antitumour polycyclic heteroaromatic compounds.
1. Holmes R. R. ,Conrady J. , and., Gutherie J. ;  J . Am. Chem. Soc., 76, 2400,
(1954) .
2. (a)Skraup Z.H., Montash,1,316,(1880) (b) Kuster A.,Klin.,Wochenschr.,41,1125
(1909)
3. (a) Papech Burtner, J.Ame.Chem. Soc., 58, 1314, (1935) (b) Ger. Patent
117,767 (1899).
4. Chu D.T., Q.Li,Copper C.S.,Fung A.K.,Lee C.M., Plattner J.J.,Ma J.and Wang
W., Abbott Laboratories, PCT int. Appl. WO9639407(1996), Chem Abstr.,
126, 117990(1997)
5. Amin K.M., Egypt. J. Pharm. Sci., 34, 741 (1994); Chem Abstr., 122,
105717 (1995).
6. Abdel-Hafez A.A., J. Chem. Tech. Biotechnol., 55, 95 (1992).
7. Sabnis R.W.,Mao F.,Naleway J.,Olson N., and Haugland R.P., Molecular Probes
Inc., U.S.Patent, 5576424 (1996); Chem Abstr, 126, 86521 (1997).
8. W.H. Watters and V.N. Ramachandran, J. Chem. Res. (S), 184 (1997).
9. Iwanaga H. and Naito K., Toshiba Corp., Japan Kokai Tokkyo Koho,JP 0987630
(1997), Chem Abstr., 127, 26627 (1997).
7. Yuda K., Kawashita H. and Harada N., Taoka Chemical Co. Ltd., Japan Kokai
Tokkyo Koho, JP 08295690 (1995); Chem Abstr., 126, 61482(1997).
8. Hara T. and Momota J., Tokuyama Corp., Japan Kokai Tokkyo Koho,
JP 08295690 (1995); Chem Abstr., 126, 89395 (1997).
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N
O
O
O
O O
NO
F F
F
O
O
O
O
O
Pyrano quinolones are structurally related to antihistaminic and anti-
allergic drug Romet ( I)12-15 and 4-oxo-10-pyrano[3,2-g]quinoline-2,8-dicar-
boxylic acid16-17 (II).
9. Wehrmann R.,Elschner A.,Michaelis S.,Thurm S., Claussen U.,Egeret G.
and Karg S., Bayer AG, European Patent Appl, EP 797376 (1997), Chem
Abstr., 127, 301086 (1997).
10. Sumitani M. and Shiraiwa N., Nippon Kayaku Co. Ltd., Japan Kokai Tokkyo Koho,
JP 09143383 (1997).
11. Seiji Yamaguchi, Kunihiro Tsuzuki, Minoru Kinoshita, Yutak Oh-hira and Yoshiyuki
Kawase, J. Hetrocyclic Chem., 26, 281 (1989).
12. Drug Data Rep, 1988,  10(5): 368.
13. Drugs Today,  1988, 24(5): 289.
14. Prous J., and Castañer J., Drugs Fut, 1987, 12(1): 37.
15. Drug Data Rep, 1984, 6(1): 26.
16. Drug Data Rep, 1986, 8(2): 133.
17. Marco JL, de los Rios C, Carreiras MC, Banos JE, Badia A, and Vivas NM.,
Bioorg Med Chem., 2001 Mar; 9(3):727-32.
18. Yamada N, Kadowaki S, Takahashi K, and Umezu K.,Biochem Pharmacol.
1992 Sep 25;44(6):1211-3
(II)
(I)
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O
NH
O O
-O
O
CH3
CH3
O
NH
O O
HO
O
CH3
CH3     (III)          (IV)
Structurally different pyrano quinolines are reported in literature. For
e.g. Inositol-1,4,5-trisphosphate-3-kinases (IP3K) A, B and C as well as
inositol polyphosphate multikinase (IPMK) catalyze the first step in the for-
mation of the higher phosphorylated inositols InsP5 and InsP6 by metaboliz-
ing Ins(1,4,5)P 3 to Ins(1,3,4,5)P 4. In order to clarify the special role of these
InsP3 phosphorylating enzymes and of subsequent anabolic inositol phos-
phate reactions, a search was conducted by Hillemeier K et al19, for potent
enzyme inhibitors starting with a fully active IP3K-A catalytic domain. In
this search epigallocatechin-3-gallate (EGCG, 120 nM)(V), was identified
as potent inhibitors with IC50 < 200 nM.
O
O
O
O
O
O
O
O
O
O
O
19. Mayr GW, Windhorst S, Hillemeier K., J Biol Chem. 2005 Jan 19.
20. Knierzinger A. and Wolfbeis O. S., J. Het. Chem., 17, 225 (1980).
21. Kappe T., and Mayer C., Synthesis, 524 (1981).
(V)
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Knierzinger and Wolfbeis20 reported 2H, 5H-pyrano[3,2-c]quinoline
diones(VII).
Kappe and Mayer21 studied formation of heterocycles at C 3-C4 posi-
tion by various b-keto esters. They prepared many pyranoquinolines(VIII)
as under.
They have also reported modified Pechmann condensation5  (IX)  with
respect to different condensates in presence of ammonium acetate.
NHR1
R
N O
OH
R
R1
N
O N
CH
R1
R
O
C6H5
N
O
R
OR1
O
R2         (VII)
Where R  = -H, -CH3,
           R1= -H, -OCH3, -N(CH3)2
           R2= -SO2C6H5, COOC2H5, CN
N
R
O
OH
R1
N
O
R
R1
O
O
R2
R3
R2
(R4)2N COOC2H5
R3
NH4OAc
N
R
O
OH
N
O
R
R1
O
O
COOC2H5
O
NH4OAc
Where R = -H, -CH3, -CH2COOC2H5    R1, R2, R3, = -H, -CH3
        (VIII)
       (IX)
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Vladimir and coworkers22 have synthesized some fused derivative
from pyrano-2-ones as well as 4-hydroxy-2-quinolones (X). It possesses
an unsymmetrically substituted diactivated methylene group and might ex-
ist in two or more tautomeric forms.
Karemmerer and coworkers23 prepared substituted N-alkyl-3-nitro -
pyrano[3,2-c]quinoline-2-ones (XI) that were tested as antiallergic agents.
Thus, N-ethyl-m-chloroaniline  was reacted with 2,4-dichlorodiphenyl mal-
onate in tetralin and the product was nitrated to obtain above compounds.
Trkovnik et al.24 prepared fused pyrano-4-quinolones derivatives (XII).
These derivatives were tested for antibacterial against various microor-
ganism like
22. Kepe Vladmir, Kocevar Marijan, and Polanc Slovenko, Heterocycles,  41(6),
(1995).
N
H
O
OH
+ R NH
O
COOH
CH(OC2H5)3
CH3COOCH(OC2H5)3
OR
OR
(CH3)2NCH(OCH3)2
AC2O
N
H
O
O
NHCOR
       (X)
Where R = -CH3, C6H5
        (XI)
Where R  = -H, alkyl
                                   R1 = -H, alkyl, alkoxy,
Cl NH
R
+
O
CH2
O
CH2
Cl
Cl
Cl
Cl
N
O
O
OH
R
OCltetralin
N
O
O
OH
R
OCl
Nitration
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S. aureus, E. faecalis, P. aenrgiizosa, Streptococcus pyogens, Strepto-
coccus faecalis, Staphylococcus aureus, Staphylococcus epiderms etc.
Masotoshi et al.25 have reported pyranoquinolines and furoquinolines
derivatives(XIII) for antibacterial agents against methicillin resistant Sta-
phylococcus aureus. These derivatives were prepared by treatment of o-
amino benzaldehydes with R 4R5C:(CH2)nCHR3OH in the presence of acid
catalysts and alkyl orthoformates.
El-Taweel and Ibrahim 26 synthesized several polysubstituted
pyrano[3,2-c]quinolones from readily available 4-hydroxy-2-quinolinones.
These compounds were evaluted for bactericidal activity against Gram
negative and Gram positive bacteria.
N
H
O
H5C2OOC
O
O
R
Where R = -H, OH, -CH3
    (XII)
CHO
NH
R2
N
O
R3
R4
R5
R2
R1 R1
R1R5C:CH(CH2)nCHR3OH
P-TSA
(XIII)
Where n  = 1-3, R1 = -C1-6 alkyl, alkoxy, halo
           R2= -R6SO2,  R6 = -C1-6alkyl, C1-10aryl
          R3= -C1-6 alkyl, R4, R5 = -C1-6 alkyl, C6-10 aryl, heterocyclyl
N
R
O
OH
R2
N
O
N
S
N
R
O
O
O
           (XIV)
 Where R1 = CH3, C2H5, R2 = -H, -COCH3, CHO
23. Karemmerer F. J., Ulrich G., Alpermann H. G., Ger. Offen 2 , 836, 470 (1980).
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Atwal Karnail27 in 1991 have prepared pyrano[3,2-c]quinolin-5-ones
as ca lc ium channe l  b lockers .  The 4-hydroxy-2-qu ino lone was
cyclocondensed with 3-methyl-2-butenal and the product N-benzylated to
give after bromination pyranoquinolinone, which was aminated to give (XV)
(R2= -OH, R7= -NH2). It was condensed with 4-chlorobutanoyl chloride to
give (XVI).
Kyotani and coworkers28 have reported pyranoquinolines (XVII) as
cardiovascular agents. The general structure of the compound is as under,
N
H
O
OH
N
H
O
O
O
CH3
CH3
N
O
O
NH2
CH3
CH3
OH
CH2C6H5
N
O
O
NH
CH3
CH3
OH
O
Cl(CH2)3COCl
CH2C6H5
1. N-benzylation
2. Bromination
3. Amination
Cl(CH2)3COCl
(H3C)2C.CHCHO
   (XVI)       (XV)
N
H
O
O
R1
R2
R3
R4
Where R1 = -alkyl, R2 = -H, -OH, alkoxy etc.,
           R3 = -H, alkyly   R4 = -H, alkyl
 (XVII)
24. Trkovnik Mladen, Iveric Z., Kelneric Z.,  EP 820, 998 (1998).
25. Masotoshi A., JP 2002 322 ,181 (2002).
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Gurjar and coworkers30 have reported calanolide A analogs(XIX) as
an anti-HIV agents, these analogs have pyranoquinolone skeleton.
Kuo-Hsiung Lee and coworkers31 have synthesized 3’,4’-di-O-(-)-
camphanoyl-(+)-cis-Khellactone(DCK) lactam analogs. These analogs were
prepared by doing bioisosteric replacement in Suksdorfin derivative.
Suksdorfin isolated from the fruit of Lomatium suksdorfil. It is a Khellactone
which possesses anti-HIV activity. Modification of khellactone yielded 3’,4’-
di-O-(-)-camphanoyl-(+)-cis-Khellactone. This compound has very potent
anti-HIV activity in acutely infected H9 lymphocytes with an EC50 value of
0.00024 mM and a therapeutic index of 119, 333 compound was about
N
H
O
R3
R2
R1
O
COOR
O
      (XVIII)
           Where R  = alkyl, sub. alkyl
           R1, R2, R3, = H, alkyl, sub. alkyl,
       alkoxy, aryl, halo etc.
N OO
O
R1
R
R6
R7
R5R4
R3
R2
CH3
CH3
    (XIX)
Where R = CH3, R1 = H or Sub. aryl
R2- R5 = H or CH3
R6, R7 = -H, OH, aryloxy
Morinaka et.al 29 had synthesized several ester derivatives of
quinolopyran-4-one, 2-carboxylic acid (XVIII). These novel compouds are
especially useful as antiallergic and for treatment of asthma.
26. El-Taweel F. M. A., Ibrahim D. A., Bollettino Chimico. Farmaceutico, 140(5),
287-296 (2001).
27. Karnail Atwal, US 5,070,088 (1991).
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225 fold more active than AZT as  comparing their EC50 values in assay.
Kuo-Hsiung and coworkers32 reported Seselin analogs which are
pyrano[6 ,5-h ]qu ino l ine-2-ones der iva t ives.  Sese l in  an angular
pyranocoumarin displays various biological activities including antifungal
and anti-HIV activities. In particular, Seselin exhibited moderate cytotoxic-
ity in a mechanism based anticancer bioassay employing DNA repair defi-
cient and repair proficient yeasts. The bioisosteres of Seselin were pre-
pared by replacing oxygen atom of the pyranocoumarin nucleus by nitro-
gen atom. These compounds were evaluated for their in vitro cytotoxicity
against a panel of human tumor cell lines. The most active compound
showed significant cytotoxic activity with GI50 values in the micromolar range.
OO O
CH3
CH3
O
O
CH3
O
O
CH3
CH3
N
H
O O
CH3
CH3
O
O
CH3
CH3
O
CH3
O
O
O
CH3
CH3
OCH3
OO O
CH3
CH3
N
H
O O
CH3
CH3
CH3
         Suksdorfin Suksdorfin analog
Seselin   DMPQ
28. Kyotani Y., Tsutomu T., Juji K., JP 05, 310,744  (1993).
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Folescutol(XX), which posses a morpholine ring attached to cou-
marin via -CH2- link proved to be a capillary protectant drug.
33
O O
N
HO
HO
O
Folescutol
NEW DRUG MOLECULES UNDER CLINICAL STUDY:
In recent years, many new drug molecules which are under study from
phase-I to Phase-IV clinical trials for different pharmacological  action have
shown that the basic characteristic of aryl amine behave as hidden amine
and has attracted many medicinal chemists to incorporate this feature in
drug design.
Few such examples are as under:
(XX)
29. Morinaka Y., Takahashi K.,   US 4, 298, 610 (1981).
NN O
N
OH
Drug Name : Pirodomas35
Chemical Structure :
Chemical Name : 4-Hydroxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-
naphthyridin-2(1H)-one
Phase : Phase II
Activity : Antiallergy/Antiasthamatic Drug
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N
O
N
H
O
HN
H
Cl
Chemical Name : N-Allyl-4-(2-ethylphenylamino)-8-thoxyquinoline-
3-carboxamide hydrochloride
Phase : Preclinical
Activity : Antiulcer Drug
Drug Name : 138586-41-1(CAS No.)36
Chemical Structure :
N
N
HN
O
HN
HN
Cl
Chemical Name : 4-(3-Chlorophenylamino)-N-methylyrrolo yrrolo
[2,3- d]pyrimidine-6-carboxamide
Phase : Biological Testing
Activity : Oncolytic Drug
Drug Name : CGP-74321(Company Code, Novartis)39
Chemical Structure :
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Drug Name : CGP-76627(Company Code, Novartis)40
Chemical Structure
N N
N
N
N
N
N Cl
Chemical Name          :  N3-(3-Aminobenzyl)-N4-(3-chlorophenyl)-1H-
pyrazolo[3,4-d]pyrimidine-3,4- diamine
Phase : Biological Testing
Activity : Oncolytic Drug
Drug Name : Not Reported41,42
Chemical Structure :
N
N
O
N O
O
NH
O
Br
Chemical Name : 4-(2-Bromo-5-methoxyphenylamino)-6-methoxy-
7-[3-(4-morpholinyl)propoxy] quinoline-3-
 carbonitrile
Phase : Biological Testing
Activity : Oncolytic Drug
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SYNTHETIC ASPECTS:
Shah and Vora43 synthesized many 4-aryl amino coumarins and stud-
ied their anti-HIV activity. All the target compounds were tested against the
replication of HIV-1 (III-B)44 and HIV-2 (ROD)45 at subtoxic concentration in
acutely infected MT-4 cell lines.46,47
The tested compounds were found to be very less active. The poor
activity may be attributed to the poor solubility of the compounds. From the
activity data of the above compounds, it may concluded that the substitu-
tions present on the coumarin skeleton did not play any important role in
anti-HIV activity. These results help us to desing new set of synthetic mol-
ecules possessing improved solublity and with basic structue modification
required for anti-HIV acitivity.
The compounds were studeid for the antituberculosis activity at TAACF.
Many compounds were synthesized for obtaining better structure-activity
reationship.
R = Cl, H, OCH3, CH3,------
R’= H, CH3, di-CH3,-----
O
NH
O
R
R’
30. Gurjar M. K., Sharma G. V. M., Illangovan A., Narayanan V., US 6,191,279
(2001).
31. Yang Zheng-Yu, Xia Yi, Xia Peng, Yoko Tachibana, Kenneth F. Bastow  and Lee.
Kuo-Hsiung, Bioorg. Med.Chem.Lett. , 9, 713-716 (1999).
32. Yang Zheng-Yu, Xia Yi, Xia Peng, Brossi Arnold, Cosentino L. M., and Lee
KuoHsiung, Bioorg. Med.Chem. Lett. , 10, 1003-1005 (2000).
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WORK DONE FROM THIS LABORATORY:
R = Cl, H, OCH3, CH3,------
R’= H, CH3, di-CH3,-----
No. R R' Reference
1
Different 4-chloro-
coumarins
Different aromatic
amines
48
2 5,6-benzo-4-chloro
coumarins
Different aromatic
amines
49
3 Different 4-
hydroxycoumarins
Different aromatic
amines
50
4 Different 4-
hydroxycoumarins
3-choloro-4fluoroanilin-
e,4-methoxyaniline, 3-
choloraniline
51
5
Different 4-
hydroxycoumarins
4-fluoroaniline,
cyclohexylamine, 4-
morpholine
52
O
NH
O
R
R’
33. Tarayre J.P., et al., Anna Pharm, France, 33, 467 (1975).
34. Rampa A., and Carrara M.; Drug Fut, 012 (01), 22 (1987).
35. Blythin  D.J., and Gala D.; Drugs Fut, 16 (12): 1099 (1991).
36. Uchida M., Morita S., Otsubo K.,Shimizu T., and  Yamasaki K, US 5215999,  June 1,
1993 Drug Data Rep 1995, 17 (10): 919.
38. Fischer R.W., and Misun M.; Org Process Res Dev , 5(6): 581 (2001).
39. Drug Data Rep  1998, 20 (5): 444.
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40. Drug Data Rep , 20(5), 444 (1998)
41. Drug Data Rep , 23(7), 710 (2001)
42. Wang Y.D., Boschelli D.H., and Ye F. ; 221st ACS Natl Meet (April 1-5, San
Diego) 2001, Abst MEDI 144.
43. Vipul Vora, Ph.D Thesis, Saurashtra University, Rajkot (2000).
44. Popovic M.M. G., Read S.E., and Gallo R.C., Detection, Isolation and
continous production of cytopathic retroviruses(HTLV-III) from patients with
AIDS and pre-AIDS. Science , 224, 497-500 (1984).
45. Clavel F., Guyader M., Guetard D., Salle M., Montagnier L., and Alizon H., Mo
lecular cloning and polymorphosm of the human immunodeficiency virus type2.
Nature, 324, 691-695 (1986).
46. Pauwels R., Clercq E. De., Desmyter J., Balzarini J., Goubau P., Herdewijn P.,
Vanderhaeghe H., and Vandeputte M., Sensitive and rapid assay on MT-4 cells
for the detection of antiviral compounds against the AIDS virus., J. Virol. Meth
ods, 16, 171-185 (1987).
47. Schols D., Bada M., Pauwels R., Desmyter J., and Clercq E De., Specific inter
action of aurintri-caboxylic acid with the human Immunodeficiency/CD4 cell
recepter., Proc. Natl. Acad. Sci. USA, 86, 3322-3326 (1989).
48. Bhatt N.S., Ph. D Thesis, Saurashtra University, Rajkot (1983).
49. Thaker D., Ph. D Thesis, Saurashtra University, Rajkot (1996).
50. Vipul Vora, Ph.D Thesis, Saurashtra University, Rajkot (2000).
51. Desai B., Ph. D Thesis, Saurashtra University, Rajkot (2000).
52. Loriya R., Ph. D Thesis, Saurashtra University, Rajkot (2002).
The present  chapter  a ims at  the b io act ive propert ies of
pyranoquinolines, if appended with the arylamine residue at C 4 position of
the pyranoquinoline skeleton, will give novel compounds which were not
studied earlier for their pharmacological profile.
Thus, the starting material was prepared form N-ethyl aniline to ob-
tain 6-ethyl-4-hydroxy-2H-pyrano[3,2-c]quinolin-2,5(6H)-dione which on
furthur treatment with various amines at high temperature afforded a se-
ries of congeners mentioned in subsequent pages.
(Reaction Scheme - 2)
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NH
CH3
REACTION SCHEME : 2
+
220oC
N
O
O
O
OH
CH3
Diethyl ether
O
O CH3O
O
CH3
Step - 1
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N
O
O
O
OH
CH3
+
NH2
R
N
O
O
O
NH
CH3
R
Where R = H, CH3, F, Cl, etc......
Microwave Fused
REACTION SCHEME : 2
Step - 2
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EXPERIMENTAL :
Peparation of 6-ethyl-4-hydroxy-2H-pyrano[3,2-c]quinoline-2,5(6H)-
dione:
A mix ture  o f  N-ethy lan i l ine(12.1gm 0.1mole)  and d ie thy l
malonate(32.0gm 0.2 mole) was taken in the three necked round bottom
flask and to this mixture, diphenyl ether (40ml) was added. The reaction
mixture was heated to 220oC for 12hrs. During the reaction liberated ethanol
was collected by distillation. After the completion of the reaction the product
was isolated by addition of 1,4 Dioxane and it was washed with diethyl
ether.The product was recrystalized in ethanol.
Elemental Analysis
Calculated        =  C (65.37%) H(4.31%) N(5.44)
Experimental               =   C (65.41%) H(4.27%) N(5.41)
Molecular formula       = C14H11NO4
          Formula Weight         =  257.24
M.P.                               =  255-258oC.
TLC System                 =  (Ethyl acetate: Hexane : 4: 6)
Yield         =  52-65%
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Peparation of 4-[(4-chlorophenyl)amino]-6-ethyl-2H-pyrano[3,2-
c]quinoline-2,5(6H)-dione.
6-ethyl-4-hydroxy-2H-pyrano[3,2-c]quinol ine-2,5(6H)-dione
(0.01mole) was taken in the flask and 4-chloroaniline (0.01mole) is addded
and put it in the microwave oven for 4-6 minutes. The resultant mass was
treated with methanol and product was filterd . The product was dried and
recrystallized from DMF in hot air oven. The yield recorded between 35-
40%. Light-yellow amorphous product was obtained after crystallization.
Elemental Analysis
Calculated        =  C (65.49%) H(4.12%) N(7.64)
Experimental               =   C (65.53%) H(4.8%) N(7.59)
Molecular formula       = C20H15Cl N2  O3
          Formula Weight         =  366.79
M.P.                               =   167-170oC.
TLC System                 =   (Ethyl acetate: Hexane : 4: 6)
Yield         = 18-30%
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SPECTRAL STUDY :
The constitutions of newly synthesized compounds were supported
by IR, NMR, and LC-MS study. The details are as under.
IR Spectral Study :
Instrument : SHIMADZU FT-IR-8400 Spectrophotometer
Sample technique :  KBr pellet
Frequency  range : 400-4000 cm -1
It is observed that in the IR spectrum of  4-[(2-Chlorophenyl)Amino]-
6-ethyl-2H-pyrano[3,2-c]Quinoline-2,5(6H)-Dione (ASM-36),  -NH band is
observed at 3440.8 cm -1. It was found that both carbonyl (-C-C=O, and -N-
C=O-) group seperates at low resolution frequency (at 0.84) 1738 and 1676
cm -1 repectively. Initially, when IR was taken at high resolution (4.00), and
both carbonyl merged only one carbonyl (-C-C=O-) was seen at 1742 cm -1.
The ether (C-O-C) of lactone appeared at 1275 cm -1.
The aromatic moiety and ring skeleton (like C-C multiple bond
stretching, C-H i.p. def. and (C-H o.o.p. def.) were observed at 1575,1490,
1442 cm -1. The halogen(C-Cl) was confirmed due a band appeared at 819.7
cm -1. Similar observations are made in all IR spectral data of the compounds
of this series. The range of frequencies of othr compounds are reported in
Tabular form on page 76 & 77.
1H NMR Spectral Study :-
Instrument : BRUKER AC 300 MHz FT-NMR Spectrometer
Internal reference : TMS
Solvent : CDCl3+DMSO d 6
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In1H NMR study of 6-ethyl--4-[(2,3-dimethylphenyl)amino]-2H-pyrano-
[3,2-c]-quinoline-2,5(6H)-dione (ASM-44) confirms structure as singlet of
two identical methyl(-CH3)protons is observed at  d 1.59 ppm. Another sin-
glet is observed at d 5.68 ppm confirms the presece of  proton of C 3 posi-
tion. In the  aromatic region,  two triplets were observed at d 7.36 ppm(J=8.7
Hz) and  d 7.82 ppm (J=8.1 Hz),  while two doublets are observed at  d
7.55ppm and  d 7.82 ppm.
In 1H NMR Spectra of 4-[(2-Chlorophenyl)amino]-6-Ethyl -2H-
pyrano[3,2-c]Quinoline-2,5(6H)-Dione (ASM-36), a singlet at  d 5.68 ppm
confirms presence of  C 3 proton of coumarin ring.  A singlet of -NH proton
is observed at d 7.26 ppm in the downfield due to substitution of chlorine
at C25 position. A triplet and quartet pattern for the ethyl group at (C24 & C25)
is observed at d 1.43 and 4.45 ppm. The value for the d obtained  for ethyl
group is higher, can be explained by the attatchment of ethyl group at N
atom. Moreover the aromatic ring skeleton are observed as multiplet at d
7.43-7.50 ppm (CH12,13,21,20) with coupling constant (J=8.7 Hz). A triplet is
observed for the protons of C11,14 at  7.799 dppm with (J=8.7 Hz.).Similar
observations are seen in 1H NMR spectra of other derivatives prepared.
The compounds, 4-[(2-Chlorophenyl)Amino]-6-ethyl-2H-Pyrano[3,2-
c]Quinolin-2,5 (6H)-Dione (ASM-36) and 4-[(2,3-dimethyl phenyl)Amino]-
6-ethyl-2H-Pyrano[3,2-c]Quinoline-2,5(6H)-12345Dione (ASM-44)  are also
confimed by 13C NMR and Mass spectra.
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Mass Spectral Study :-
Instrument : VG 70-S (70eV) Spectrograph for El
Instrument : JEOL SX 102/DA-6000 Spectrograph for FAB
The molecular ion peak is concormitant with the molecular weight.
The newly synthesized compounds were subjected to FAB Mass study. The
Fast bombardment study revealed the Molecular ion peak, base peaks and
other relevant fragmentation pattern to confirm the structure of the molecules.
In the Fab Mass of 6-Ethyl-4-[(2,3-dimethylphenyl)amino]-2H-
pyrano[3,2-c]quinoline-2,5(6H)-dione (ASM-44), base peak is observed at
361.0 m/z, while molecular ion peak is also at 361.00 m/z as (M+1) peak,
while in (ASM-40) structure is confirmed by base peak at 258.00 m/z and
347.00  m/z (M+1) peak.
The details of other FAB-Mass spectra are recorded.
13C NMR :
The compound ASM-36 was subjected for 13C NMR spctroscopy and
the results of these data shows the predicted sturcture is in agreement with
the carbon skeleton of respective compound.
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Instrument                                      : SHIMADZU FT IR-8400
Sample technique                         : KBr Pellet
Frequency range                           : 4000-400 cm-1
ASM36
N
O O
NHO
CH3
Cl
IR Spectrum of 6-ethyl-4-[(2-chlorophenyl)amino]-2H-pyrano[3,2-
c]quinoline-2,5(6H)-dione(ASM-36)
Type Vibration mode Frequency
cm-1
Carbonyl -C-C=O & -N-C=O 1739.7 & 1676
Amine -N-H Str. 3440.8
Aromatic
ring skeleton vib. 1660,1550,1500,1446
o.o.p.bending vib.
(1,2,3-tri sub.)
765.7
819.7
Halogen C-Cl str. 1114.8
Alkyl -CH3 1352.0
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Chapter-2
74 Synthesis of 6-ethyl-4-hydroxy-2H-pyrano.........
ASM-38
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1444.6
1487.0
1550.7
1614.3
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3440.8
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O O
NHO
CH3
OCH3
IR Spectrum of 6-ethyl-4-[(2-methoxyphenyl)amino]-2H-pyrano[3,2-
c]quinoline-2,5(6H)-dione(ASM-38)
Type Vibration mode Frequencycm-1
Carbonyl -C-C=O & -N-C=O 1739.7 & 1676
Amine -N-H Str. 3440
Aromatic
ring skeleton vib.
1550
1488
1444
o.o.p.bending vib.
(1,2,3-tri sub.)
765
819
Alkyl -CH3 str. 1350
Ether C-O-C 1274
Instrument                                      : SHIMADZU FT IR-8400
Sample technique                         : KBr Pellet
Frequency range                           : 4000-400 cm-1
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Type Vibration mode Frequency
cm-1
Carbonyl -C-C=O &-N-C=O 1739.7 & 1676
Amine -N-H Str. 3421.5
Aromatic
ring skeleton vib.
1575
1552
1487
1444
o.o.p.bending vib.
(1,2,3-tri sub.)
819
867
Alkyl -CH3 str. 1350
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N
O
CH3
O
O NH CH3
ASM-46
IR Spectrum of  6-ethyl-4-[(3-methylphenyl)amino]-2H-
pyrano[3,2-c]quinoline-2,5(6H)-dione(ASM-46)
Instrument                                      : SHIMADZU FT IR-8400
Sample technique                         : KBr Pellet
Frequency range                           : 4000-400 cm-1
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Instrument                : BRUKER AC 300 MHz FT-NMR
Standard                  : TMS
Solvent                     : CDCl3+ DMSO d6
ASM-36
1H NMR Spectra of 6-ethyl-4-[(2-chlorophenyl)amino]-2H-
pyrano[3,2-c]quinoline-2,5(6H)-dione(ASM-36)
10
5
9
6
8
N
7
2
3
O
1
4
14
13
12
11
O
23
O
15
NH
16 17
18
22
19
21
20
24
CH325 Cl
26
Chemical
Shift
d  ppm
No. of
Proton
Muliplicity Inference J. Value
1.43 3H Triplet CH(25)      -
4.45 2H Quartet CH(24)      -
5.68 1H Singlet CH(3)      -
7.26 1H Singlet NH(16)      -
7.43-7.50 4H Multiplet CH(12,13)
CH(21,20)
   8.7
7.799 2H Triplet CH(11,14)    8.7
8.35-8.37 2H Doublet CH(19,12)    8.1
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ASM-44
1H NMR Spectra of 6-ethyl-4-[(2,3-dimethylphenyl)amino]-2H-
pyrano[3,2-c]quinoline-2,5(6H)-dione(ASM-44)
12
13
11
8
10
9
14
5
6
N
7
2
3
O
1
4
O
15
NH
16
O
23
24
CH325
17
18
22
19
21
20
CH326
CH327
Chemica l
Shift
d  ppm
No.  of
Proton
Muliplicity Interence J. Value
1.43 3H Triplet CH(25)      -
1.59 6H Singlet CH(26,27)      -
4.47 2H Quartet CH(24)      -
5.68 1H Singlet CH(3)      -
7.26 1H Singlet NH(16)      -
7.36 1H Triplet CH(21) 8.7
7.55 1H Doublet CH(10,11)
7.77-7.82 2H Triplet CH(20,22)
8.37 2H Doublet CH(9 ,12)    8.1
Instrument                : BRUKER AC 300 MHz FT-NMR
Standard                  : TMS
Solvent                     : CDCl3+ DMSO d6
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ASM-46
1H NMR Spectra of 6-ethyl-4-[(3-methylphenyl)amino]-2H-pyrano[3,2-
c]quinoline-2,5(6H)-dione(ASM-46)
12
13
11
8
10
9
14
5
6
N
7
2
3
O
1
4
NH
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21
20
22
19
17
18
CH326
O
23
O
15
24
CH3 25
Chemical
Shift
d  ppm
No. of
Proton
Muliplicity Interence J. Value
1.41 3H Triplet CH(25)      -
1.51 3H Singlet CH(26)      -
4.45 2H Quartet CH(24)      -
5.68 1H Singlet CH(3)      -
7.26 1H Singlet NH(16)      -
7.40 2H Triplet CH(18,19)      -
7.51-7.61 2H Doublet CH(10,11)    8.7
7.72-7.82 2H Triplet CH(20,22)    8.7
8.35-8.37 2H Doublet CH(9,12)    8.1
Instrument                : BRUKER AC 300 MHz FT-NMR
Standard                  : TMS
Solvent                     : CDCl3+ DMSO d6
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13C NMR Spectral study of 4-[(2-CHLOROPHENYL)AMINO]-
6-ETHYL-2H-PYRANO[3,2-C]QUINOLINE-2,5(6H)-DIONE
(ASM-36)
Instrument   :BRUKER  AC 300 MHz FT-NMR
Solvent                       : DMSO- d6
d PPM No. of carbons Inference
28.7 1C -CH3(13)
89.6 1C -CH(12)
98.0 1C -C(9)
114.1 1C -C(3)
115.3 2C -CH(15,16)
116.1 1C -C(2)
120.8 1C -CH(6,)
123.0 1C -CH(4)
121.4 1C -CH(19)
129.5 2C -CH(17,18)
134.6 1C -C(5)
135.4 1C -C(1)
138.8 1C -C(14)
158.8 1C -C=O(10)
162.5 1C -C(7)
168.5 1C -C(8)
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Introduction
Coumarin and its annulated derivatives are reported to possess
bactericidal and fungicidal properties10,11 coronary dilatory12, hypothermal13,
anticoagulant14, antiviral15-17, and antiinflamatory18-21 activities.
The coumarins are large group of natural ly occurr ing oxygen
heterocycles. Many natural coumarins have been reported for their wide range
of biological activities1-5.  As a result, several methods for their synthesis have
been developed and anticoagulants like Tromexan6, Warfarin7, Cyclocoumarol8,
Marcoumar9, came into market.
O O
OH
CH3
O
1. Murry, R. D. H., Hendez, J. and Brown, S. A. ;  The Natural Coumarins, Willey
New York (1982).
2. Sreenivasulu, B., Murthy, V. S. and Rao, N. V. S.; Proc. Indian Acad. Sci. Sect A ,
79, 41 (1974).
3. Moffet, R. S.; J. Med. Chem., 7, 446 (1964).
4. Nagesam, M. and Raju, M. S.; J. Ind. Chem. Soc. 64, 418 (1987); ‘ibid’, Indian J.
Pharm. Sci., 50, 49 (1988)’ ‘ibid’, J. Ind. Chem. Soc. 69(9), 592 (1992).
5. Collota, V., Cecehi, I., Melani, F., Falicchiani, G., Martini, G, Gelli, S. and
Lucacchi, A. T.; Farmaco, 46, 1139 (1991).
6. Eunter, R. B. and Stibling; Lancet,  11, 611 (1954).
7. Link, K. P., Sullivan, N. I. D., Huebner, C. F. and Scheel.; J. Biol., 5, 153 (1944).
8. Ikawa, M., Stahmann, M. A. and Link, K. P.; J. Am. Chem. Soc., 66, 902 (1944).
9. Harter, H. and Hartert, I.; Khim. Wochschr, 31,  852  (1953).
Cyclocoumarol
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4-Hydroxy coumarins are only a minor constituent of natural coumarins.
Some important derivatives have oxygen function at C 4 almost free.  Though
more often, it is methylated or sometimes involved in a pyran or furan ring
formulation with an isoprene unit at C 3.  The 3-position is free or occupied by
an isoprene or multi isoprene units. However the physiological active
compounds have various substituents. Ferulenol is one of such important
natural product.
O O
OH CH3 CH3
CH3
CH3
10. i) Firanz, E., Klaubo, E. & Hammann, I., Ger. Pat. 3012642 (1981); Chem. Abstr.,
96, 14276 (1982).
ii) Reddy, Y. D. & Somayayulu, V V.; J. Indian Chem. Soc., 58, 599 (1981).
           iii) Bourgain, R. H. Oriesshe, R. V. & Smith, P.; Arch. Inst. Parmacodyn. Ther.
195, 240, (1972).
          iv) Rao, A. K., Raju, M. S .Raju K. M.; J Indian chem. Soc., 58, 1021 (1981).
11. Cingolani, G. H.Gualtieri, F. & Pigini , M.; J Indian chem. ,12 , 531 (1969).
12. mathur ,C. N .,miter, C .R ., Krishnawamy , N .R ., Kulshreshtha , R.K.& Arora,
R. B .; Arch. Inst. Pharma.,153 , 218 (1965);Chem  Abstr., 63 , 12154 (1965)
13. Kitagawa, H. & Iwaki, R.; Yakugaku Zasshi,  79, 639 (1959);  Chem. Abstr.  53,19158,
(1959).
14. Sionae, T. O.; J. Pharma Sci., 53, 231  (1964).
15. Kasman, Y., Gustafson, K. R., Fuller, R.W., Cardellina, J. H., McMahon, J. B.,
Currens, Buckheif, R. W., Cragg, G. M. & Boyd, M.R.; J. Med. Chem., 35,  2735
(1992).
Ferulenol
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SYNTHESIS OF 4-HYDROXY COUMARINS :-
Several methods are reported for the synthesis of 4-hydorxy coumarins
and their substituted derivatives namely : Anschitz22, Kaneyuki23 , Pauli
Lockemann synthesis24 ,Robertson synthesis25 , Sonn’s synthesis26 , Mentzer’s
synthesis27, Garden’s method28, Ziegler and Junek29, Resplandy’s method30,
Jain, Rohtag and Sheshadri’s method31, and  Bose and Shah’s method32.
Shah and co-workers32 have prepared 4-hydroxy coumarin derivatives
in good yield by condensation of different phenols with malonic acid. The
method is useful as single step-preparation of many 4-hydroxy coumarin
derivatives substituted on benzenoid part.
Synthesis of chalcones:-
A general method for synthesis of chalcone consists in condensing a
ketone with an aromatic aldehyde in presence of appropriate  condensing
agent.  Several condensing agents  are employed.  Out of these, dry  hydro-
gen chloride and ethanolic aqueous potassium hydroxide are found to be most
satisfactory.  During the course of reaction a water molecule  its eliminated.
16. Fuller, R. W., Bokesch, H. R., Gustafson, K.R., Mckee, T. C., Cardellina, J. H.,
McMohan, J. B. Cragg, G. M. Soejarto, D. D. and  Boyd., M. R.; Bioorg. Med.  Chem.
Lett, 44, 1961  (1994).
17. Patil, A. D., Freyer, A. J., Eggleston,  D. S., Haltiwanger, R. C. Bean, M. F., Taylor,
P.. B. Coranfa, M. J. Breen, A. L., Bartus, H. R. Johnson, R. K., Hertzberg.  R. P. &
Westly, J. W.; J. Med. Chem., 36,  4131(1993).
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On condensing acetone with benzaldehyde in presence of zinc chloride
and acetic anthydride, Claisen and Deparede33 prepared benzylidene acetone
identical with Engler and Leist’ acetocinnamone34.
Extending the above condensation to on aromatic ketone, benzylidine
acetophenone were Prepared by using hydrogen chloride gas as a condens-
ing agent.  During the condensation of 4-nitro benzaldehyde with  acetone,
Bayer and Balker35 isolated an intermediate Aldol type product.
C
O
R CH3 + C
O
H R C
O
R CH CH R + H2O
COCH3 CH3 + CHO Ph COCH3 CH CH Ph
C
O
CH3
+ CHO
C
O
CH CH
HCl
gas
Acetone Benzaldehyde Acetocinnamone
18. Chakravarty, B. K. Rao, Y. N., Gombir, S. S & god,  K. D.;  Planta Med., 43, 64
(1981).
19. Romen, R.;  Res Commun Pathol Pharmacol.,  11,  552  (1975).
20. Singh, I. P., Kumar, A, Gurtu, S., Sinha, J. N. & Shanker, K.; Arch Pharma.
(Weinheim),  317, 984  (1984).
21. Kumar, A., Verma, M., Saxena, A. K. & Shanker, K.; India J. Chem.  26B, 378(1987).
22. Anschitz, R. ; Ber., 465  (1903).
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Recently screening work by Tummino and co-workers36 identified several
related structures with significantly better anti-HIV activity, including the 4-
hydroxy coumarin PD 099560 and the 4-hydroxypyrone.This has given new
impetus to this pyran skeleton.
O O
OH
S
R
OH
CH3
O O
OH
O
(CH2)n
O
OH
O
S
PD. 099560 R=cyclophentyl
23. Kaneyuki, H. ;  Bull.  Chem.  Soc. Japan, 35,  579  (1962).
24. Pauli, H. and Lockemann,  K.; Ber., 48,  48  (1915).
25. Boyd, J. and  Robertson,  A. ;  J. Chem. Soc., 174  (1948).
26. Sonn, A. ;  Ber., 50,  1292  (1917) .
27. Urbain,  G. and  Mentzer, C. ;  Bull. Soc. Chem.  11,  171  (1944).
28. Garden,  J. F., Hayes,  N. F.  and Thomson,  R. H. ;  J. Chem. Soc.  3315 (1956).
29. Ziegler,  E. and  Junek,  H.; Monatsh,  86,  29  (1955);  C. A. 50, 256  (1956).
30. Resplandy,  A. ;  Compt.  Rend., 260,  6479  (1965).
31. Jain, A. C., Rohtagi,  V. K. and  Sheshadri,  T. R.;  Tetrahedron  Lett., 2701 (1966).
32. Bhatt, N. S., Shah, A. K. Raval,  R. V. and Thakor,  V. M. ;  Curr. Sci.  53 (24) 1289
(1984).
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33. Claisen, L. and Claparede ; Ber., 14, 2460 (1881).
34. Engler, C. and Leist’s ; Ber., 6,  254  (1973).35. Bayer, A. and  Balker ;  Ber.,
16,  1968  (1883).
36. Tummino, P. J., Ferguson, D., Hupe, L. and Hupe, D.; Biochem Biophys Res
Commun., 200, 1658-64 (1994).
37. Jorg I, Fenyvesi T, Harenberg J. 43 : Expert opin Durg saf . 2002, sep ; 1(3); 287-94.
38. Dholakia, V. N., Parekh, M. G. and Trivedi, K. N. ; Aust. J. Chem., 21, 2345-7 (1968).
39. Trkovnik, M., Kules, M., Lacan, M. and Bobarevic, B.; Nautreforsch, 29B, 580-581
(1974).
40. Haefely, W.; In Advances in Drug Research, 14, London, Academic Press, 166(1985).
41. Parmar, K.; Ph.D. Thesis, Saurashtra University, Rajkot, (1993).
42. Karia, D.; Ph.D. Thesis, Saurashtra University, Rajkot (1999).
43. Mungra, N.; Ph.D. Thesis, Saurashtra University, Rajkot (2000).
44. Wolzt M, Bostrom SL,Sarich TC.: Pathophysiol Haemost Thromb. 2003 Mar-
Apr; 33(2):68-74.
45. Kudo S.,and  Masabuchi M., Japan Patent Appl. 8324(1963); Chem Abstr.,
59,174(1963).
Kudo and coworkers 45 repor ted the format ion o f  2- imino-3-
ethoxycarbonyl-4-phenyl-5-oxodihydro-pyrano[3,2 c] benzopyran46, from con-
densation reaction of -4-hydroxy cournarin and ethylbenzylidene-cyanoacetat
in the presence of water.   Another structure was also reported by Darbarwar
and coworkers47.
O
O
O
O
R
COOCH 2CH3
X
R = C6H5, 4-Cl-C6H4, 4-OCH3-C6H4, 4-NO2-C6H5, 3-NO2-C6H4
O
O
O
NH
R
COOCH 2CH 3
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46. Darbarwar M., Sundarmurthy V., Synthesis , 337(1982).
47. Plattner J. J., Norbeck D. W., Drug Discovery Technologies, Clark C. R., and Moos
W.  H. (Eds.), Harwood Ellis; Chichester, 92-126 (1990)
48. Kappe T., and Mayer C., Synthesis, 524 (1981).
49. Malikov, V. M.; and Saidkhodzhaev, A. I. Chem. Nat. Compd., 34, 202(1998).
50. Murray R. D. H. Nat. Prod. Rep. , 6, 591(1989).
51. Murray R. D. H. Prog. Chem. Org. Nat. Prod. , 58, 83(1991).
52. Murray R. D. H. Nat. Prod. Rep. , 12, 477(1995).
53. Murray R. D. H. Prog. Chem. Org. Nat. Prod. , 72, 1(1997).
54. Estevez-Braun, A., and  Gonzalez, A. G. Nat. Prod. Rep. , 14, 465(1997).
Y O
OH
C C
COOC2H5
R3R2
(R4)2N
NH4OAc
C C
COOC2H5
R3O
R2
NH4OAc
Y
O
O
O
R3
R2
R1
R1
Where
Y  = O, NH, NH-CH3
R1= H, CH3,
R2= CH3, C6H5, CH2COOC2H5,
R3= H, CH2C6H5,
Kappe and coworkers 48 reported the reaction of 4-hydroxycoumarin and
some 4-hydroxy-2-quinolones with b-enamino esters and with b-Keto esters
in the presence of equivalents of ammonium acetate to prepare compounds .
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55. Shah A., Bhatt S., Deo K., and Kundu P., Arzneim Forsch/Drug Res., 53(3), 196(2003).
56. Bonsignore L.; Cottiglia F.; Lavagna S. M.;and  Loy G.; Secci, D. Farmaco , 53,
693(1998).
57. Mario C., Antonio D., Francesco S., Rend Acad Sci, Fis. Mat. Naples,
36, 361 (1969)Chem Abstr.,75,48942(1971).
58. Duker Gerald, Frundt Peter, Markwitz Hardu, Henkel Gerald; J. Org. Chem.  1998.
59. Emam H. A.  Hassan S. M.,  EL - Maghaby A. A.,  J. Serb.  Chem. Soc.1997; Chem.
Abstr., 127,  190698v  (1997).
60. Ahmad Sallem,  Stein  Phillip D., Ferram rancis N.,  Atwal  Karnil S.; PCT nt. Appl.
WO, 98  36, 749;  US  Appl.  36,  317  (1997).
61. Jacobsen Poul, Trappendhi Svend, Bury Paul Stanley, Kanstrup Anders. Chrostoansen
Lise Brown; PCT Int. Appl.  WO98 18, 777;  Chem.  Abstr.,128, 321562s  (1998).
62. Alcaraz Lilian, Tamaj, Anzik Borut Kuzman Tadeja, Mesar Tomaj, KoczanDarko;
Eur. Pat. Appl. Ep  854, 143;  Chem. Abstr., 129, 95339m  (1998).
63. Coper Auton, Salmajer Tomaj, Anzik Borut Kuzman Tadeja, Mesar Tomaj, Ko czan
Darko; Eur. Pat. Appl.  Ep  854, 143;  Chem. Abstr., 129,  148908e  (1998).
64. Assy M. G.  Hataba  A. A.; J. Indian  Chem. Soc.,  1997;  Chem.Abstr., 127,
5060v (1997).
65. Gilkerson Terence, Shaw Robert William;Eur. PAt. Appl. Ep.-310,186’ Chem.
Abstr., 111, 231259x  (1989).
66. Tvanov E.I.,  Konupl. P., L A.,  Stepanov  D. E.,  Grishchak V.,  Khim-arm Zh.
1993;  Chem. Abstr.,  121,  35462w  (1994).
67. Scott  Keneth R., Nicholson Jesse M., Edafiogho Ivan O.
PCT Int. Appl. WO 93  17, 678;  Chem. Abstr., 120, 133914u  (1994).
68. Krichevshkii E. S., Alekseeva L. M., Anisimova O. S., Parshin V. A.,
Ashina V.V., Granik V.G.;  Khim,  Farm, Zh. 1997;  Chem. Abstr.,  128,
69. Krichevshki E.S.,Alekseeva L.M.Anisimova O.S.,Parshin V.A.,Ashina V.V., Granik
V. G.; Khim.farm, Zh. 1997 ;Chem.Abstr. 128,244027s(1998).
70. Shimazaki Toshiyuki. Toshiyuki Yamashita, Hiroyasi; Jpn. Kokai Tokyo koko JP 09
118,653 ;Chem. Abstr. 127, 3410j (1997)
71. Collis David J., Cullen John D., Stone Graant M.; Aust. J. Chem. 1999 ;  Chem.
Abstr. 110, 94655g (1989) .
72. Ahluwalia V.K., Sharma Pooja, Goyal Bindu;  I . J. Chem. Vol. 36B, (1997).
73. Nagarajan K., Shenoy S. J.; Indian J. Chem. Sec. B. 1987 ; Chem. Abstra. 108,150224p
(1988).
74. Albaugh Pamela ,Liu Gang, Hutchison  Alan, Nagao Suhara ;  U.S. US5, 723, 462
(1998); Chem. Abstr. 128, 204804m (1998).
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Coumarins are members among the most important classes of natural
products. The first member of this class, unsaturated coumarin (a natural
flavouring agent), was discovered in 1820. This scaffold is prolific in the plant
kingdom but may also be found in fungi and bacteria, providing an enormous
diversity in substitution patterns on the core scaffold.49-54
O O
O O
OH
CH3
O
The therapeutic potential of these compounds are immense. Coumarin
is the parent molecule of warfarin, which is used clinically as an anticoagulant
and as a rodenticide. Coumarins have been reported to exhibit antibacterial
and antifungal41activity and to act as diuretics and analgesics42. There have
also been reports that structures containing the coumarin ring reduce tissue
swelling due to various kinds of trauma or disease.
Mario and coworkers57 reported that equimolar amount of 6-iodo-4-
hydroxycoumarin and ethyl a-cyano-b-phenylacrylate in methyl cellulose when
treated with piperidine, the formation of 2-amino-3-ethoxycarbonyl-4-phenyl-
5-oxo-9-iodo-4H, 5H-pyrano[3,2-c]benzopyran is obtained. Further, Warfarin
is refluxed in 80% CH3COOH yeilded corresponding 2,4-dioxo-3-carboxy-4-
aryl-2,3-dihydro-4H, 5H-pyrano[3,2-c]benzopyran.
Warfarin is heated in vaccum at 180oC with evolution of gas,  gave 2,5-
dioxo-4-aryl-2,3-dihydro 4H,5H-pyrano[3,2-c]benzopyrans.
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O
O
NH2 O
O
R
I
Ar
OC2H5
O
O
O
R
I
Ar
O
O
H
O
O
O
O
R
I
Ar
O
R  = H
Ar = C6H5, 4-NO2-C6H4
(I)
(III)
(II)
(1) A review of the earlier litrature by Gerald et  al58  describes repre-
sentative synthetic procedure of cyclohexeonone derivative (I).
O
Eman H. A. et al.59 have prepared cyclohexenone derivative  (II)  for    chal-
cone.
NX SO
2
C CH CH
O
EAA K2CO3/Acetone
NX SO
2
O O
O
CH3
R
R
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O O
OOH
CH3
O
O O
OH N N
CH3
O O
O
O
CH3
O O
NH
CH3
N NH2
O O
N
N
O
OH
CH3
O O
OH
N O
CH3
O O
N
NOH
CH3
2N HCl
o-phenylene diamine
NH2OH. HCl
3,4-diamino
benzophenone
R
R R R
R
R
R
Shah et. al.79-81  have prepared various heterocycles derivatives from 3-
acetoacetyl-4-hydroxy coumarin like pyrano chromendiones, benzopyrano
pyrazoles, 1-4diazepine, isoxazoles, phenyl pyrazoles by known methods38-40.
They also studied antimicrobial41, antifungal41, anti HIV42,43 and antitubercular
activity of these compounds.  This suggests the importance of nitrogen
containing heterocycles in most of the cases with 5 or 7 member systems. It
was essential to study the xoygen containing heterocycles, if appended with
4-hydrosy skeleton, some pharmacological profile may alter.
R=H,CH3, di CH3.....
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Usefulness of cyclohexenone clubbed with other heterocycle in various
medicinal applications such as anthelmintic, hypoglycemic, nematocidal, an-
tibacterial, antifungal, antiviral, analgesic etc are wellknown.  Anti-arrhythmic
act iv i ty60 of  some cyclohexenone der ivat ives have been reported.
Cyclohexenone possess Cardiovascular, Osteoporosis, Menpausal Symptoms,
estrogen dependent, cancers activities, which was reported by Jacobsen Poul
et al61.
These derivatives are reported for large spectrum of physiological prop-
erties viz. antibiotic62-63, bactericidal64, herbicidal65, antimicrobial66, and anti-
convulsant67. Alekseeva L.M. and co-workers68, have reported this class as
neurotropic activity.Toshiyuki et al.69, have prepared some novel cyclohexenone
and screened for allergy inhibitor, antithrombitic platelet aggregation inhibi-
tors and fibrinogen antagonist activity.
Collins David J. et al.70, have documented cyclohexenone derivatives
which possess estrogenic activity As reported by V. K. Ahluwalia et al.71  also
as some new cyclohexenone are active as anti-HIV-1, gastric secretion inhibi-
tors and pesticidal activity.  Nagarajan and Shenoy72 have prepared substi-
tuted cyclohexenone which has shown to possess marked antiinflammatory
activity.  Nagao et al73 have reported antiarrhythmics activity.  Inverse agonist
for GABA activity74 of some derivatives have been investigated.
Recently, antimicrobial activity have been studied by Salama and
Atshikh75, cyclohexenone possess neutro  peptide g- receptor antagonist ac-
tivity which was reported by Takehiro & co-workers76.
Broughton Howard77  have demonstrated these molocules as GABA a5
receptor ligands for enhancing cognition properties. Cyclohexenone possess
inhibitory activity against the growth of lettuce seedling found by Kimura & co-
workers 78.
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(1) The current chapter deals with a 5 step synthesis of the coumarin com
pounds possessing many oxygen atoms in the scaffold at C 3 position
believed to be essential pharmacophore for various biological activiti
es including chemotherapeutics (anti-tubercular,anti-viral & anti-cancer).
(2) Thus, 4-hydroxy coumarin prepared was acetylated to get 3-acetyl-4-
hydroxy coumarin which was furthur converted into respective chalcone
derivative which was furthur on cyclocondensation with ethylacetoacetate
to give the final compounds.
(3) A series of Ethyl 6-(3-bromophenyl)-4-(4-hydroxy-2-oxo-2H-  chromen-
3-yl) -2-oxocyclohex-3- ene-1-carboxylates have been synthesized in
this chapter.
EAA
O O
OH O
Br
O O
OH
O O
O
CH3
Br
(II)
(I)
K2CO3
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REACTION SCHEME : 3
Step-1
Step-2
Acetic acid
OH
+ OH
O
O
OH
Anhyd. ZnCl2
O O
OH
POCl3
O O
OH O
CH3
POCl3
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REACTION SCHEME : 3
Step-3
Step-4
Piperidine
O O
OH O
CH3
+
CHO
R
O O
OH O
R
CHCl3
O O
OH
O O
O
CH3
R
Solvent
K2 CO3
+E A A
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EXPERIMENTAL :
(1) Preparation of 4-hydroxy coumarin :
It was prepared according to method of Shah and coworkers79-80.
Phenol (9.4 gm, 0.1 mole) and malonic acid (10.8 gm, 0.1 mole) was added to
a mixture of phosphorous oxychloride (40 ml) and anhydrous zinc chloride
(30 gm) which was preheated to 60-70  0C and the reaction mixture was heated
on water bath at 70 0C for 10 hours. It was then cooled to room temperature
and decomposed with ice and chilled water to afford solid, which was filtered
and washed with water. It was then treated with 10% sodium bicarbonate solu-
tion and filtered. The filterate was slowely acidified with diluted hydrochloric
acid. At the neutral point, the precipitates obtained were washed with water
and dried. The product was recrystallized from ethanol with 72% yield obtained,
m.p. 210-212 0C (Reported80 m.p. 209-210).
(2) Preparation of 3-Acetyl-4-hydroxy coumarin :
4-hydroxy coumarin (5 gm, ) was mixed with glacial acetic acid (25 ml).
Phosphorous oxychloride (20 ml) was added slowely to the mixture and it was
heated on water bath for 4 hours. Then the reaction mixture was cooled and
poured into crushed ice, filtered, dried and recrystallized from ethanol. The
product obtained in 75% Yield, m. p. 112-15oC (Reported81 M.P. 113-114 oC )
(3) Preparation of 3-[(2Z)-3-(4-bromophenyl)prop-2-enoyl]-
      4-hydroxy-2H-chromen-2-one : (General Method)
3-acetyl-4-hydroxy coumarin (0.05 mole) and unsaturated aromatic al-
dehyde (0.05 mole) were dissolved in 30 ml of chloroform. The catalytic amount
of piperidine (0.02 ml) was added and the reaction mixture was refluxed for 6
hours on a water bath, then it was allowed to cool at room temperature. The
chloroform was distilled out and the residue was washed with methanol. It was
then dried and recrystallised from chloroform.
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Elemental Analysis
Calculated        =  C (58.24%) H(2.99%)
Experimental               =   C (58.71%) H(2.91%)
Molecular Formula       = C18H11ClBrO4
          Formula Weight         =  371.18
M.P.                               =   170-72oC.
TLC System                 =   (Ethyl acetate: Hexane : 4: 6)
Yield         =  65-75%
Synthesis  of Ethyl 4-(3-bromo-2-oxo-2H-  chromen-3-yl)-2-
oxo-6-(2-methoxyphenyl) cyclohex-3-enecarboxylate.
(General Method)
A mixture of chalcone [3-[(2Z)-3-(3-bromophenyl)prop-2-enoyl]-4-hy-
droxy-2H-chromen-2-one](3.71g,0.01 mol) in 50ml of dry acetone, anhydrous
K2CO3(5.42g, 0.04mol)and ethyl acetoacetate(2.60g,0.02mol)was stirred at
room temperature overnight and was filtered. The solvent from the filtrate on
distillation gave a solid which was crystallized from ethanol .
Elemental Analysis
Calculated        =  C (59.64%) H(3.95%)
Experimental               =   C (52.71%) H(3.88%)
Molecular formula       = C24 H19 Cl Br   O6
          Formula Weight         =  483.30
M.P.                               =   108-10oC.
TLC System                 =   (Ethyl acetate: Hexane : 4: 6)
Yield         =  58-65%
Similarly other compounds were synthesized (Table 3.1,3.2,3.3).
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SPECTRAL STUDY :
The constitution of newly synthesized compounds were supported by
IR, 1H NMR, Mass and 13C NMRspectral study. The details are as under.
IR Spectral Study :
Instrument       : SHIMADZU FT IR-8400 Spectrophotometer
Sample technique     :  KBr pellet
Frequency  range       : 400-4000 cm-1
As per spectral study of the newly synthesized coumarin compounds,
the carbonyl (>C=O) for the ring and the ester  stretching is observed at range
of ~1680-1620 cm -1 and 1740-1710 cm -1 respectively for the carbonyl
functionality.The two carbonyl (>C=O) for the chromone & coumarin ring does
not get sparate due to merging in some cases. The confirmation of hydroxyl
group is the O-H stretching in range of ~3400-3200 cm -1.
In case of ethyl 6-(3-hydroxyphenyl)-4-(4-hydroxy-2-oxo-2H-chromen-3-
yl)-2-oxocyclohex-3-ene-1-carboxylate (ASM-12), a broad band of -OH (hy-
droxyl) is observed at 3413 cm -1  & 3207 cm -1 indicating the presence of two -
OH group. The sharp carbonyl band (>C=O) is seen at 1710.7cm -1 which indi-
cates the presence of ester(>COOR) group compare to 1750 cm -1. The ring
carbonyl (>CO) stretching is observed at 1620.7cm -1 .
The aromatic moiety and ring skeleton (like C-C multiple bond stretch-
ing, C-H i.p. def. and C-H o.o.p. def.) were observed at 1592, 1528 and 1402
cm -1  & 762 cm -1 .
Similarly, other compounds were studies for their characteristic study.
1H NMR Spectral Study :-
                Instrument :BRUKER AC 300 MHz FT-NMR
      Internal reference :TMS
      Solvent            :CDCl3  or DMSO d6
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1H NMR analysis of  Ethyl  4-(4-hydroxy-2-oxo-2H-
chromen-3-yl)-2-oxo-6-phenyl cyclohex-3-enecarboxylate
(ASM-25).
During 1H NMR study of compounds synthesized in this Chapter, the me-
thyl triplet of CH3a is observed at d 0.824 ppm along with a quartet for CH2b at
d 3.91ppm respectively, confirming the presence for the ethyl group (CH2-CH3).
The high value of CH2  signal is due to attatchment of ethyl to the ester group.
A doublet for the Hc & He is observed at d 3.017 & 2.23 ppm indicating the
presence for the single proton  present at the cyclohexenone ring. This single
proton Hd gives the signal at d 3.6ppm as multiplet.The signal for the ethylene
H atom of the cyclohexenone ring as Hg is observed as singlet at d 1.896ppm.
These signals confirms the proof for the cyclohexanone substituted ring.
Refering to the protons of the substituted phenyl ring of the cyclohexenone
ring,  the multiplet obtained in the spectra shows coupling between the ortho-
protons at the value d 7.15-7.28 along with the multiplet for the coumarin phe-
nyl ring protons Hm,l at d 7.08ppm. The remaining proton Hj of this ring gives
multiplet at d 7.31ppm due to ortho- and para- coupling protons. The doublet
format in the spectra is seen for the protons at the coumarin ring for the Hk &
Hn at d 7.85ppm.
The hydroxyl group present in the coumarin ring is confirmed by the IR
spectral value along with the signal obtained as singlet in 1H NMR spectra of
(ASM-25) at d 2.502ppm.
In the 1H NMR spectra of (ASM-6), the substitution of methoxy group at
the 2nd position of the phenyl ring exhibits the singlet obtained in the downfield
region d 3.334ppm. In the similar spectra, a pair of doublet and quartet for the
ethyl group is also observed at d 0.937-0.984ppm & d 4.06ppm respectively.
The remaining proton signals came out to be same as the above pattern of
other compounds of the series.
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The 1H NMR spectra of compounds (AM-6) and (AM-25) are given on
page no. 22 & 23.
Mass Spectral Study :-
Instrument : VG 70-S (70eV) Spectrograph for El
Instrument : JEOL SX 102/DA-6000 Spectrograph for FAB
The newly synthesized compounds were subjected to FAB Mass
study.The Fast bombardment study revealed the Molecular ion peak, base
peaks and other relevant fragmentation pattern to confirm the structure of the
molecules.The molecular ion peak is concormitant with the molecular weight
of  the compounds.
While in Fab Mass of Ethyl 4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-2-oxo-
6-(3-chloro phenyl) cyclohex-3-enecarboxylate (ASM-12) base peak is ob-
served at 154.00 m/z, while molecular ion peak is also at 438.00 m/z.
In the Fab Mass of  Ethyl 4-(4-hydroxy-2-oxo-2H-cromen-3-yl)-2-oxo-6-
(3-methoxyphenyl)cyclohex-3-enecarboxylate (ASM-6), a base peak is ob-
served at 361.0 m/z, while molecular ion peak is at 433.00 m/z (M+1) peak.
The mass spectra of representative compounds are given on page no.
115  & 117.
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Sample technique : KBr Pellet
Instrument : SHIMADZU FT IR-8400
Frequency range : 4000-400 cm-1
IR Spectrum  of Ethyl 4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-2-oxo-6-(2-
methoxyphenyl) cyclohex-3-enecarboxylate  (ASM-5)
ASM-5
 
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmasm-5
 401.2
 419.5
 668.0
 757.5
 904.3
 958.8
 984.1
1029.9
1096.7
1111.6
1149.5
1216.8
1242.3
1293.4
1358.3
1395.4
1465.6
1493.0
1592.6
1610.5
1706.4
1731.9
2837.6
2908.0
3440.8
3745.5
T y p e V i b r a t i o n  m o d e F r e q u e n c y  c m -1
C a r b o n y l
> C = O  s t r .  (e s te r ) . 1 7 3 1 . 9
> C = O  s t r .  ( r i n g ) . 1 7 0 6 . 4
H y d r o x y - O H  s tr. 3 4 4 0 . 8
M e th y l
A s s y m e t r i c  s t r . 2 8 3 7 . 6
S y m m e t r i c  s t r . 2 9 0 8 . 0
B e n d i n g 1 3 5 8 . 3
A r o m a t ic
r i n g  s k e l e t o n  v i b .
1 4 6 5 . 5
1 4 9 3 . 0
1 5 9 2 . 6
o .o .p . b e n d i n g  v i b .
( 1 , 2 , 3 - t r i  s u b . )
7 5 7 .5
O O
OH
O O
O
CH3
H3CO
Chapter-3
Synthesis of Ethyl 4-(3-bromo-2-oxo-2H- ......... 108
Sample technique : KBr Pellet
Instrument : SHIMADZU FT IR-8400
Frequency range : 4000-400 cm-1
IR Spectrum  of Ethyl 4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-2-oxo-6-(3-
hydroxyphenyl) cyclohex-3-enecarboxylate  (ASM-12)
ASM-12
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Sample technique : KBr Pellet
Instrument : SHIMADZU FT IR-8400
Frequency range : 4000-400 cm-1
ASM-23
O O
OH
O O
CH3
O
Br
IR Spectrum of Ethyl 4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-2-oxo-6-(3-
bromophenyl) cyclohex-3-enecarboxylate  (ASM-23)
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1H NMR Spectra of Ethyl 4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-2-
oxo-6-(3-methoxyphenyl) cyclohex-3-enecarboxylate  (ASM-6)
C h e m i c a l
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d  p p m
N o .  o f
P r o t o n
M u l i p l i c i t y I n f e r e n c e
0 . 8 4 5 3 H T H a
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4 . 0 5 3 H S - O C H 3
4 . 1 5 1 H D H c
4 . 2 6 1 H M H d
6 . 7 4 1 H Q H k
6 . 8 6 1 H M H
j
7 . 0 6 3 H " H
i
Instrument             : BRUKER AC 300 MHz FT-NMR
Standard                  : TMS
Solvent                    : CDCl3 + DMSO d6
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1H NMR Spectra of Ethyl 4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-2-oxo-6-
phenylcyclohex-3-ene-1-carboxylate (ASM-25)
ASM-25
O
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O
O O
O
CH3
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M H h , h , i , i
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Instrument                : BRUKER AC 300 MHz FT-NMR
Standard                  : TMS
Solvent                     : CDCl3 + DMSO d6
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Instrument                : BRUKER AV 300 MHz FT-NMR
Solvent                     : CDCl3 + DMSO d6
ASM-23
 13C Spectra of Ethyl 4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-2-oxo-6-(3-
bromophenyl) cyclohex-3-enecarboxylate  (ASM-23)
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Introduction
Coumarin-containing antibiotics such as novobiocin (I)amino coumarin
core produced byStreptomyces species, have gained renewed interest since
the discovery that they are potent inhibitors of bacterial DNA gyrase, which is
essential for cell viability1a,b. In addition,these coumarin antibiotics are potent
against methicilin resistant strains (mrs) of S taphylococci species, currently
one of the major concerns in the treatment of bacterial infections.2
O O
OH
NH
O
OH
CH 3
CH3
H
O
O
CH3
CH3
H3CO
O
NH2
O OH
1. (a) Maxwell, A. Trends Microbiol. , 5, 102, (1997).
(b) Calia, H.;Hoerman, L.; Schultz, P.; Lebeau, L.; Mallouh, V.; Wigley, D. B.;
Wang,J.C.; Mioskowski, C.; Oudet, P. J. Mol. Biol. , 236, 618,1994).
2. Boehm H. J.; Boehringer M.; Bur D.; Gmeunder H.; Huber W.;Klaus W.; Kostrewa
D.;Kuehne H.; Luebbers T.; Meunier-Keller N.; and Mueller F . J. Med. Chem. , 43,
664,(2000).
3. Shiozawa et al., Proc. Am. Assoc. Cancer Res. 43, 2460, (2002).
4. Nakatomi et al., Jpn. J. Cancer Res., 92, 1973, (2001).
5. Taraye J.P., Am. Pharm. Franc., 33, 467(1975); Merck Index 12th Ed.,
p.715,4252(1996); C.A., 60, 4113, (1964).
Effective reversal of breast cancer resistant protein(BCRP)-mediated
drug resistance by novobiocin was studied by Shozawa et al.,3 and Nakatomi
et al.4 This has renewed interest in coumarin based compounds.
Folescutol (2), a known capillary protectant drug5, 6,7-dihydroxy-4-(4-
morpholinyl methyl)-2H-1-benzopyran-2-one has been prepared by the reac-
tion of 4-chloromethyl-6,7-dihydroxy coumarin with morpholine. Folescutol has
-CH 2- linkage between coumarin and morpholine.
     (I)
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The chemical reaction of 4-methyl-2-oxo-2H-benzopyran-7-yloxy acetic
acid hydrazide with some different reagents, such as anhydride compounds,
aromatic aldehydes, carbon disulphide, and nitrous acid, yielded the
corresponding phthalazine derivatives,  hydrazone derivatives, 1,3,4-oxadiazol
derivative and acid azide  respectively. Treatment of these  compounds  with
absolute alcohols, amines and ethyl amino acid esters gave the corresponding
carbamate derivatives,  substituted urea derivatives  and substituted ethyl
acetate respectively. The biological activities of some of the synthesized
compounds were evaluated6-13 in this reported work.
Coumarin-3 and 4-acetic acids comprises within their molecules a
double bond between carbon atoms 3 and 4 in the pyrone ring and a reactive
methylene group attatched to either of these atoms. A study of the action of
chlofine and bromine on these acids was, therefore, expected to yield results
of considerable interest by revealing the relative affinities for halogen of the
methylene group and the ethenoid linkage.
OOH O
H2C
N
O
OH
(II)
6.    M.E. Abdel-Fateh, Chemistry Department, Faculty of Science, Suez Canal University,
      Ismallia,Egypt (1998)
7. Gaplovsky, A.; Donovalova, J.; Lacova, M.; Mracnova, R.; El-Shaaer H. M., Journal of
Photochemistry and Photobiology- A: Chemistry, 61,136,(2000).
8. Eicher, T.; Hauptmann, S., The Chemistry of Heterocycles, Georg Thieme Verlag
Stuttgard, New York ,(1995).
9. Edwards, A.M.; Howell, J.B.L., Clinical and Experimental Allergy: , 30, 756, (2000).
10. Nohara, A.; Ishiguto, T.; Sanno, Y., Tetrahedron,13, 1183, (1974).
11. Stankovicova,H.; Lacova, M.; Gaplovsky, A.; Chovancova J.; Pronayova, N., Tetrahedron
57,3455, (2001).
12. Sabitha G., Aldrichimica Acta,29,15,(1996)
13. Galema, A.S., Chemical Society Reviews,26, 233, (1997).
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If the usual rule of the halogen attacking primarily the doublebond in the
pyrone ring were followed in this case without the interference of any possible
influence exerted by the reactive methylene group, an unstable dihalide readily
changing, in the case of the coumarin-3-acetic acids into the 4-halogen acids
should result thus : -
It is to be noted, however, that if the induced polarities of carbon atoms
3 and 4 in the crotonoid system -CH=CH=C=O, contained in coumarins be
taken into account, they would be expected to influence materiallyu these re-
actions and diminish greatly the probability of bromine being added to the
double bond, particularly, in coumarin-3-acetic acids.
Premilinary experiments showed that there was very litttle action at labo-
ratory temperature and exposure to direct sunlight did not effect any improve-
ment.
O O
Br
HOOC
Br
O O
Br
HOOC
O O
HOOC
Br2
O O
COOH
Br2
O O
COOHBr
Br
O O
COOHBr
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The best results were obtained by heating in glacial acetic acid at the
temperature of boiling water bath though in the case of the coumarin-4-acetic
acids, a considerable amount of decarboxylation ensued and the product, a
mixture of the halogenated acid and the decarboxylated body, had to be sepa-
rated finally by cold sodium carbonate. It was observed as a general rule that
decarboxylation occured to a smaller extent with the chloro than with the bromo
acids, the neutral compounds being the main product obtained in the later
case under the conditions of experiment. B-Napthapyrone-4-acetic acid pro-
vided the only exceptional  case in which neither chlorination nor bromination
caused any appreciable decarboxylation, but the product in this case is differ-
ently constituted.
The halogenation of the coumarin-3-acetic acids was found to proceed
much more slowly, a period for 5-6 hours heating at 100o  C being normally
required for completing the reaction. There was, however, no decarboxylation
in this case and the product dissolved completely in cold sodium carbonate.
This is to be explained by the superior stability of hte 3-acetic acids which
unlike the 4-acetic acids, do not decompose even at their melting points.
The halogenated acids, as is to be expected, proved to be stronger
acids than the parent compounds, while the latter were easily liberated from a
solution of their sodium salts by dilute acetic acids, at the halogenated bodies
did not separate from the alkaline solutions until they were treated with min-
eral acids. This difference has been utilised in working out an excellent method
of separating a mixture of the two acids. The halogencoumarin-4-acetic acids
decomposed at their melting points quantitatively into CO2  and halogen-4-
methyl-coumarins which were found in every case to be identical with the prod-
uct, insoluble in sodium carbonate, obtained during halogenation.
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These were neutral compounds, very sparingly soluble in boiling alco-
hol and having an irritant action on the skin. Nascent hydrogen (zinc-copper
couple) reduced them to the 4-methyl coumarins,  the replacement of halogen
by hydrogen occuring smoothly and quantitatively.
The position of the halogen in the products is deduced from the follow-
ing considerations : That the halogen could not have entered the benzene ring
is proved by (a) their behaviour with boiling aqueous alkali which completely
removes the halogen, and (b) oxidation, halogen-free salicyclic acid and
hydroxynapthoic acids or their homologues being formed. Their remains little
doubt, therefore, that the halogen has either entered the pyrone ring or substi-
tuted one of the methylene hydrogen atoms, the following alternative structure s
for the halogenated coumarin-4-acetic acids thus predicted.
O O
HOOC X
X
O O
HOOC
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SYNTHETIC ASPECT :
Coumarin 4-acetic acid were synthesized by many researchers using
different methods, Limaye14 synthesized coumarin-4-acetic acid from phenol
and citric acid using concentrated sulfuric acid. Dixit and Gokhale15,16 con-
densed, phenols with coumarin-4-acetic acids. Dixit and Padukone17,18 pre-
pared 6-methyl coumarin-4-acetic acid from citric acid and hydroquinone.6-
methyl coumarin-4-acetic acid was prepared from resorcinol and acetone-di-
carboxylic acid in presence of different Lewis catalysts like aluminium chlo-
ride and also either phosphorous oxychloride or phosphorous pentoxide or
thionyl chloride under different reaction time and temperature conditions.
14. Limaye D., J. Ind. Chem. Soc., 4, 159, (1927).
15. Dey B.B., J. Chem. Soc., 107, 16,(1915).
16. Dixit V., and Gokhale G.J.,  Uni. Bombay, 3, 95-105(1934), C.A., 29, 4753(1953).
17. Dixit V.M., and Padukone V.V., J. Ind. Chem. Soc., 22, 127-30, (1950), C.A., 45,
8515g, (1951).
18. Dixit V.M., Kankundti A.M., and Mulay L.M., J. Chem. Soc., 22, 207-13(1945);
C.A.,40, 4045(1946); C.A., 46, 11188c,(1952).
  (III)
O O
CH3
O
OH
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Dey19, Dixit20, Fries21, and Radhabai22, have studied the reaction of phe-
nol with acetone dicarboxylic acid and also using citric acid. Gokhale, Ghosh23,
Chakravati24, and Banerjee25 have studied the formation of coumarin-4-acetic
acid from substituted phenol and acetone dicarboxylic acid using sulfuric acid
as condensing agent. Burton and Muller26-27 have found that condensation of
resorcinol with diethyl acetone dicarboxylate afforded 6-methyl coumarin-4-
acetic acid(I).
Schiff bases are important intermediates for the synthesis of some
bioactive compounds such as b-lactams28-31. Furthermore, they are reported
to show a variety of interesting biological actions, including antibacterial32-37,
antifungal17,18,23, anti mouse hepatitis virus (MHV)38, inhibition of herpes sim-
plex virus type 1 (HSV-1) and adenovirus type 5 (Ad 5)39, anticancer40-43, anti-
mosquito larvae44 and herbicidal activities45.
19. Dey B.B., J. Chem. Soc., 107 , 16, (1915).
20. Dixit V., and Gokhale G., J. Uni. Bombay,  3, 95-105,(1934); C.A., 29, 4753,(1953).
21. Fries K., and Volk W., Ann. 379 , 90,(1911).
22. Dey B.B., and Radhabai K., J. Ind. Chem. Soc., 11, 635,(1934).
23. Chakravarti D., and Ghosh B., J. Ind. Chem.Soc., 12, 622,(1935).
24. Chakravarti D., and Mukherjee H., J. Ind. Chem. Soc., 14, 725,(1937).
25. Chakravarti D., and Banerjee H., J. Ind. Chem. Soc., 13, 619,(1936).
26. Burton H., and Pechmann., Ann., 261, 166,(1981).
27. Muller D., Ber., 58, 2202,(1925).
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28. Venturini A.; Gonzalez, J. J. Org. Chem.  , 67, 9089-9092(2002).
29. Taggi A. E.; Hafez  A. M.; Wack H.; Young B.; Ferraris D.; Lectka, T. J. Am.
Chem.Soc. , 124, 6626-6635,(2002).
30. Delpiccolo C. M. L.; Mata E. G.  Tetrahedron: Asymmetry , 13, 905-910(2002).
31. More P. G.; Bhalvankar R. B.; Pattar S. C. J. Indian Chem. Soc.  , 78, 474-
475,(2001).
32. Pandeya S. N.; Sriram D.; Nath G.; De Clercq E. Il Farmaco , 54, 624-628(1999).
33. Baseer M. A.; Jadhav V. D. ; Phule, R .M.; Archana, Y. V.; Vibhute, Y. B. Orient.J.
Chem., 16, 553-556,(2000).
34.  El-Masry A. H.; Fahmy H. H.; AbdelwahedS. H. A. Molecules , 5,1429-1438
(2000).
35. Karia F. D.; Parsania P. H.  Asian J. Chem. , 11, 991-995,(1999).
36. Kabeer  A. S.; Baseer M. A.; Mote N. A.  Asian J. Chem. , 13, 496-500(2001).
37. Singh W. M.; Dash  B. C. Pesticides , 22, 33-37,(1988).
38. Wang  P-H.; Keck  J. G.; Lien E. J.; Lai M. M. C.; J. Med. Chem. , 33,608,(1990).
39. Das  A.; Trousdale M. D.; Ren S.; Lien E.;  J. Antiviral  Res., 44, 201-208,(1999).
40. Desai S. B.; Desai P. B.; Desai K.R. ; Hetrocycl. Commun.,  7, 83-90,(2001).
41. Pathak P.; Jolly V. S.; Sharma K. P.; Orient. J. Chem;   16, 161-162,(2000).
42. Kuz’min V. E.; Lozitsky V. P.; Kamalov G. L.; Lozitskaya R. N.; Zheltvay A. I.;
Fedtchouk A.S.; Kryzhanovsky D. N.;  Acta  Biochim. Polon., 47, 867-876,(2000).
43.  Phatak P.; Jolly V. S.; Sharma K. P.; Orient. J. Chem.; 16, 493-494,(2000).
44. Das B. P.; Choudhury R. T.; Das K. G.; Choudhury D. N.; Choudhury B.;  Chem.
Environ. Res. ,  3, 19-23,(1994).
45. Samadhiya S.; Halve A.;  Orient. J. Chem;.  17, 119-122,(2001).
46. Drug Data Rep, 7(5): 299,(1985).
47. Drug Data Rep , 7(10): 724,(1985).
48. Drug Data Rep , 12(7): 524,(1990).
49. Drug Data Rep, 12(9): 697,(1990).
50. Drug Data Rep, 12(11): 865,(1990).
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Some Coumarin structures as lead molecules:
Looking to the importance of coumarin system 51-55with 7-Hydroxy group, num-
ber  of derivations have successfully entered into the clinical trial. It is very interesting to
note that in all cases, the majority of such lead molecules bear a hydroxy group for a
wider pharmacological spectrum like antiplatelet, antipsychotic, antidiabetic,
antiparkinson, and ischemic disease.
Few such lead molecules are summarised as bewlow :
Chemical Name : 7-[5-(1-Imidazolyl)pentyloxy]coumarin46
Therapeutic Group : Antiplatelet Therapy
Highest Phase : Biological Testing
Chemical Structure :
OON
N
O
Chemical Name : 4-Methyl-6-(dimethylaminomethyl)-7-hydroxy-8-
allyl-coumarin47
Therapeutic Group : Antiplatelet Therapy
Highest Phase : Biological Testing
Chemical Structure :
OOH O
N
CH3
CH3
CH2
CH3
Chemical Name : 8-Piperazino-2H-1-benzopyran-2-one48
Therapeutic Group : Antipsychotic Drug
Highest Phase : Biological Testing
Chemical Structure :
O O
N
N
H
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Chemical Name : 1-(2-Oxobenzo[b]pyran-6-ylsulfonyl)imidazolidine-
2,4-dione
Therapeutic Group : Antidiabetic Agents
Highest Phase : Biological Testing
Chemical Structure :
O O
S
N
NH
OH
O
O
O
Chemical Name : 7-(4-Isopropylbenzyloxy)coumarin49
Therapeutic Group : Antiparkinson Drug
Highest Phase : Biological Testing
Chemical Structure :
O OO
CH3
CH3
Chemical Name : 3,4-Dimethyl-7-[3-(1-methylcyclopropyl)isoxazol-5-
ylmethoxy]coumarin50
Therapeutic Group : Antiparkinson Drug
Highest Phase : Biological Testing
Chemical Structure :
O OO
ON
CH3
CH3
CH3
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The hydrazides attatched to heterocycles like pyridine, pyrazines is
believed to be wonderful chemotherapeutic agents. The isoniazide and
pyrazinamide are classical examples of such drugs used as antitubercular
agents. In the same vein, the coumarin scaffold when appended with -CH2-
C=O- linker gave very good antiviral properties.
On the basis of these findings, in the present work, it was planned to
club coumarin moiety with a spacer -CH2-C=O- with an aim to prepare
compounds which mimick “hydrazide” like properties.
In the present chapter, coumarin-4-acetic acids were prepared by
literature method & the acids were furthur converted into respective esters,
which on treatment with hydrazine hydrate afforded to give 22 new compounds.
In the present work 6-methyl coumarin-4-acetic acid (III) was prepared
by Pechmann condensation of resorcinol and citric acid using sulfuric acid as
condensing agent.
The compounds were prepared by the hydrazide with appropriately
reacting aldehydes to obtain N’-[(1)-ethylidene]-2-(6-methyl-2-oxo-2H-chromen-
4-yl)acetohydrazide in good yields.
51. Nohara, A.; Umetani, T.; Sanno, Y.; Tetrahedron , 30, 3553,(1974).
52. Lacova, M.; Stankovicova, H.; Odlerova, Z.; Il Farmaco ,50, 885,(1995).
53. Lacova, M.; Chovancova, J.; Konecny, V.; Chem. Papers 1986, 40, 121.
54. Vaugham, C. D.; J, Soc. Cosmet. Chem. 1985, 33, 319.
55. Conner, D. E.; Ger. Offen 3.002304; Chem. Abstr. 1981, 94, 36119.
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OH
CH3
+
COOH
COOH
OH
COOH
O O
O
OH
CH3
O O
O
OCH3
CH3
Conc. H2SO4
CH3CH2OH
Conc. H2SO4
REACTION SCHEME - 4
Step-1
Step-2
Reflux
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O O
O
OCH3
CH3
NH2NH2
Reflux
O O
O
NH
NH2
CH3
Methanol
Reflux
REACTION SCHEME - 4
Step-3
Step-4
R
CHO
R
O O
O
NH
N
CH3
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EXPERIMENTS:
Preparation of (6-metheyl-2-oxo-2H-chromen-4-yl)acetic acid:
Citric acid (0.1M) and concentrated sulfuric acid (32 ml) were mixed in
a RBF and shaken for half an hour. The mixture was then slowly warmed on a
water bath up to 700C temperature. The mixture was left at this temperature
for 10-15 minutes and as soon as gas slackened, the flask was removed from
the bath allowed to stand for 15 minutes, till the liquid becomes clear, free
from gas bubbles and then cooled to 10oC in ice bath. p - cresol  (0.1M) and
concentrated sulfuric acid (14ml) were added gradually to the solution and the
mixture was shaken, taking care that the temperature doesn’t rise above 10oC.
The dark color solution was left for 48 hour at room temperature. It was then
poured into ice-cold water, when a bulky solid separated. It was filtered and
treated with sodium bicarbonate (10%) solution and then insoluble matter was
removed by filtration. The filtrate, on acidification gave (6-methyl-2-oxo-2H-
chromen-4-yl) acetic acid. The purity of the compound was checked by
TLC(Acetone: Benzene: 5:5).
M.P. 185-187oC(M.P. Reported = 181oC73 ) {Rf Value : 0.54}
Preparation of ethyl (6-methyl-2-oxo-2H-chromen-4-yl) acetate:
(6-methyl-2-oxo-2H-chromen-4-yl) acetic acid (10 gm) was taken into
250 ml RBF and to this, 70 ml ethanol along with few drops of sulfuric acid
was added and this reaction mixture was allowed to reflux on water bath for
4hr and the reaction was monitored with TLC (Ethyl Acetate: Hexane : 4:6).
The reaction mixture was poured into ice-water to obtain the product which
was filtered and washed with distilled water. M.P.136oC
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Preparation of 2-(6-methyl-2-oxo-2H-chromen-4-yl) acetohydrazide:
A mixture of ethyl (6-methyl-2-oxo-2H-chromen-4-yl) acetate(10gm)   and
hydrazine hydrate(98% 20ml) was  allowed to reflux for 8hr in the heating metal.
The completion of reaction was observed by TLC. The reactio mixture was
poured in ice, filtered and crystallised from alcohol. M.P. >300oC.
Preparation of N’-[(1)-ethylidene]-2-(6-methyl-2-oxo-2H-chromen-4-
yl)acetohydrazide:
A mixture of 2-(6-methyl-2-oxo-2H-chromen-4-yl)acetohydrazide
(0.01mol) and aldehyde (0.01 mol) was refulxed in absolute alcohol for 12hrs.
The reaction mixture was cooled to room temperature and was poured to ice
and filtered the product. The product was recrystallised from alcohol.
Elemental Analysis
Calculated =  C (71.24%) H(5.04%) N(8.74%)
Experimental =   C (71.20%) H(5.00%) N(8.70%)
Molecular formula = C19 H16N2O3
Formula Weight = 320.34
M.P. = 209-211oC.
TLC System = (Ethyl acetate: Hexane : 4: 6)
Rf Value =  0.32
Yield           = 58-65%
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SPECTRAL STUDY :
The constitutions of newly synthesized compounds were supported by
IR, 1H NMR, Mass and 13C NMR spectral study. The details are as under.
IR Spectral Study :
Instrument  : SHIMADZU FT IR-8400 Spectrophotometer
Sample technique  :  KBr pellet
Frequency  range  : 400-4000 cm-1
As per the spectral study of the newly synthesized 2H-chromene-4-
carbohydrazide ,the carbonyl (>C=O) for the ring and the ester stretching of
side chain is observed at range of ~1720-1700 cm -1 and 1740-1710 cm -1 re-
spectively. The confirmation of methyl group in the ring shows the CH3 bend-
ing in range of ~1385-1360 cm -1 and 2854-2823 cm -1 (MSB-1).
In case of  N’-[(1E)-(Phenyl)methylene]-6-methyl-2-oxo-2H-chromene-
4-carbohydrazide (MSB-1),  a sharp band of -NH stretch  is observed at 3423
cm -1. The sharp carbonyl band (>C=O) is seen at 1718 cm -1 which indicates
the presence of carbonyl (>C=O) group in the ring . The  (>C=O) for the amide
carbonyl bending is observed at 1654 cm -1 .
The aromatic moiety and ring skeleton (like C-C multiple bond stretch-
ing, C-H i.p. def. and C-H o.o.p. def.) were observed at 1604 ,1535 , and
1425 cm -1  & 759 cm -1 .
Similar important values for the various functional group repre-
sentative peak of the aromatic moiety are seen in the other IR graphs.(Please
see Table 4.4)
1H NMR Spectral Study :-
                Instrument :BRUKER AC 300 MHz FT-NMR
      Internal reference :TMS
      Solvent          :CDCl3  or DMSO+ d6
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In 1H NMR Spectrum of N’-[(1E)-(phenyl)methylene]-6-methyl-2-oxo-2H-
chromene-4-acetohydrazide (MSB-1), presence of methylene protons-CH2(C12)
is confirmed by observing a singlet in upfield at 3.52 dppm, another singlet at
2.26dppm, indicates the presence of  C3 proton of coumarin ring (C15). The
protons of the substituted phenyl ring gives different signal pattern. The signal
at 7.46 dppm observed as multiplet for the C20,24 protons exhibiting ortho-, meta-
coupling. Along with this signal, the the signal for the proton of N 16 is merged
and obtained as multiplet which can be calculated by the number of protons.
The signal for the protons of C 21,22,23  is observed as multiplet at 7.91 dppm. A
singlet for the proton of C 18 is observed in very down field at 9.55 dppm due to
the presence of neighbouring N atom.
For the signals of coumarin ring it can be observed that a doublet for
the C10 proton is seen at 7.258 dppm due to meta coupling with the C 8 proton.
A quartet is observed at 6.70 dppm for the C7 & C8 protons due to ortho and
meta coupling with each other with (J=8.1 Hz and J=2.0 Hz). The proton at the
C18 is observed as singlet in the down field region due to presence of
neighbouring N atom at 9.55 dppm.
In 1H NMR of N’-[(1E)-(4-chlorophenyl)methylene]-6-methyl-2-oxo-2H-
chromene-4-acetohydrazide (MSB-11), the singlet for -CH3  (C15) group is ob-
served at 2.24 dppm due to conjugation with ring double bond. The signal for
the protons of C 12 is observed at 3.45 dppm due to presence of >C=O group.
For the signal of substituted phenyl ring, a multiplet is seen in the spectra at
6.9 dppm for the protons of C 20,21,23,24  due to internal ortho and meta coupling
with each other. (J=8.4 Hz & J=2.1 Hz). For the proton signal of coumarin ring ,
a multiplet is observed at 7.29 dppm for the C 7,8,10  with internal coupling. The
signal for the C 18 proton is observed at 7.414 dppm. A singlet for the -NH pro-
ton N16 is observed at 6.24 dppm.
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Mass Spectral Study :-
Instrument : VG 70-S (70eV) Spectrograph for El
Instrument : JEOL SX 102/DA-6000 Spectrograph for FAB
The molecular ion peak is in concommitant with the molecular weight of
the compounds. The newly synthesized compounds were subjected to FAB
Mass study. The Fast Atom Bombardment study revealed the molecular ion
peak, base peak and ohter relevant fragmentation pattern ot confirm the struc-
ture of the molecules.
In the Fab Mass of N’-[(1E)-(3-methoxyphenyl)methylene]-2-(6-methyl-
2-oxo-2H-chromen-4-yl)acetohydrazide (MSB-8) base peak and molecular ion
peak both are observed at 351.00 m/z.
In the Fab Mass of N’-[(1E)-(4-chlorophenyl)methylene]-2-(6-methyl-2-
oxo-2H-chromen-4-yl)acetohydrazide (MSB-11) base peak is observed at
157.00 m/z, while molecular ion peak(m+1) is at 355.00 m/z.
In the Fab Mass of  N’-[(1E)-(3,4-dimethoxyphenyl)methylene]-2-(6-me-
thyl-2-oxo-2H-chromen-4-yl)acetohydrazide (MSB-7) base peak is observed
at 154.0 m/z, while molecular ion peak is at 379.00 m/z as (M+1) peak.
Similarly other compounds were studied for Mass spectral details.
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T y p e V i b r a t i o n  m o d e F r e q u e n c y  c m -1
C a r b o n y l
> C = O  S t r  ( R i n g ) 1 7 1 8 .4
> C = O  S t r  ( A m i d e ) 1 6 5 4 . 2
A m i n e - N H  S t r . 3 4 2 3 .4
A r o m a t i c
r i n g  s k e l e t o n  v i b .
1 6 0 4 . 7
1 5 3 5 . 2
1 4 2 5 . 3
o . o . p . b e n d i n g  v i b .
(1 , 2 , 3 - t r i  s u b . )
8 0 4 . 3
7 5 9 .9
A l k y l
-C H 3  ( A s s y m e t r i c ) 2 8 5 4 .5
-C H 3  ( s y m e t r i c ) 2 9 2 3 .9
-C H 3  (B e n d .) 1 3 6 1 . 7
Instrument  : SHIMADZU FT IR-8400
Sample technique  : KBr Pellet
Frequency range   : 4000-400 cm-1
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O
IR Spectrum of  N’-[(1E)-(phenyl)methylene]-6-methyl-2-oxo-2H-
chromene-4-acetohydrazide(MSB-1)
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IR Spectrum  of  N’-[(1E)-(2-hydroxyphenyl)methylene]-6-methyl-2-
oxo-2H-chromene-4-acetohydrazide(MSB-3)
O
CH3 O
NH N
O OH
T y p e V i b r a t i o n  m o d e F r e q u e n c y  c m -1
C a r b o n y l
> C = O  S t r  ( R i n g ) 1 7 0 6 . 9
> C = O  S t r  ( A m i d e ) 1 6 6 4 . 5
A lky l
-C H 3  (A s s y m e t r i c ) 2 8 5 4 .5
-C H
3  
( sym m e t r i c ) 3 0 3 9 .6
A m i n -NH St r . 3 3 4 2 .4
A r o m a t i c
r i n g  s k e l e t o n  v i b .
1 5 4 1 .0
1 5 0 6 . 3
1 4 3 1 .1
o . o . p . b e n d i n g  v i b .
(1 ,2 ,3 - t r i  sub . )
7 7 7 .3
7 5 6 .0
Instrument  : SHIMADZU FT IR-8400
Sample technique  : KBr Pellet
Frequency range   : 4000-400 cm-1
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MSB-10
IR Spectrum of  N’-[(1E)-(2-chlorophenyl)methylene]-6-methyl-2-oxo-
2H-chromene-4-carbohydrazide(MSB-10)
O
CH3 O
NH N
O Cl
1664.5
T y p e V i b r a t i o n  m o d e F re q u e n c y  c m -1
C a r b o n y l
> C = O  S t r  (R i n g ) 1 7 1 0 . 7
> C = O  S t r  ( A m i d e ) 1 6 6 4 . 5
A m i n e - N H  S t r. 3 3 3 4 . 7
A r o m a t i c
r i n g  s k e le t o n  v i b .
1 5 5 2 . 6
1 4 3 1 . 1
1 4 3 1 . 1
o . o . p . b e n d i n g  v i b .
( 1 , 2 , 3 - t r i  s u b . )
7 8 8 .8
7 4 4 .5
A l k y l
-C H 3  ( A s s y m e t r i c ) 2 8 5 8 . 3
-C H 3  ( s y m m e t r i c ) 3 0 5 5 . 0
-C H 3  ( B e n d . ) 1 3 7 3 . 2
Instrument  : SHIMADZU FT IR-8400
Sample technique  : KBr Pellet
Frequency range   : 4000-400 cm-1
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1H NMR Spectra of  N’-[(1E)-(phenyl)methylene]-6-methyl-2-oxo-2H-
chromene-4-acetohydrazide (MSB-1)
MSB-1
C h e m i c a l
S h i f t
d  p p m
N o .  o f
P r o t o n
M u l i p l i c i t y I n f e r e n c e J .  V a l u e
2 . 2 6 6 3 H S C ( 1 5 )
3 . 5 2 2 H S C ( 1 2 )
5 . 8 7 1 H S C ( 3 )
6 . 6 7 - 6 . 7 0 2 H Q C ( 7 , 8 )
J = 8 . 1  H z  &
J = 2 . 0  H z
7 . 2 5 8 1 H D C ( 1 0 )
7 . 3 9 - 7 . 4 6 2 H + 1 H M
C ( 2 0 , 2 4
N ( 1 6 ) )
7 . 7 8 - 7 . 9 1 3 H M C ( 2 1 , 2 2 , 2 3 )
9 . 5 5 1 H S C ( 1 8 )
Instrument :BRUKER AC 300 MHz FT-NMR
Standard :TMS
Solvent :DMSO d6
6
57
108
9
2
3O
1
4
O
11
CH315
12
13
O
14
NH
16
N
17
18
19
20
24
21
23
22
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1H NMR Spectra of  N’-[(1E)-(4-chlorophenyl)methylene]-6-methyl-2-
oxo-2H-chromene-4-acetohydrazide (MSB-11)
C h e m i c a l
Sh i f t
d  p p m
N o .  o f
P r o t o n
Muliplicity In fe rence J .  Va lue
2 .24 3 H Single C ( 1 5 )
3 .45 2 H s C ( 1 2 )
6 .02 1 H s C ( 3 )
6 .24 1 H s N ( 1 6 )
6 .79 -690 4 H m
C ( 2 0 , 2 1 ,
2 3 , 2 4 )
(J=8.4 Hz &
J=2.1 Hz)
7 .06-7 .29 3 H m C(7 ,8 ,10 )
7 .414 1 H s C ( 1 8 )
Instrument :BRUKER AC 300 MHz FT-NMR
Standard :TMS
Solvent :DMSO d6
6
57
108
9
2
3O
1
4
O
11
CH315
12
13
O
14
NH
16
N
17
18
19
24
20
23
21
22
Cl
25
MSB-11
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Instrument :BRUKER AC 300 MHz FT-NMR
Standard :TMS
Solvent :DMSO d6
O
O
CH3
O
NH
N
OCH 3
1
23
45
6
7
8
9
10
11
12
13
14
15
16
1718
19
MSB-8
13C Spectra of  N’-[(1E)-(3-methoxyphenyl)methylene]-6-methyl-2-oxo-
2H-chromene-4-carbohydrazide(MSB-8)
    C h e m i c a l
S h i f t
d  p p m
N o . o f  c a r b o n s I n f e r e n c e
3 9 . 5
5 4 . 6
8 2 . 2
1 0 4 . 9
1 1 2 . 5
1 1 3 . 3
1 1 7 . 8
1 1 9 . 2
1 2 9 . 9
1 2 4 . 5
1 3 0 . 0
1 3 7 . 2
1 4 2 . 1
1 5 1 . 3
1 5 5 . 3
1 5 6 . 2
1 5 9 . 0
1 5 9 . 1
1 C
1 C
1 C
1 C
1 C
1 C
1 C
1 C
1 C
1 C
1 C
1 C
1 C
1 C
1 C
1 C
1 C
1 C
- C H
3
( 7 )
- C H ( 1 9 )
- C H ( 8 )
- C H ( 1 2 )
- C H ( 3 , 4 )
- C H ( 5 )
- C H ( 1 )
- C H ( 2 )
- C H ( 6 )
- C H ( 1 3 )
- C H ( 1 4 )
- C H ( 1 8 )
- C H ( 1 6 )
- C H ( 1 7 )
- C H ( 1 5 )
- C H ( 9 )
- C H ( 1 0 )
- C H ( 1 1 )
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Introduction:
Coumarin nucleus is found in a variety of natural products, which exhibit various
pharmacological effects. Derivatives of coumarin are also important drugs having var-
ied properties. There are excellent monographs and review articles1-5 describing the
structure, synthetic reactions and properties of coumarins. Numerous reports have ap-
peared in the literature describing anitmicrobial6,7, antiradiation8,9and antiparasitic prop-
erties of the thiazole ring.
Pechmann reaction have been studied by many resesrchers, using various sub-
stituted phenols and different b -ketonic esters.
Biginelli10 condensed quinole with ethyl oxalo acetate in presence of sulfuric acid
and obtained 6-hydroxy-coumarin-4-acetic acid . Pechmann, Kraft11 and Graeger12 ex-
tended this reaction to other phenols.
1. O.Wawzonek, Heterocyclic Compounds, John Wiley and Sons, New York,173, 2 (1975).
2. F.M.Dean, Naturally ocuring oxygen ring compounds 2nd edn, Butterworhs, London
176, (1963).
3. R. Livingstone Rod’s Chemsitry of carbon compounds 2nd Edn,Elsevier, Amsterdam ,
96, 4,(1977)
4. J. Stauton, Comprehensive Organic Chemsitry edited by D.H.R. Barton and W.D.Olis, Oxford,
629, 4 (1979)
5. A.R.Kartritzky and CW Reees comprehensive Heterocyclic Chemistry, Pergaman Press,
Oxford,  3, (1984).
6. M.D.Friedman,P.L.Stotter,T.A.Porter and K.J.Flokers, J.Med.Chem. 1314,16 (1973).
7. A.S. Hamam and H.S. Hamam and H.S. Elkasher Egyotian Pharmaceutical Congress,
Cairo- 7-10 Dec. 110,10 (1975).
8. R.D. Westland,M.H.L. in Jr. R.A.Colley, M.L. Zuriester and M.M. Gergan, J.Med.Chem.,
328,16 (1973).
9. P.S. Furmer, C.C.Heung and M.K. Luie, J.Med.Chem., 411,16,(1973).
10. Biginelli P.; Gazetta 491, 24,(1894).
11. Pechmann H, Kraft E.; Ber., 421,34,(1901).
12. Pechmann H, Graeger E.; Ber.,378, 34  (1901).
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Thiazole and coumarin der ivat ives have been associted with diverse
pharmacological activit ies such as antibiotics, anti inflammatory,antidiabetic,
antimicrobial and fungicidal properties.Coumarin associated with thiazole at 3-position
exhibited the antibacterial activity against both Gram positive and Gram negative
bacteria.  Kalluraya and co-workers13 found that 2-aryl-4-(3-coumarin) thiazoles (I)
showed antibacterial activity against S. aureus, E.coli, B. subtilis, P. aurogenosa,
Klebesiella and Shigella in compare to nitrofurazone as a standard drug.
OH
R +
O O
CH2COOH
R
CH2 COOC2H5
C
CH2 COOC2H5
O
O O
R1
N
S
R
R1 = H, Br
R=Aryl, Heteroaryl
Coumarin ring linked through –CH2-NH group with benzothiazoles were also
studied and gave very good antimicrobial activity.  Shinde et al14have proved that the
Mannich bases of 4-methyl-7-hydroxy coumarins with various aliphatic amines15 and
those derived from benzoxaoles have been found to possess antimicrobial and also
CNS stimulating activity.  Antifungal activity of 4-methyl-7-hydroxy/acetoxy coumarins
and substituted amino benzothiazoles (II) have been reported16-17.
13. Kalluraya B, Chimbalkar R, Vishwanatha P and Kotain Mohan; Ind.  J. Het. Chem.,  5, 153-54
(1995).
(I)
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O
O
NH
S
N
RR1
R2
R3 R4
R =H, Cl, CH3, NO2
R1, R2, R3, R4 = H, CH3, C2H5, OH
Werder have synthesised over one hundred derivatives of coumarin-3-carboxylic
acid. These acids have not yet been found to occur in the vegetable kingdom. He has
investigated their utility as medicines. They are sedative in small doses and hypnotic in
large doses. Among the derivatives of these acids, the diethylamide has proved to be a
good drug in general nervous disease and in varoius neurasthenic and hysterical ail-
ments mannich has found that some hydroxy coumarins possenssing the power of
absorbibg ultraviolet light are extensively used as medicinals in skin diseases.
O O
CH
2
COOH
Alrestatin had an IC50 of 10
-5 - 10-6 m against bovine lens aldose reductase with
glyceraldehyde or galactose as substrate. Not only did alrestatin at a concentration of
10-3 m prevent swelling and the formation of galactinol in lens tissue cultures exposed to
30 mm galactose, it was the first aldose reductase inhibitor to display in vivo activity
after oral dosing. 5,6-benzo coumarin-4-acetic acid being the most potent representa-
tive had IC50 of 20 mm against boving lens aldose reductase.
(II)
(III)
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Recently thiazole & coumarin bearing compound has other uses.In order to find a
highly sensitive fluorophore, 3-azolyl-7-diethylaminocoumarin derivatives were
synthesized. Both the absorption and fluorescence maxima of the coumarin-thiazole
compounds showed red shifts with increase of the molar absorptivities and fluorescence
intensities, in comparison with those of the corresponding coumarin-oxazole compounds.
Among them, 3-(5-ethoxycarbonyl-1,3-thiazol-2-yl)-7-diethylamino-2H-chromen-2-one
(IV) was one of the most promising candidate as a fluorophore accessible for analytical
purposes in the fields of analytical and biological chemistry.
O ON
N
S
O
O
The introduction of a phenyl group at the 3-position of the coumarin ring causes
bathochromic shifts in absorption and fluorescence maxima with increases in the molar
absorptivity and fluorescence intensity. Development of 7-diethylamino-3-[4-
(bromomethyl)-phenyl]-2H-chromen-2-one(MPAC-Br) and 4-(7-diethylaminocoumarin-
3-yl)benzoyl cyanide (DACB-CN), which are among the most sensitive and practically
useful fluorescent derivatization reagents for carboxylic acids and for alcohols,
respectively. In order to develop more highly sensitive fluorophores, the introduction of
an azole in the place of the phenyl group at the 3-position of a coumarin ring was
considered.
There are a few examples of studies on 3-(benzazol-2-yl) coumarin derivatives,
but little is known about the systematic study of 3-azolyl-substituted coumarins.The
synthesis and spectroscopic properties of 3-azolyl-7-diethylamino coumarins as
screening in for fluorophores.
(IV)
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14. Bhavsar S. B, Mane D. V,  Shinde D. B, Shingare, M. S., Deokate A. S and Gangawane L. V.;
Ind. J. Het. Chem. ,  135-138, 6, (1996).
15. Gupta V. N., Sharma B. R  and Arora R. B.  J. Sci. Ind. Res., 300,20B, (1961).
16. Khan  M. H  and Giri S.; Ind. J. Chem.   984,32B,   (1993).
17. Sengupta A. K.  Garg M  and  Chandra V.;  J. Ind. Chem.  Soc., 1230, 56, (1979).
18. Haruko Takechi, Yoshiyuki Oda, Naozumi Nishizono, Kazuaki Oda, and Minoru Machida.,
Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Chem. Pharm.
Bull., 1702—1710,48,(11) (2000)
2-Aminothiazoles and their derivatives have long been used as precursors for
the synthesis of biologically active molecules. Because of the wide spectrum of activity
shown by the thiazole moiety, numerous thiazoles substituted with different groups at
various positions have been prepared. In recent years, several new methods for the
preparation of 2-aminothiazole derivatives and reactions have been reported, including
waste-free techniques. 2-Amino-4-substituted-1,3-thiazoles, in the presence of various
reagents, undergo different types of reactions to yield other heterocyclic compounds,
e.g., thiazolo[3,2-a]pyrimidine-5-ones, thiazolo[3,2-a]-pyrimidine-7-ones, imidazo[2,1-
b]thiazoles, thiazolo[3,2-a]benzimidazoles, etc. Consequently we were interested in
surveying the synthetic utility of 2-amino-4-substituted-thiazoles.
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Synthesis of 2-amino-4-substituted-1,3-thiazoles from ketones
(1) Using halogen and thiourea
Methyl ketones of the type 1 react directly with one mole of halogen and two
moles of thiourea to give 2-aminothiazoles (2) in excellent yield19, 20 (R=phenyl)
substituted phenyl, â-naphthyl, 2-thienyl, methyl, t-butyl; X=Br, I).
(2) Using NBS and thiourea
Methyl ketones 1 react with thiourea in the presence of N-bromosuccinimide
(NBS) using benzoyl peroxide as radical initiator to furnish 2-aminothiazoles (3)21,22.
(3) Using oxidizing agents and thiourea
An oxidative process can accomplish the formation of 2-aminothiazoles from a
ketone and thiourea. Thus, mixtures of thiourea and acetophenone have been treated
with various oxidizing agents, namely sulfuryl chloride, chlorosulfonic acid, thionyl
chloride, sulfur monochloride, sulfur trioxide, sulfuric acid, nitric acid and sulfur. In each
case a considerable quantity of 2-amino-4-phenylthiazole (4) was obtained23.
155
Chapter-5
Synthesis of substituted N-1,3-thiazol-2-ylacetamide..........
19. Dodson, R. M. and King, L. C., J. Am. Chem. Soc., 2242,67, (1945).
20. King, L. C. and Hlavacek, R. J., J. Am. Chem. Soc., 3722,72, (1950).
21. Dahiya, R. and Pujari, H. K., Indian J. Chem. , 966, 25B, (1986).
22. Vardhan, V. A. and Rao, V. R., Indian J. Chem. , 1085,36B, (1997).
23. Dodson, R. M. and King, L. C., J. Am. Chem. Soc., 871,68, (1946).
24.. K. Alfread,D. Silva; J. Hetero. Chem. ; 1821-1824,25(6), (1988).
25. K. Alfred, D. Silva; Phosphoruous Sulfur Relat. Elem. ; 3-4, 123-128 (40) (1988).
26. P.N.Bhargava and K.V. Prasad; J. Indian Chem. Soc.;165,38,(1961). Chem Abstr.;33,222,
88,(1976).
27. D.R.Rao, S.G.Gibson; Eur. Pat. Appl. EP 385,525; Chem. Abstr.  ; 114,164207u (1991)
28. N.Atsuo, S. Yoshiisa, K. Yutaka, H. Katini; JPN Kokai Tokyo JP 04,3352,770,995,35,770;
Chem. Abstr., 118, 254924z (1993).
29. N.Atsuo, S. Yoshiisa, K. Yutaka, H. Katsno; PCT Int. Appl WO 92,21,667; Chem. Abstr .,
118,191727g (1933).
30. S.Masara, I. Hisataka,I. Kouichi, F.Noriyaki, S. Inko, T. Yasuaki, M. Hidenao, N. Kanji; PCT
Int. Appl. WO 92,15,570; Chem. Abstr. 118,191727g (1993).
N-Phenyl-N’-(2-thiazolyl) urea have displayed potential anti-parkinson, anthelm-
intic and trichimodial activities.24,25 Bhargava 26 have synthesized 2,6-diaryl-3-ethoxy
cabonyl-4-piperidino acetyl-2’-amino-4’-phenyl thiazole (V) as local anaesthetic.
2-substuituted amino thiazole derivatives were prepared as antipsychotics agent
by Rao27,N.Atsuo28,29 and S.Masaru30, et.al. have synthesized 2-amino 4,5-diphenyl de-
rivatives and are useful as inhibitors of blood platelet aggregation.
(V)
S
N
NH
O
N
O
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A new series of such thiazole compounds were studied by Patnaik31 bearing 2-
substituted amino thiazoles moiety in the structure having fungicidal activity.
31. Patnaik J.M.,Patnaik M. and Bhatta D., Ind. Jour. Chem.; Vol. 1304-1306,37B, (1998)
32. Bambas L. L.; J. Am. Chem. Soc. 671,67, (1945).
33. Lombardino J. G.; US Patent 4,307,106 (1981), Chem. Abstr.  122784,96, (1981).
34. Turner Thomas; J. Med. Chem. Soc., 4517,73, (1951).
35. Hulin B,Clark d.A.,Golstein S. W. et.al., J. Med.Chem. , 1853,35, (1992).
36. Satzinger G.; Arzneimittel-Forsch., 1742-1817, 27, (1977).
(VI)
Few important thiazole bearing drug molecules are reported here which have
desired pharmacological profile.
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Chemical Name : 5-[(4-aminophenyl)sulfonyl]-1,3-thiazol-2-amine
Activity : Anti-bacterial Drug
Drug Name : Thiazol-sulfone32
Chemical Structure :
Some thiazole containing drugs :
S
O
O
NH2
N
S
NH2
Chemical Name : 4-phenyl-N-(2-phenylethyl)-1,3-thiazol-2-amine
Activity : Immuno regulating
Drug Name : Fanetizole33
Chemical Structure :
NH N
S
Chemical Name : (2Z)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-4-oxo-
 1,3-thiazolidin-2-ylidene)acetamide
Activity : Anti-convulsant
Drug Name : Ralitoline34
Chemical Structure :
Cl
CH3
NH
O
N S
CH3
O
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Chemical Name :4-{4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl] ben-
  zyl}-1,3-thiazolidine-2,5-dione
Activity : Antidiabetic
Drug Name : Dargliatzone35
Chemical Structure :
O
N
CH3
O
NH
S
O
O
Chemical Name : Ethyl (2E)-(3-methyl-5-piperidin-1-yl-1,3-thiazolidin-2-
  ylidene)acetate
Activity : Diuretic
Drug Name : Etozoline36
Chemical Structure :
S
N
N
CH3
O
CH3O
As mentioned earlier, some important findings were obtained in this laboratory
for the antiviral properties of coumarin derivatives linked by -CH2-C=O-NH spacer
with thiazole units. The promising results has encouraged us for the furthur
derivatization of these compounds.
Thus in the current chapter, 7-hydroxy-4-acetic acid is prepared by Pechmann
condensation which was converted into ethyl ester & it was treated with substituted 2-
amino thiazoles to obtain the title compounds.
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OHOH
+ COOH
COOH
OH
COOH
Conc. H2SO4
O OOH
O
OH
CH3CH2OH
Conc. H2SO4
Reflux
O OOH
O
OCH3
REACTION SCHEME : 5
Step - 1
Step - 2
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REACTION SCHEME : 5
CH3
O
Cl
NH2
NH2
S
+ H2O
S
N
NH2
Cl
I2
+
Diphenyl Ether
O OOH
O
OCH3
O O
NH
O
S
N
Cl
OH
POCl3
Step - 3
Step - 4
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EXPERIMENTS:
Preparation of (7-hydroxy-2-oxo-2H-chromen-4-yl)acetic acid:
Citric acid (0.1M) and concentrated sulfuric acid (32 ml) were mixed in a RBF
and shaken for half an hour. The mixture was then slowly warmed on a water bath up to
700C temperature. The mixture was left at this temperature for 10-15 minutes and as
soon as gas slackened, the flask was removed from the bath allowed to stand for 15
minutes, till the liquid becomes clear, free from gas bubbles and then cooled to 10oc in
ice bath. Resorcinol  (0.1M) and concentrated sulfuric acid (14ml) were added gradually
to the solution and the mixture was shaken, taking care that the temperature doesn’t
rise above 10oC. The dark color solution was left for 48 hour at room temperature. It was
then poured into ice-cold water, when a bulky solid separated. It was filtered and treated
with sodium bicarbonate (10%) solution and then insoluble matter was removed by
filtration. The filtrate, on acidification gave (7-hydroxy-2-oxo-2H-chromen-4-yl) acetic
acid. The purity of the compound was checked by TLC(Acetone: Benzene: 5:5).
M.P. 205-207oC(M.P. Reported = 209-210oC36)
Preparation of ethyl (7-hydroxy-2-oxo-2H-chromen-4-yl) acetate:
(7-hydroxy-2-oxo-2H-chromen-4-yl) acetic acid (10 gm) was taken into 250 ml
RBF and to this, 70 ml ethanol along with few drops of sulfuric acid was added. The
reaction mixture was allowed to reflux on water bath for 4hr and the reaction was
monitored with TLC(Ethyl Acetate: Hexane : 4:6). The reaction mixture was poured into
ice-water to obtain the product which was filtered, washed with distilled water and dried.
M.P.146oC (Reported = 147-149 oC36).
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Preparation of 4-(4-chlorophenyl)-1,3-thiazol-2-amine:
They were prepared by reported methods50. Following compound were repared.
Melting Point
2-Aminothiazole 88-91 0 C (Repoted m.p.164-650 C)
4-Chlorophenyl-2-aminothiazole                      160-610 C(Repoted m.p.164-650 C)
4-Metheylphenyl-2-aminothiazole                   123-250 C
2-Hydroxyphenyl-2-aminothiazole                   168-690 C
Preparation of N-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-(7-hydroxy-2-oxo-2H-
chromen-4-yl) acetamide :
A  mixture of 7-hydroxy coumarin -4-ethyl ester(0.01mole) and 4-(chlorophenyl)-
2-amino thiazole  (0.01 mole) was taken in diphenyl ether (6-8 ml. along with 2-4 drops
of POCl3. The mass was refluxed for 10 hours with stirring and excess of diphenyl ether
was distilled out the resultant mass was poured into solvent. It is then washed, filtered
and then dried for the cyrstallization. The crystallization carried out in ethanol.
 Elemental Analysis
Calculated =  C (58.18%) H(3.17%)  N(6.79%)
Experimental =   C (58.02%) H(3.15%)  N(6.75%)
Molecular formula = C20H13ClN2 O4S
          Formula Weight =  412.84
M.P.           =  153-155oC.
TLC System = (Ethyl acetate: Hexane : 4::6)
Rf Value = 0.41
Yield =  33.2%
Similarly all other compounds were prepared by employing different substituted
2-amino thiazoles.
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SPECTRAL STUDY :
The constitutions of newly synthesized compounds were supported by IR, 1H NMR,
Mass and 13C NMRspectral study. The details are as under.
IR Spectral Study :
Instrument  : SHIMADZU FT IR-8400 Spectrophotometer
Sample technique  :  KBr pellet
Frequency  range  : 400-4000 cm-1
In coumarin, fused thiazole ring the values for the ring carbonyl and the amide
carbonyl  group are recognised in the IR peaks at around 1730 cm -1 and 1668.3 cm -1
respectively. The peak for the -NH stretch group is observed at around 3300 cm -1.The
aromatic ring stretching are observed at around 2990-2800 cm -1. The ring C=C skel-
eton bending vibrations are observed at around 1600-1450 cm -1.
In case of N-[4-(2-hydroxyphenyl)-1,3-thiazol-2-yl]-2-(6-methyl-2-oxo-2H-chromen-
4-yl) acetamide (ASM-55),  a broad band of -NH is observed at 3423.4cm -1.  The sharp
carbonyl band (>C=O) for the ring is seen at 1735cm -1 which is slightly higher due to
presence of O atom while the amide linkage carbonyl (>C=O) is observed at 1654.2
cm -1. The hydroxy group present is identified by a broad band at 3353 cm -1. The methyl
group present is observed as bending at 1375.2 cm -1.
The aromatic moiety and ring skeleton (like C-C multiple bond stretching, C-H
stretch and bending ) were observed at 1625, 1571, and 1494 cm -1. The band for (C-S)
inthe inplane bending region is observed at 1242-1163 cm -1.
The characteristic bands and comparative chart of other synthesized compounds
are rePorted in Table 5.4 on page 171.
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1H NMR Spectral Study :-
                Instrument :BRUKER AC 300 MHz FT-NMR
      Internal reference :TMS
      Solvent          :CDCl3  or DMSO d6
1H NMR analysis of 2-(7-hydroxy-2-oxo-2H-chromen-4-yl)-N-
1,3-thiazol-2-ylacetamide (ASM-50).
The spectra of compound (ASM-50), shows the presence of the thiazole ring as
confirmed by  signals obtained as doublet in the down field region at 7.225 dppm &
7.485 dppm for the protons at C 4 and C5 with coupling constant (J=3.6 Hz).
The -CH2 group linkage at the C 9 position gives signal as singlet at 4.020 dppm
due to presence of (>C=O) group of amide linkage.The amide linkage -NH gives signal
at 7.948 dppm as a broad singlet.
The signal for the -OH group at 7 th postition of coumarin is obtained at 10.5 dppm
as broad singlet.The proton at C15 is obtained as singlet at 6.25 dppm. The signal for
the proton at C 19 position is obtained as doublet due to meta-coupling with proton of C 17
at 6.73 dppm with (J=2.1 Hz). Similarly, the proton at C 17 gives signal at 6.79-6.82 dppm
as double of  doublet with (J=6.3 Hz & J=2.1 Hz). This is because this proton undergoes
ortho-coupling with proton of C 16 and meta-coupling C 19 proton.
The signal for the C16 proton is obtained at 7.6 dppm with (J=8.1 Hz) bearing
ortho-coupling with C17 proton.
Similarly, other protons were identified in other compounds and are recorded.
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Mass Spectral Study :-
Instrument : VG 70-S (70eV) Spectrograph for El
Instrument : JEOL SX 102/DA-6000 Spectrograph for FAB
The newly synthesized compounds were subjected to FAB Mass study. The Fast
bombardment study revealed the Molecular ion peak, base peaks and other relevant
fragmentation pattern to confirm the structure of the molecules. The molecular ion peak
is in concormitant with the molecular weight of  the compounds.
In case of Fab Mass of 2-(7-hydroxy-2-oxo-2H-chromen-4-yl)-N-1,3-thiazol-2-
ylacetamide (ASM-50), base peak is observed at 154.0 m/z, while molecular ion peak
is at 303.00 m/z (M+1) peak.
In case of Fab Mass of 2-(7-hydroxy-2-oxo-2H-chromen-4-yl)-N-[4-(2-
hydroxyphenyl)1,3-thiazol-2-yl]acetamide (ASM-52) base peak is observed at 259.0 m/z,
while molecular ion peak at 394.00 m/z.
In the Fab Mass of 2-(2-oxo-2H-benzo[h]chromen-4-yl)-N-1,3-thiazol-2-
ylacetamide (ASM-62) base peak is observed at 259.0 m/z, while molecular ion peak
is at 394.00 m/z.
The mass fragmentation pattern of newly synthesized molecules is in total agree-
ment with the suggested structures.
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IR Spectrum of N-[4-(2-hydroxyphenyl)-1,3-thiazol-2-yl]-2-(6-methyl-2-oxo-2H-
chromen-4-yl)acetamide (ASM-55)
Instrument : SHIMADZU FT IR-8400
Sample technique : KBr Pellet
Frequency range : 4000-400 cm-1
(ASM-55)
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Instrument : SHIMADZU FT IR-8400
Sample technique : KBr Pellet
Frequency range : 4000-400 cm-1
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ASM-50
12
11
19
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14
15
O
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10
OH
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O
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9
7
NH
62
N
34
S
1
5
O
8
1H NMR Spectra of 2-(7-hydroxy-2-oxo-2H-chromen-4-yl)-N-(1,3-thiazol-2-yl)
acetamide (ASM-50)
C h e m i c a l
S h i f t
d  p p m
N o .  o f
P r o t o n
M u l i p l i c i t y J .  V a l u e
4 . 0 2 0 2 H S i n g l e t C 9
6 . 2 5 1 H S i n g l e t C 1 5
6 . 7 3 1 H D o u b l e t C 1 9 J 1 9 , 1 7 = 2 . 1 H 2
6 . 8 2 - 6 . 7 9 1 H
D o u b le
D o u b l e t
C 1 7 J 1 7 , 1 6 = 6 . 3 H 2
    J 1 7 , 1 9 = 2 . 4 H 2
7 . 2 2 5 1 H D o u b l e t C 4 J 4 , 5 = 3 . 6 H 2
7 . 4 8 5 1 H D o u b l e t C 5 J 5 , 4 6= 3 . 6 H 2
7 . 6 1 H D o u b l e t C 1 6 J 1 6 , 1 7 = 8 . 1 H 2
7 . 9 4 8 1 H B r o a d  S i n g l e t C 6 ( - N H - )
1 0 . 5 1 H B r o a d  S i n g l e t - O H
Instrument : BRUKER AC 300 MHz FT-NMR
Standard : TMS
Solvent : DMSO d6
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Present chapter deals with X-ray crystallography of molecules
w h i c h have  been syn thes ized .  Th is  inc ludes  de f in ing  mo lecu la r
structure, ident i fy ing al l  the atoms present along with their  space
patterns,  and establ ishing corre lat ion wi th physical  and chemical
p r o p e r t i e s o f  t h e s u b s t a n c e s , a r r a n g e m e n t  o f  i o n s ,  a t o m s , a n d
molecules in a crystal. The symmetry and geometry exhibited  by  their
a r rangement  a re  par t  o f  the  s t ruc tu ra l   p roper t ies  so  i t  i s  ve ry
important  to have detailed study of important molecules.
The first step for the crystallographer is often the hunt for a decent
single crystal, and in the macromolecular field, even this is being automated.
Julie Wilson (New York) on the Automatic Evaluation of High-Throughput
Crystallisation Trials gave a mathematical approach to finding crystals. The
wells of crystallisation plates were scanned for “interesting objects” which
were evaluated according to the shape of the object’s boundary. The
parameters were chosen such that single well-formed crystals gave the best
score, and with each well indexed, the best samples could be traced more
quickly and save the crystallographer’s time, eyesight and sanity.
The study of crystal structures through X-ray diffraction
techniques.
When an X-ray beam bombards a crystalline lattice in a given orientation,
the beam is scattered in a definite manner characterized by the atomic structure
of the lattice. This phenomenon, known as X-ray diffraction, occurs when the
wavelength of X-rays and the interatomic distances in the lattice have the same
order of magnitude.
Introduction of X-ray Crystalography & Polymorphism:
Definition:
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In 1912, the German scientist Max von Laue predicted that crystals
exhibit diffraction qualities. Concurrently, W. Friedrich and P. Knipping
created the first photographic diffraction patterns. A year later Lawrence
Bragg successfully analyzed the crystalline structures of potassium chloride
and sodium chlor ide using X-ray crystal lography, and developed a
rudimentary treatment for X-ray/crystal interaction (Bragg’s Law). Bragg’s
research provided a method to determine a number of simple crystal
structures for the next 50 years. In the 1960s, the capabilities of X-ray
crystallography were greatly improved by the incorporation of computer
technology. Modern X-ray crystallography provides the most powerful and
accurate method for determining single-crystal structures. Structures
containing 100–200 atoms now can be analyzed on the order of 1–2 days,
whereas before the 1960s a 20-atom structure required 1–2 years for
analysis. Through X-ray crystallography the chemical structure of thousands
of organic, inorganic, organometall ic, and biological compounds are
determined every year.
Theory
In many cases, an image of a microscopic object is generated by
focusing the rays of the visible spectrum using a lens as in light microscopy.
However, because the wavelength of visible light is long compared to atomic
bond lengths and atoms themselves, it is necessary to use radiation with
shorter wavelengths, such as X-rays. Employing shorter wavelengths implies
abandoning microscopy and true imaging, however, because there exists no
material from which a lens capable of focusing this type of radiation can be
created. (That said, scientists have had some success focusing X-rays with
microscopic Fresnel zone plates made from gold).
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Generally, in diffraction-based imaging, the only wavelengths used are
those that are too short to be focused. This difficulty is the reason that crystals
must be used.
Because of their highly ordered and repetitive structure, crystals are
an ideal material for analyzing the structure of solids. To use X-ray diffraction
as an example, a single X-ray photon diffracting  of one electron cloud will
not generate a strong enough signal for the equipment to detect. However,
many X-rays diffracting of many electron clouds in approximately the same
relative position and orientation throughout the crystal wil l  result in
constructive interference and hence a detectable signal.
Technique
Some materials studied using crystallography, DNA for example, do
not occur naturally as crystals. Typically, such molecules are placed in
solution and allowed to crystallize over days, weeks, or months through vapor
diffusion. A drop of solution containing the molecule, buffer, and precipitants
is sealed in a container with a reservoir containing a hygroscopic solution.
Water in the drop diffuses to the reservoir, slowly increasing the concentration
and allowing a crystal to form. If the concentration were to rise more quickly,
the molecule would simiply precipitate out of solution, resulting in disorderly
granules rather than an orderly and hence usable crystal.
Once a crystal is obtained, data can be collected using a beam of
radiation. Although many Universities that are engage in crystallographic
research have their own X-ray producing equipment. Synchrotrons are often
used as X-ray sources,because of the purer and more complete patterns such
sources can generate.
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Synchrotron sources also have a much higher intensity of x-ray beams,
so data collection takes a fraction of the time normally necessary at weaker
sources.
The first protein crystal structure was of sperm whale myoglobin, as
determined by Max Perutz and Sir John Cowdery Kendrew in 1958, which
led to a Nobel Prize in Chemistry. The X-ray diffraction analysis of myoglobin
was originally motivated by the observation of myoglobin crystals in dried
pools of blood on the decks of whaling ships. X-ray crystallography played a
major role in elucidating the double-helix structure of DNA.Today X-ray
crystallography is often used to determine how drugs, such as anti-cancer
medications, can be improved to better influence their protein targets.
Biology :
X-ray crystallography is the primary method for determining the
molecular conformations of biological macromolecules, particularly protein
and nucleic acids such as DNA and RNA. In fact, the double-helical structure
of DNA was deduced from crystallographic data. The first crystal structure
of a macromolecule was solved in 1958 {Kendrew, J.C. et al. (1958). A three-
dimensional model of the myoglobin molecule obtained by X-ray analysis.
Nature 181, 662-666.)}.
The molecule must be crystallized because one photon diffracted by
one electron cannot be reliably detected. However, because of the regular
crystalline structure, the photons are diffracted by corresponding electrons in
many symmetrically arranged molecules. Because waves of the same
frequency whose peaks match reinforce each other, the signal becomes
detectable.
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To determine a structure, one must first grow crystals of the molecule of
interest using some method of crystallization. This can be a painstaking
procedure for macromolecules such as protein and DNA complexes. The
crystals are harvested and often frozen with liquid nitrogen. Freezing crystals
both reduces radiation damage incurred during data collection and decreases
thermal motion within the crystal. Crystals are placed on a diffractometer, a
machine that emits a beam of x-rays. The x-rays diffract off the electrons in the
crystal, and the pattern of diffraction is recorded on film and scanned into a
computer. These diffraction images are combined and eventually used to
construct a map of the electron density of the molecule that was crystallized,
atoms are then fit to the electron density map and various parameters such as
position are refined to best fit the observed diffraction data.
Before the development of X-ray diffraction crystallography (see below),
the study of crystals was based on the geometry of the crystals. This involves
measuring the angles of crystal faces relative to theoretical reference axes
(crystallographic axes), and establishing the symmetry of the crystal in
question. The former is carried out using a goniometer.
The position in 3D space of each crystal face is plotted on a stereoraphic
net, e.g. Wolff net or Lambert net. In fact, the pole to each face is plotted on
the net. Each point is labelled with its Miller Index. The final plot allows the
symmetry of the crystal to be established.
Crystallographic methods now rely on the analysis of the diffraction
patterns that emerge from a sample that is targeted by a beam of some type.
The beam is not always electromagnetic radiation, even though X-rays are the
most common choice.
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For some purposes electrons or neutrons are used, which is possible due to
the wave properties of particles that are described by quantum mechanics.
Crystallographers often explicitly state the type of illumination used when
referring to a method, as with the terms.
X-ray diffraction, neutron diffraction and electron diffraction. X-rays are
useful for visualizing the electron clouds around atoms, whereas neutron
diffraction methods will reveal the atomic nuclei. Thus far, electron diffraction
has not been widely used. Crystallography by itself typically implies X-rays.
It is important to note that even after obtaining crystals suitable for
diffraction analysis, current X-ray sources and detectors limit the measurement
of only the diffracted photon intensities and not their respective phases, the
latter encoding the majority of the information about the actual shape of electron
density. A combination of experimental and computational methods are typically
used to solve the phase problem, in order to estimate phases and obtain an
initial map of the electron density.
After phases are estimated, a model made up of atoms is built and
refined against the observed data. Once a model of a molecule’s structure
has been determined, it is often deposited in a crystallographic database .
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Polymorphism : “Ability of a molecule to crystallise in to
more than one different crystal structure”.
Drugs which form crystalline solids often exist in more than one crys-
tal form, each of which many have distinct properties in terms of solubility,
melting point etc.  Invariably, one of the crystal forms may be more stable or
easier to handle than another although the conditions under which the vari-
ous crystal forms appears may be so close as to be very difficult to control
on the large scale. This effect can create differences in the bioavailability of
the drug which leads to inconsistencies in efficacy.  In some cases, one crys-
tal form can be transformed into another during storage and this called as
polymorphism.
Polymorphs of a drug differ in properties that affect its shelf life or
ease of manufacture. A newly discovered polymorph may turn out to be a
more effective and convenient than the original product.
The Food and Drug Administration requires all companies to register
the precise polymorph of any drug that they produce. Pharmaceutical manu-
facturers also have to demonstrate that each polymorph is stable and can
be reproduced reliably. Otherwise, it would be hard to set a drug’s effective
dosage.
It also comes down to fundamental chemistry. Polymorphism has elic-
ited enough excitement and fear in the drug business that a growing num-
ber of  reseachers in academia and in private companies are taking a closer
look at how crystals grow, and what these scientists discover could shape an
entire industry1,2
1. Threfall, T. L. Analyst, 120, 2435-2460, 1995,
2. Brittain, H. G. J. Pharm. Sci. , 86, 405-412.1997,
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Drug companies are becoming increasingly aware that different poly-
morphs can translate into more or less profit. Because each polymorph is
legally defined as a unique, patentable composition of matter, a company
that develops a new drug will patent all the polymorphs that it has discov-
ered and produced3-5.
Polymorphs and patents from a chemist’s point of view :-
This talk will present some of the chemical issues that were raised in a
number of recent patent litigations involving crystal forms (polymorphs and
solvates).
(1) Disappearing and reappearing polymorphs .
(2) Seeding: intentional and non-intentional .
(3) Polymorph identity and polymorph purity .
(4) Polymorphic stability and polymorphic conversion .
A generic perspective on crystal polymorphs :-
The importance of the physical form and polymorphism of active
pharmaceutical ingredients has grown dramatically over the last few years.
Obviously the physical form is vital for obtaining the desired therapeutically
ef fect ive product.However,  the generic pharmaceut ical  industry is
increasingly researching into novel polymorphic forms of actives to allow
early entry into the market place and also to maintain their market position.
3. N.Hall, Predicting Polymorphism. Pharmaceutical formulation & quality, February/
March-2000.
4. Bernstein, J. Polymorphism in Molecular Crystals ; IUCR Monographs on
Crystallography 14; Oxford Science Publications: OUP, Oxford, U.K., 2002.
5. Byrne, S. R.; Pfeiffer, R. R.; Stowell, J. G. Solid State Chemistry of Drugs, 2nd ed.;
SSCI Inc.: West Lafayette, IN, pp 489-498.1999.
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The focus is on some important aspects relating to the development of
a generic pharmaceutical.
(1) The commercial benefits for polymorphism discovery and patents
for a generic company
(2) Techniques used for the discovery and characterisation of
polymorphs
(3) Recent litigation case studies to illustrate the importance of
polymorph protection and patents.
Computat ional  predict ion of  crystal  structures and
polymorphism :-
Computational methods of predicting organic crystal structures have the
potential to confirm that all polymorphs have been identified, and aid
characterisation of polymorphs from low quality powder diffraction data. The
development of such methods presents some fundamental challenges to our
understanding of polymorphism, and this session will explore the progress that
has been made and how computation can currently aid polymorphism studies.
(1) Exploring the practicalities of computer modelling of polymorphism .
(2) Example case studies on generic pharmaceuticals .
(3) Progress, problems to date and future prospects .
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Crystallography as a strong tool for comprehensive
solid state studies:-
Using single crystals or micro-crystalline powders, crystallography
represents the ultimate tool for the study of subtle phenomena occurring at the
atomic level. This technique combined with molecular modelling is able to
elucidate the main issues of the solid state such as polymorphism, phase
transitions, solid solutions or chirality. This session will illustrate the contribution
of crystallography to the fine characterisation of pharmaceutical compounds
by way of:
(1) The description of state of the art x-ray sources and detectors
that allow the investigation of the tiny crystalline samples.
(2) The application of computational methods to the simulation of
crystal packing and the prediction of polymorph stability.
(3) Rehabilitating the role of the human eye in the detection and
isolation of concomitant polymorphs or furtive species.
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There are various methods of growing single crystals:
For X-ray crystallography, it is necessary to grow crystals with edges
around 0.1-0.3 mm. Crystals are formed as the conditions in a supersaturated
solution slowly change. There are three degrees of saturation in solution, and
crystallographers take advantage of these when growing crystals:
Unsaturated - where no crystals will form or grow.
Low supersaturated - where crystals will grow but no new ones will form.
High supersaturated - where crystals will both form and grow.
One theory of crystal growth is to start by getting a few crystals to grow
in the highly supersaturated solution. Then the crystals are exposed to a less
saturated solution so they can grow. This is done either by moving the crystals
or changing the saturation of the solution.
For small molecules, growing large enough crystals is relatively simple
then other molecules. By taking a supersaturated solution and gradually
changing the conditions, crystals will begin to grow. If left undisturbed for a
few days ideally a few large crystals will grow.
Some known techniques for growing single crystals:
Batch crystallization :  A saturated solution left in a sealed container to let
the crystals grow.
Microbatch crystallization:  A drop of solution is put in inert oil and left to
grow. Here there probably is some diffusion of proteins into the oil, lowering
the saturation over time.
Macroseeding: A crystal is grown in a highly saturated solution and placed in
a less saturated one where only growth of the crystal will occur.
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Microseeding: A few crystals are grown, then crushed, and put into a final
solution that combines them into a few nice crystals. This involves quite a bit
of experimentation with solution’s concentrations to get the desired number of
crystals.
X-ray Crystallography of some important molecules :-
Looking to the importance of our earlier molecules which were very
very important research molecule in various pharmacological study. We
planned to get the molecular structure and some information about the
skeleton of the molecules. The work of X-ray crystalography of molecules
synthesized by our research group was undertaken. This includes defining
molecular structure, identifying all the atoms present along with their space
patterns, and establishing correlation with physical and chemical properties
of the substances, arrangement of ions, atoms, and  molecules in a crystal.
The symmetry and geometry exhibited  by  their arrangement are part of the
structural  properties.
We studied the different molecules especially the 1,4-dihydropyridines
class. Moreover we have proved the crystal structure of  1,4-DHPs. The crystal
structure of the same class was  reported by our reseach group.
We undertake the work for following three molecules.
(1) 4-(4-methoxyphenyl)-N3,N5-bis (3-Chloro-4-fluorphenyl)-2,6-dimethyl
-1, 4-dihydro-3,5-pyridinedicarboxamide (AM-26).
(2) 4-(N,N-dimethylphenyl)-N3,N5-bis (4-fluorphenyl)-2, 6-dimethyl -1, 4-
dihydro-3,5-pyridinedicarboxamide (AM-60).
(3) 4-(3-Chlorophenyl)-N3,N5-bis (4-fluorphenyl)-2, 6-dimethyl -1, 4-
dihydro-3,5-pyridinedicarboxamide (AM-46).
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Experimental protocols :
The original Hantzsch pyridine synthesis, which consists of condensation
of acetoacetic ester with aldehyde and ammonia is now extended and
substituted acetoaetanilide was used instead of acetoacetic ester. All the
chemicals obtained from industrial sources. The crystallization of all carried
out on silica Gel-G as stationary phase and purchased from MERCK India
Ltd. Ethyl acetate: Hexane (4:6) was used as a Mobil phase. The other solvent
system lime acetone: benzene, methanol: chloroform was also employed but
the best results were obtained for  mixture of ethyl acetate and hexane(4:6) .
Preparation of 4-(4-methoxyphenyl)-N3,N5-bis(3-chloro,4-
f luoropheny l ) - 2 ,6 -d imethy l -1 ,4 -d ihydropyr id ine -3 ,5 -
dicarboxamide:
Acetoacetanilide(0.02 mol), 4-methoxybenzaldehyde(0.01mol) were
dissolved in 25ml methanol and heated on water bath t i l l  the sol id
disappeared in the reaction mass. Concentrated ammonia(3ml) was added
to the reaction and it was further refluxed on a water bath for a period of 10-
12hrs. The completion was monitored by TLC(Merck 60 F 254). After completion
of reaction it was allow to come to room temperature and solid mass will
appear in the flask. The product was filtered and washed with ether. It was
recrystallized from ethanol+acetone.
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Method for obtaining single crystal:
4-(4-methoxyphenyl)-N3,N5-bis(3-Cl,4-fluorophenyl)-2,6-dimethyl-1,4-
dihydropyridine-3,5-dicarboxamide (2.5 gm) was taken in 30 ml solvent mixture
[Ethanol + DMF (7.5:2.5)]. 1 gm Charcoal was added and heated on a heating
device for 6 minutes. The solution was filtered while hot through whatmann 41
filter paper. The solution was kept in a stopper conical flask slightly opened.
The Crystals was grown up due to thin film evaporation.
AM-26
ORTEP diagram of AM-26
N
H
OO
NH
OCH 3
CH3 CH3
NH
Cl
F
Cl
F
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Spectral Data for AM-26 :
IR Spectral study:
The infrared spectrum was recorded on Shimadzu FT-IR-8400 on KBr pellet.
The frequency range is 400-4000cm -1
1611(>C=O), 3262 (N-H str.), 3309 ( CONH atom. str,), 1453 (C-H ben.,
alk.), 1158, 1081 (C-O-C str. asy. sym.)
NMR spectral Data:
The 1H NMR spectrum was analyzed on Bruker AC (300 MHz) FT-NMR and
deuterated chloroform (CDCl3) was used as solvent, TMS being internal
standard. [2.073 (s, 6H, 2xCH3), 3.654 (s, 3H,-OCH3), 6.785 (d, 2H, Ar-H),
7.136 (d, 2H, Ar-H),7.333(t, 2H,Ar-H), 7.510 (m, 4H,C6H4), 7.907(q, 2H Ar-
H),8.150 (s, 1H,dhp-NH),9.508 (s, 2H,Ar-NH)].
MASS Spectral Data:
The FAB MASS was recorded on JEOL SX 102/DA-6000.
Mwt.558.40 [m/e (%)] : M + 559 (70), 449 (Base peak), 412 (86),280  (29),266
(21), 240 (20),154 (12), 136 (10).
Elemental Analysis:
[Calculated % C (60.27%)H (4.19%) N (7.58%) Cl (12.73%) F(6.85%)]
[Obtained  % C (60.23%)H (4.15%) N (7.53%) Cl (12.70) F(6.80%)]
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Reaction scheme for (AM-60):-
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+
Hantzsch synthesis
AM-60
Experimental:
Preparation of 4- (N,N-dimethylphenyl ) -N 3,N 5-b is(2-
f luoropheny l ) - 2 ,6 -d imethy l -1 ,4 -d ihydropyr id ine -3 ,5 -
dicarboxamide (Scheme-2):
Sub.acetoacetanil ide(0.02mol),N,N-dimethylaminobenzaldehyde
(0.01mol) were dissolved in 25ml methanol and heated on water bath till the
solid disappeared in the reaction mass. Concentrated ammonia(3ml) was
added to the reaction and it was further refluxed on a water bath for a period
of 10-12hrs.  and solid mass will appear in the flask.   and washed with ether.
It was recrystallized from ethanol+acetone.
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ORTEP diagram for AM-46
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Packing of Molecule (AM-26) down a
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Packing of Molecule (AM-26) down b
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Packing of Molecule (AM-26) down c
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Packing of Molecule (AM-46) down a
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Packing of Molecule (AM-46) down b
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Packing of Molecule (AM-46) down c
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Biological Activity Study:
The present work deals with the antimicrobial screening of the
compounds (AM,ASM, MS & AKSM sereris) synthesized in earlier Chapters.
The minimum inhibition concentration (MIC) values were determined
in the present study.
Protocol-1
Determination of MIC by Agar-dilution method was carried out
as per the NCCLS guidelines M7-A5
Preparation of plates containing the antimicrobial agent:
To Mueller-Hinton agar (19 ml) medium (Hi Media), cooled to ap-
proximately 500C, 1 ml of antimicrobial agent, dissolved in DMSO is added.
The antimicrobial agent is mixed thoroughly into the medium and poured
into Borosil glass petriplates of 9 cm diameter and allowed to solidify.  The
7 test cultures selected for the determination of MIC are spot-inoculated
(2 ml/spot) on a single plate prepared.
Preparation of solutions of antimicrobial agents to be incorporated
into the agar-based medium
10mg of the antimicrobial agent is dissolved in 5ml of DMSO to
prepare the main stock of the compound to be tested.  1ml of this main
stock is added to 19 ml of Mueller Hinton agar medium to make the final
concentration of 100 mg/ml in the agar medium. The main stock solution is
further diluted in DMSO by two-fold dilution procedure to obtain the de-
sired concentration in the agar medium.
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Preparation of inoculum of the test cultures:
For all cultures other than M.smegmatis strains
One loopful of culture from slant is inoculated into 5mL Muellar Hinton
broth (HiMedia) in a test tube.  The tube is incubated at 37 0C till the absor-
bance at 625nm equals that of 0.5 Mc. Farland standard (Section 5). The
absorbance readings are taken against a sterile Mueller Hinton broth blank.
The cultures are then transferred to 2-8oC temperature and maintained this
temperature till the time of inoculating the plates.  Appropriate dilutions of
the cultures (either 10 or 100 fold, depending on the culture) are made based
on the viable count of the cultures, previously done to establish the rela-
tionship between absorbance at 625mn and viable count, before inoculat-
ing the plates containing the antimicrobial test agents. 2ml of this diluted
culture is used to spot-inoculate the plates with antimicrobial test agents.
For M.smegmatis strains
One loopful of the culture from slant is used to inoculate 25 ml
Mycoseed brotha with 2-3 glass beads.  The broth is incubated at 35 0C for
5 days on 250rpm shaker.  2 ml of undiluted, 1:10 and 1:100 fold diluted
culture is spot-inoculated on a Mueller Hinton agar control plate (section 6)
and the spots are observed for confluent growth. The maximum dilution of
the culture that gives a confluent growth of the spot on the Mueller Hinton
agar control plates is selected for spot inoculation of the plates containing
the antimicrobial test agents.
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Preparation of 0.5 Mc. Farland standard
The 0.5 Mc. Farland standard solution as a reference for turbidity
measurement is prepared as per the NCCLS guidelines M7-A5.
Briefly, 0.5mL of 1.175% w/v BaCl2 solution is added to 99.5 ml of
1% V/V H2SO4 solution with constant stirring.  The absorbance of the solution
is measured at 625nm against a D.M.water blank by a uv-visible
spectrophotometer. The absorbance lies in the range of 0.08 to 0.1. The
Mc. Farland standard solution is stored in dark at room temperature and
vortexed vigorously prior to use
Controls:
Two control plates (i.e.plates without any antimicrobial agent
incorporated into the agar medium) with 1ml DMSO in 19mL Mueller Hinton
agar medium are kept with each MIC experiment to check the growth of the
cultures inoculated on the plates and the effect of the solvent (DMSO) on
the cultures.  2 ml of all the test cultures are spot-inoculated onto these two
plates.
Incubation time and temperature:
The plates are incubated at 35oC for 48 hours for M.smegmatis
and 24 hours for all other cultures before taking the results of MIC.
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Evaluation of the results:
The antimicrobial test compounds that show the growth of all the
cultures at a concentration of 100 mg/ml are not tested further for the
determination of the MIC. The compounds that show no growth of any of
the culture at 100 mg/ml concentration are further tested with lower doses
of the test compounds for the determination of the MIC values.
If the test culture that show 1-5 colonies per spot instead of the
confluent growth as in the control plate, it is considered to be inhibited by
the test compound.
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Table 7.1 :- Antimicrobial Activity data (as per Protocol 1)
Sr.
No
Code
Microorganism (MIC, mg/ml)
S.coccus
pyogens
A77
S.
aureus
SG511
S. aureus
E710
E.coccus
faecalis
M.smegm-
atis
(MY-1)
M.smegmat-
is
(MY-2)
1 AM-13 2.5 5.0 5.0 10.0 5.0 5.0
2 AM-14 2.5 5.0 5.0 10.0 5.0 5.0
3 AM-15 1.25 5.0 5.0 - 5.0 5.0
4 AM-16 100 - - - - 50
5 AM-17 100 - - - - 100
6 AM-25 2.5 - - - 12.5 10.0
7 AM-26 5.0 - - - 12.5 12.5
8 AM-27 1.25 2.5 2.5 5.0 5.0 5.0
9 AM-33 25 - 50 - 100 50.0
10 AM-34 2.5 - - - 12.5 10.0
11 AM-43 12.5 - - - 100 12.5
12 AM-48 - - - - - -
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Sr.
 No
Code
Microrganism (MIC in mg/ml )
S.coccus
pyogens
A77
S.
aureus
SG511
S.
aureus
E710
E.coccus
faecalis
M.smeg-
matis
(MY-1)
M.sme-
gmatis
(MY-2)
13 AM-49 2.5 - - - - 50
14 AM-61 - - - - - -
15 AM-68 - - - - 100 100
16 AM-69 - - - - 50 -
17 AM-70 - - - - - -
18 AM-71 - - - - 100 100
19 AM-72 - - - - - -
20 AM-73 - - - - - -
21 AM-74 - - - - - -
22 AM-75 - - - - - -
23 AM-76 - - - - - -
Table 7.1 :- Antimicrobial Activity data (as per Protocol 1)
(continue)
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Sr No Code
Microorganism (MIC in mg/ml)
S.coccus
pyogens
A77
S.
aureus
SG511
S.
aureus
E710
E.coccus
faecalis
M.smeg-
matis
(MY-1)
M.smeg-
matis
(MY-2)
24 AKSM-7 25.0 - - - 100
25 AKSM-12 5.0 - - - 12.5 12.5
26 AKSM-19 5.0 - - - 100 100
27 AKSM-20 2.5 - - - 50 -
28 AKSM-28 12.5 - - - - -
29 AKSM-32 2.5 - - - - -
30 AKSM-33 - - - - - -
31 AM-35 5.0 - - - - 12.5
32 AM-37 - - - - - -
33 AM-38 100 - - - - -
34 AM-39 - - - - 100 100
35 AM-40 100 - - - 100 -
36 AM-41 - - - - - -
37 AM-46 100 - - - - -
38 AM-47 100 - - - - -
39 AM-55 - - - - 100 -
Table 7.1 :- Antimicrobial Activity data as per (Protocol 1)
(Continue)
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Protocol-2
All of  these compounds were screened for their antibacterial activity
using strains like E. Coli, S. aureus.
For these screening:
• All compounds were dissolved in 10% DMSO in methanol.
• Fluconazole (0.5 mg/ml) was used as control.
• (h) denotes hazy zone.
• Solvent control was taken into consideration 10% DMSO in methanol.
It was carried out by using cup-plate method (2-4) which has been
described as under:
The purified products were screened for their antibacterial activity.
The nutrient agar broth prepared by the usual method was inoculated
espeticallly with 0.5 ml for 24 hrs. Old subcultures of E. coli/ S. aureus/
S. aureus 209p were taken in separate conical flask at 40o-50oC and
mixed well by gentle shaking. About 25ml of the content of the flask were
poured and evenly spread in petridish (13 cm in diameter) and 10mm
bore in agar medium and filled with 0.05ml solution of sample in 10%
DMSO in methanol.The plates were incubated at 37oC for 24 hrs and the
control wasalso maintained with 10% DMSO in methanol in similar manner.
The zones of inhibition of the bacterial growth were measured in mm
diameter.
2. F. Simoncini et al.; Farmaco, 23, 559 (1968); C. A.  69, 109851 (1968).
3. Bhatt, S., Deo, K., Kundu, P., Chavda, M. & Shah, A.; Indian J. Chem., Sect 42B,
      1502  (2003).
4. Chavda, M., Shah, A., Bhatt, S., Deo, K. & Kundu, P.; Arzneim-Forsch, Drug,
     Res., 53, 196   (2003).
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C o m p o u n d
1 m g / 1 0 0 m l
Gram Posi t ive
S.  aureus
G r a m  N e g a t i v e
E. coli
AKSM-3 1 5 -
AKSM-8 1 4 -
A K S M - 1 1 2 9 -
A K S M - 1 2 2 5 -
A K S M - 1 3 1 6 -
A K S M - 1 4 - -
A K S M - 1 6 2 6 -
A K S M - 1 8 11 -
A K S M - 2 2 - -
Table 7.2 :- Antimicrobial Activity data (as per Protocol 2)
*  Diameter zones of growth inhibition in mm.
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Protocol - 3
It was carried out using agar diffusion method. The purified products
totaling nine compounds from ASM and MSB series (Chapter-2,3 & Chapter-
4) were screened for their detailed antibacterial activity.
Preparation of Muller Hinton agar plates with antibacterial test
agents:
10 mg of compound was dissolved in 2 ml of DMSO to prepare stock
solution of the compound to be tested. 1 ml of this stock  was added to 19
ml of molten Muller Hinton agar medium and poured in a sterile empty plate,
allowed it to solidify. It gave the final concentration of the compound 1000
mg/ml in the agar  medium. The stock solution was further diluted by two
fold dilution procedure to obtain the desired concentration of the compound
in the agar medium plate. i.e. 1000 mg/ml, 500 mg/ml,  250 mg/ml, 125 mg/
ml , 75 mg/ml , 37 mg/ml  and 18 mg/ml.
Incubation of Microbial Cultures:
5 ml of  Muller Hinton broth media were innoculated with the needed
microbial cultures and kept for 2 to 6 hrs for incubation at 37OC temperature.
After getting proper growth the culture solution were read against sterile
Muller Hinton broth blank, using 0.5 Mc farlan standard at  620nm wavelength
in spectophotometer.
Appropriate dilution of microbial culture were made to match 0.5
Mc farland standard. The final dilution of microbial cultures contains 104
cells/ml. 2 ml of this diluted microbial culture were used to spot  innoculate
the plates.
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The plates with antimicrobial test agents:
a) Controls:
Solvent control was kept adding 1 ml of DMSO only to check the
inhibitory effect on microbes. Organizm control was kept without adding
compound.
b) Evaluation:
The plates were kept at 37OC temperature for 24 hrs to get visible
growth of microorganisms. Plates were check for growth. Microbes grown
in big colony if not inhibited, grown in small size colonies or scanty growth
if inhibited, no growth was found in case when they were killed by cideal
effect of synthetic compound.
Various organisms used in study of antibacterial activity are:
Gram positive:
1. S.aureus
2. B.subtilis
Gram negative:
1.  E.coli
2. P.aeruginosa
3. K.pneunonae
4. Enterobacter
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ASM-8
O O
OH
O O
O
CH3
OO
O
CH3
CH3
CH3
O O
OH
O O
O
CH3
OH
Sr.
N o . Strain
Minimum Inhibi tory Concentrat ion
(MIC, m g/ml)
1 Escher ich ia  Co l i - - - - - -
2 Enterobacter - - - - - -
3
P s e u d o m o n a s
Aerug inosa
500 +/- +/- >75 - -
4
Staphy lococcus
Aureus
500 250 125 >75 - -
5
Kle ibs ie l l
P n e u m o n a e
500 250 - - - -
6 Baci l lus Subt i l is ND
ASM-15
Sr.
N o .
Strain
Minimum Inhibi tory Concentrat ion
(MIC, m g/ml)
1 Escher ich ia  Co l i 500 - 125 >75 - -
2 Enterobacter - - - - - -
3 P s e u d o m o n a s
Aerug inosa
+/- - - - - -
4 Staphy lococcus
Aureus
500 250 125 75 37 >18
5 Kleibs ie l l
P n e u m o n a e
- - - - - -
6 Baci l lus  Subt i l is 500 250 125 75 37 >18
Table 7.3 :- Antibacterial Activity data (as per Protocol 3)
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ASM-20
ASM-26
O O
OH
O O
O
CH3
F
O O
OH
O O
O
CH3
O
Sr.
N o . Strain
Minimum Inhibi tory Concentrat ion
(MIC, m g/ml)
1 Escher ich ia  Co l i - - - - - -
2 Enterobacter 500 250 - - - -
3
P s e u d o m o n a s
Aerug inosa
500 250 125 >75 - -
4
Staphy lococcus
Aureus
500 250 125 >75 - -
5
Kle ibs ie l la
P h e u m o n a e
500 250 125 >75 - -
6 Baci l lus Subt i l is 500 250 125 >75 - -
Sr.
N o . Strain
Minimum Inhibitory Concentrat ion
(MIC, m g/ml)
1 Escher ich ia  Col i - - - - - -
2 Enterobacter - - - - - -
3
Pseudomonas
Aerug inosa
++/- ++/- 125 75 - -
4
Staphy lococcus
Aureus
500 250 125 75 - -
5
Kle ibs ie l l
P n e u m o n a e
- - - - - -
6 Baci l lus Subt i l is N D N D ND N D N D N D
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ASM-30
ASM-32
N
O
O
O
NH
CH3
Cl
N
O
O
O
OHCH3
Sr.
N o . Strain
Minimum Inhibi tory Concentrat ion
(MIC, m g/ml)
1 Escher ich ia  Co l i - - - - - -
2 Enterobacter 500 250 >125 - - -
3
P s e u d o m o n a s
Aerug inosa
500 250 >125 - - -
4
Staphy lococcus
Aureus
500 250 125 >75 - -
5
Kle ibs ie l l
P n e u m o n a e
500 250 - >75 - -
6 Baci l lus Subt i l is 500 250 125 >75 - -
Sr.
N o . Strain
Minimum Inhibi tory Concentrat ion
(MIC, m g/ml)
1 Escher ich ia  Co l i - - - - - -
2 Enterobacter 500 - 125 - - -
3
P s e u d o m o n a s
Aerug inosa
500 250 - - - -
4
Staphy lococcus
Aureus
500 250 125 - - -
5
Kle ibs ie l la
P n e u m o n a e
500 250 125 - - -
6 Baci l luc Subt i l is 500 250 125 75 - -
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ASM-33
ASM-36
N
O
O
O
NH
CH3
Cl
F
N
O
O
O
NH
CH3
Cl
S r.
N o . Strain
Minimum Inhibi tory Concentrat ion
(MIC, m g/ml)
1 Escher ich ia  Col i 500 +/- +/- - - -
2 Enterobacter 500 250 125 - - -
3
P s e u d o m o n a s
Aerug inosa
500 +/- - - - -
4
Staphy lococcus
Aureus
500 250 125 75 <37 -
5
Kle ibs ie l la
P h e u m o n a e
500 250 125 75 <37 -
6 Baci l lus Subt i l is 500 250 +/- 75 <37 -
S r.
N o . Strain
Minimum Inhibi tory Concentrat ion
(MIC, m g/ml)
1 Escher ich ia  Col i - - - - - -
2 Enterobacter - - - - - -
3
P s e u d o m o n a s
Aerug inosa
- - - - - -
4
Staphy lococcus
Aureus
500 250 125 <75 - -
5
Kle ibs ie l la
P h e u m o n a e
- - - - - -
6 Baci l lus Subt i l is 500 250 125 <75 <37 -
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ASM-40
ASM-43
N
O
O
O
NH
CH3
CH3
N
O
O
O
NH
CH3
CH3
CH3
Sr.
N o . Strain
Minimum Inhibitory Concentrat ion
(MIC, m g/ml)
1 Escher ich ia  Co l i 500 - - - - -
2 Enterobacter - - - - - -
3
P s e u d o m o n a s
Aerug inosa
- - <125 - - -
4
Staphy lococcus
Aureus
500 250 125 75 37 <18
5
Kleibsie l la
P h e u m o n a e
500 250 125 75 +/- -
6 Baci l lus Subt i l is 500 250 125 75 37 <18
Sr.
N o . Strain
Minimum Inhibitory Concentrat ion
(MIC, m g/ml)
1 Escher ich ia  Co l i - - - - - -
2 Enterobacter 500 250 125 - - -
3
P s e u d o m o n a s
Aerug inosa
500 250 - - - -
4
Staphy lococcus
Aureus
500 250 125 <75 - -
5
Kleibs ie l l
P n e u m o n a e
500 250 125 <75 - -
6 Baci l lus Subt i l is 500 250 125 <75 - -
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ASM-44
Sr.
N o .
Strain
Minimum Inhibi tory Concentrat ion
(MIC, m g/ml)
1 Escher ich ia  Co l i 500 250 125 75 37 <18
2 Enterobacter 500 250 - - <37 -
3
P s e u d o m o n a s
Aerug inosa
- 250 - - - -
4
Staphy lococcus
Aureus
500 250 125 75 37 <18
5
Kle ibs ie l la
P h e u m o n a e
500 250 125 - 37 <18
6 Baci l lus Subt i l is 500 250 125 75 37 <18
ASM-47
N
O
O
O
NH
CH3
Cl
N
O
O
O
NH
CH3
CH3CH3
Sr.
N o . Strain
Minimum Inhibitory Concentration
(MIC, mg/ml)
1
Escherichia
Coli
1000 500 +/- +/- >75 +/- -
2 Enterobacter - - - - - - -
3
Pseudomonas
Aeruginosa
1000 - - - - - -
4
Staphylococc-
us Aureus
1000 500 250 125 75 3 7 <18
5
Kleibsiel la
Pheumonae
1000 500 250 125 75 3 7 +/-
6
Baci l lus
Subti l is
1000 500 250 125 75 3 7 <18
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MSB-1
MSB-2
O O
O
NH
N
CH3
O O
O
NH
N
CH3
OCH3
Sr.
N o .
Strain
Minimum Inhibi tory Concentrat ion
(MIC, m g/ml)
1 Escher ich ia  Co l i 500 250 125 75 37 <18
2 Enterobacter 500 - 125 75 37 <18
3 P s e u d o m o n a s
Aerug inosa
- - - - - -
4 Staphy lococcus
Aureus
500 250 125 75 37 <18
5 Kle ibs ie l la
P h e u m o n a e
- 250 125 - - <18
6 Baci l lus Subt i l is 500 250 125 75 37 <18
Sr.
N o .
Strain
Minimum Inhibi tory Concentrat ion
(MIC, m g/ml)
1 Escher ich ia  Co l i - - - - - -
2 Enterobacter - - - - - -
3
P s e u d o m o n a s
Aerug inosa
500 250 - - - -
4
Staphy lococcus
Aureus
500 250 <125 - - -
5
Kle ibs ie l l
P n e u m o n a e
- - - - - -
6 Baci l lus Subt i l is ND
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MSB-7
MSB-8
O O
O
NH
N
CH3
OCH3
OCH3
O O
O
NH
N
CH3
OCH3
Sr.
N o .
Strain
Minimum Inhibi tory Concentrat ion
(MIC, m g/ml)
1 Escher ich ia  Co l i - - - - - -
2 Enterobacter - - - - - -
3
P s e u d o m o n a s
Aerug inosa
500 <250 - - - -
4
Staphy lococcus
Aureus
- - - - - -
5
Kle ibs ie l la
P n e u m o n a e
- - - - - -
6 Baci l lus Subt i l is ND N D N D N D ND N D
Sr.
N o .
Strain
Minimum Inhibi tory Concentrat ion
(MIC, m g/ml)
1 Escher ich ia  Co l i 500 250 125 >75 - -
2 Enterobacter - - - - - -
3
P s e u d o m o n a s
Aerug inosa
<500 - - - - -
4
Staphy lococcus
Aureus
- - - - - -
5
Kle ibs ie l la
P h e u m o n a e
500 - - - - -
6 Baci l lus Subt i l is 500 - - - - -
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Sr.
N o .
Strain Minimum Inhibi tory Concentrat ion (MIC,  m g/ml)
1 Escher ich ia  Co l i - - - - - -
2 Enterobacter - - - - - -
3
P s e u d o m o n a s
Aerug inosa
500 250 125 >75 - -
4
Staphylococcus
Aureus
500 250 125 >75 - -
5
Kle ibs ie l la
P h e u m o n a e
500 250 125 >75 - -
6 Baci l lus Subt i l is 500 250 125 >75 - -
MSB-9
Sr.
N o .
Strain Minimum Inhibi tory  Concentrat ion (MIC, m g/ml)
1 Escher ich ia  Co l i - - - - - -
2 Enterobacter - - - - - -
3
P s e u d o m o n a s
Aerug inosa
500 250 - - - -
4
Staphy lococcus
Aureus
500 250 125 <75 - -
5
Kleibs ie l l
P n e u m o n a e
- - - - - -
6 Baci l lus Subt i l is N D
MSB-10
O O
O
NH
N
CH3
Cl
O O
O
NH
N
CH3 Cl
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MSB-11
S r.
N o .
Strain Minimum Inhibitory Concentrat ion (MIC,  m g/ml)
1 Escher ich ia  Co l i - - - - - -
2 Enterobacter 500 250 - - - -
3
P s e u d o m o n a s
Aerug inosa
500 - - - - -
4
Staphy lococcus
Aureus
500 250 125 75 37 <18
5
Kle ibs ie l la
P h e u m o n a e
500 250 125 75 37 <18
6 Baci l lus  Subt i l i s 500 250 125 75 37 <18
MSB-12
S r.
N o .
Strain Minimum Inhibitory Concentrat ion (MIC,  m g/ml)
1 Escher ich ia  Co l i - 250 125 >75 - -
2 Enterobacter 500 - - - - -
3
P s e u d o m o n a s
Aerug inosa
- - <125 - - -
4
Staphy lococcus
Aureus
- - - - - -
5
Kle ibs ie l la
P h e u m o n a e
500 250 - - - -
6 Baci l lus  Subt i l i s 500 250 - - - -
O O
O
NH
N
CH3
Cl
O O
O
NH
N
CH3
NO2
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Conclusion:
Three types of antimicrobial studies were carried out.
(1) In the FIRST study, Protocol-1 was followed and the minimum
inhibition concentration were determined of 40 compounds against
Streptococcus pyogens A77,  S.aureus SG511,  S.aureus E710,
Enterococcus Faecalis,M. Smegmatis MY-1 and M. Smegmatis MY-2.
Many compounds have shown very proming MIC at 1.25 mg/ml, 2.5
mg/ml, 5 mg/ml and 10 mg/ml against some of the species discussed above.
(2) In the SECOND study, the biological activity was studied against
Gram positive and Gram negative strains like S. aureus and E. coli. The
compounds were screened for preliminary data collection. Zone of inhibition
are reported as Table 7.2.
(3) The THIRD study is based on the antibacterial study of individual
compounds at various concentration.
(4) The  compound  AM-13 shows MIC at 50 mg (Protocol-3), against
three different strains which is found most active in the present series. Many
of the compounds has shown MIC value upto 100 mg/ml against two or three
strains. While some compounds like (AM-14, AM-15, AM-25, AM-26, AM-
27, AM-34 and AKSM-12,20 &32) do not show any activity aganist any
strain.
